



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/00, A01N 63/00, 43/04</b>		A1	(11) International Publication Number: <b>WO 99/66036</b> (43) International Publication Date: 23 December 1999 (23.12.99)
(21) International Application Number: <b>PCT/US99/13850</b>		(74) Agent: CLARK, Paul, T.; Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110-2214 (US).	
(22) International Filing Date: 18 June 1999 (18.06.99)			
(30) Priority Data: 09/099,994 19 June 1998 (19.06.98) US		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/099,994 (CIP) Filed on 19 June 1998 (19.06.98)			
(71) Applicant (for all designated States except US): GENZYME CORPORATION [US/US]; One Kendall Square, Cambridge, MA 02138 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): MICKLE, Donald, A., G. [CA/CA]; 7 McGillivray Avenue, Toronto, Ontario M5M 2X9 (CA). LE, Ren-Ke [CA/CA]; 75 Ardgowan Crescent, Scarborough, Ontario M1V 1B4 (CA). WEISEL, Richard, D. [CA/CA]; 413 Sackville Street, Toronto, Ontario M4X 1S8 (CA).		Published With international search report.	

(54) Title: TRANSPLANTS FOR MYOCARDIAL SCARS

## (57) Abstract

A method is provided for forming a graft in heart tissue which comprises the transplantation of cells chosen from cardiomyocytes, fibroblasts, smooth muscle cells, endothelial cells and skeletal myoblasts. The grafts are especially useful in treating scar tissue on the heart.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## TRANSPLANTS FOR MYOCARDIAL SCARS

5

### FIELD OF THE INVENTION

The present invention relates to novel methods of cell transplantation into cardiac scar tissue to improve heart function, stimulate angiogenesis, and salvage myocardial tissue.

10

### BACKGROUND OF THE INVENTION

Normal cardiac contractile activity in the heart is dependent upon a healthy myocardium. The myocardium is a cellular syncytium composed primarily of interconnected heart muscle cells, the cardiomyocytes. Damage to the myocardium, such as that resulting from oxygen deprivation, results in cardiomyocyte death. Because cardiomyocytes do not regenerate within the myocardium, the damaged region of myocardium is replaced by cardiac scar tissue.

15

In contrast to myocardial tissue, cardiac scar tissue contains no cardiomyocytes. Instead, it is composed of connective tissue cells, such as fibroblasts, and non-cellular components, such as collagen and fibronectin. Cardiac scar tissue is non-contractile, and, therefore, interferes with normal cardiac function. Moreover, its lack of contractility increases the physical demands upon the remaining cardiomyocytes, which often leads to further myocardial damage and cardiac scarring.

20

Because the presence of non-contractile cardiac scar tissue places an additional physiological burden on the remaining myocardium, which often results in disease progression, there is a need for therapies that would inhibit or reverse the formation of such scar tissue. Ideally, such therapies would also allow improvement of contractile function, minimization of myocardial remodeling, stimulation of angiogenesis, salvation of damaged cardiomyocytes, rebuilding of the myocardium, and provide delivery vehicles for gene therapy. The present invention addresses these needs.

25

## SUMMARY OF THE INVENTION

It is an object of the present invention to provide cell transplantation methods for treating diseased myocardial tissue and myocardial scar tissue which overcome deficiencies in the prior art. The invention illustrates that atrial cardiomyocytes, skeletal myoblasts, smooth muscle cells, endothelial cells, and fibroblasts can be successfully transplanted into the scar tissue formed after ventricular necrosis and into tissue membranes and porous synthetic membranes. The cell grafts form tissue that survived the three month duration of the study, improved myocardial function, limited myocardial remodeling, and stimulated angiogenesis. The presence of the grafts did not induce overt cardiac arrhythmias. When auto-cell transplantation occurred, immunorejection did not occur.

In a first aspect, the invention features a method of forming a stable myocardial graft in a mammal comprising, transplanting cells into myocardial tissue or scar tissue in the heart. Cells are chosen from the group consisting of: adult cardiomyocytes, fetal cardiomyocytes, pediatric cardiomyocytes, adult fibroblasts, fetal fibroblasts, smooth muscle cells, endothelial cells, and skeletal myoblasts.

In preferred embodiments of the first aspect of the invention, cells may be chosen from adult or fetal smooth muscle cells and fibroblasts, adult cardiomyocytes and endothelial cells may be co-transplanted, adult cardiomyocytes may be derived from atrial tissue, the graft may be derived from auto-, allo- or xenotransplantation, and the graft may comprise adult cardiomyocytes derived from autotransplantation, such as cardiomyocytes derived from atrial tissue.

In another preferred embodiment of the first aspect of the invention, the cells may be directly introduced into the myocardial tissue or the scar tissue, for example, by injection, and the injection site may be sealed with a biological adhesive to prevent leakage of the cells.

In other preferred embodiments of the first aspect of the invention the cells may be suspended on a biodegradable or non-degradable mesh, or may be transfected to

deliver recombinant molecules to the myocardial tissue or the scar tissue.

In still another embodiment of the first aspect of the invention, the cells may be used in myocardial reconstructive surgery, and may be attached to the outer surface of the myocardial tissue or the scar tissue with a biological adhesive, or may be transplanted following an inflammatory response in the myocardial tissue. In addition, growth factors may be co-transplanted with the cells. Growth factors are chosen from the group consisting of: insulin-like growth factors I and II; transforming growth factor- $\beta$ 1, platelet-derived growth factor-B, basic fibroblast growth factor, and, vascular endothelial growth factor.

In yet other preferred embodiments of the first aspect of the invention, the cells are transplanted into scar tissue, and at least 10%, 20%, or 30% of the scar tissue area is occupied by transplanted cells four weeks after transplantation.

In a second aspect, the invention features a therapeutic graft for application in mammalian myocardial tissue or scar tissue in the heart, comprising transplanted cells chosen from the group consisting of: adult cardiomyocytes, pediatric cardiomyocytes, fetal cardiomyocytes, adult fibroblasts, fetal fibroblasts, adult smooth muscle cells, fetal smooth muscle cells, endothelial cells, and skeletal myoblasts.

In preferred embodiments of the second aspect of the invention, the graft may comprise adult cardiomyocytes and endothelial cells, the transplanted cells may be chosen from smooth muscle cells and fetal fibroblasts, the adult cardiomyocytes may be derived from atrial tissue, or the graft may be derived from auto-, allo- or xenotransplantation. The graft may comprise adult cardiomyocytes derived from autotransplantation and the cardiomyocytes may be derived from atrial tissue. The cells of the graft may be introduced into myocardial tissue or scar tissue by injection, and the cells may be transfected to deliver recombinant molecules to myocardial tissue or scar tissue. The graft may further comprise growth factors, for example, insulin-like growth factors I and II, transforming growth factor- $\beta$ 1, platelet-derived growth factor -B, basic fibroblast growth factor, and, vascular endothelial growth factor.

Cells of the graft also may be suspended on a mesh (e.g., a biodegradable mesh).

In a third aspect, the invention features a therapeutic graft, for implantation into mammalian myocardial tissue or scar tissue in the heart, comprising a suitable biodegradable or non-biodegradable scaffolding having cells supported thereon. The 5 cells are chosen from the group consisting of: adult cardiomyocytes, pediatric cardiomyocytes, fetal cardiomyocytes, adult fibroblasts, fetal fibroblasts, smooth muscle cells (e.g., adult smooth muscle cells or fetal smooth muscle cells), endothelial cells, and skeletal myoblasts.

In preferred embodiments of the third aspect of the invention, adult 10 cardiomyocytes may be derived from atrial tissue, and the graft may comprise adult cardiomyocytes and adult endothelial cells. The graft may be used in cardiomyoplasty. The scaffolding of the graft may comprise Dacron or polyglycolic acid polymers with or without polylactic acid polymers, the cellular material may consist of cardiomyocytes, smooth muscle cells or endothelial cells, and the graft may further include an implantable pacemaker. 15

Grafts according to the third aspect of the invention may be used for closing cardiac defects, and for myocardial reconstructive surgery.

In a fourth aspect, the invention features a method of culturing cardiomyocytes from pediatric mammalian myocardial tissue comprising: a) comminuting said 20 myocardial tissue; b) digesting said tissue for 15 minutes in a digesting solution containing 0.2% trypsin and 0.1% collagenase dissolved in phosphate buffered saline and separating the digested tissue solution from the remaining myocardial tissue; c) adding to the digested tissue solution a culture medium comprising Iscove's modified Dulbecco's medium (IMDM), 10% fetal bovine serum, and 0.1mM  $\beta$ -mercaptoethanol; culture medium being added in a ratio of 20 volumes of culture 25 medium to 1 volume of digesting solution; d) centrifuging the resulting solution at 581 x g for 5 minutes and discarding the supernatant; e) re-suspending the pellet in fresh culture medium; f) culturing the suspension in 10% fetal bovine serum and 0.1 mM  $\beta$ -mercaptoethanol.

mercaptoethanol; and, g) isolating cardiomyocytes from the culture.

In preferred embodiments of the fourth aspect of the invention the method may further include passaging cardiomyocytes by sub-culturing with a sub-culturing enzyme solution comprising 0.01% trypsin, 0.02% glucose, and 0.5 mM EDTA. The 5 method of the fourth aspect may further include storing the cardiomyocytes by a) dissociating cultured cardiomyocytes from the culture plate using sub-culturing enzyme solution; b) adding culture medium in a ratio of 5 volumes of culture medium to 1 volume of sub-culturing enzyme solution; c) centrifuging the solution at 581 x g for 5 minutes; d) discarding the supernatant and re-suspending the pellet in 1 mL 10 IMDM containing 20% fetal bovine serum and 20% glycerol; and, e) freezing and storing the resulting suspension in liquid nitrogen. The method may further include thawing the frozen sample at 37° C and culturing the cardiomyocytes for 3 to 5 days in a solution of IMDM containing 20% fetal bovine serum.

In a fifth aspect, the invention features a method of culturing cardiomyocytes 15 from adult mammalian myocardial tissue comprising: a) comminuting said myocardial tissue; b) digesting the tissue for 15 minutes in a digesting solution containing 0.2% trypsin and 0.1% collagenase dissolved in phosphate buffered saline; c) separating the digested tissue solution and digesting the remaining tissue with fresh digesting solution for 10 minutes; d) combining both digested tissue solutions from steps (b) and 20 (c) and adding a culture medium comprising Iscove's modified Dulbecco's medium (IMDM, containing 10% fetal bovine serum, and, 0.1mM  $\beta$ -mercaptoethanol) in a ratio of 20 volumes of culture medium to 1 volume of said digesting solution; e) centrifuging the resulting solution at 581 x g for 5 minutes and discarding the supernatant; f) re-suspending the pellet in fresh culture medium; g) culturing the 25 suspension in 10% fetal bovine serum and 0.1 mM  $\beta$ -mercaptoethanol; and, h) isolating cardiomyocytes from the culture.

In a preferred embodiment of the fifth aspect of the invention, the method may further include passaging the cardiomyocytes using sub-culturing enzyme solution

comprising 0.01% trypsin, 0.02% glucose, and 0.5 mM EDTA.

The method of the fifth aspect also may further include storing cardiomyocytes by a) dissociating cultured cardiomyocytes from the culture plate using sub-culturing enzyme solution; b) adding culture medium in a ratio of 5 volumes of culture medium to 1 volume of sub-culturing enzyme solution; c) centrifuging the solution at 581 x g for 5 minutes; d) discarding the supernatant and re-suspending the pellet in 1 mL IMDM containing 20% fetal bovine serum and 20% glycerol; and, e) freezing and storing the resulting suspension in liquid nitrogen.

In another embodiment of the fifth aspect, the method may further include thawing the frozen sample at 37° C and culturing the cardiomyocytes for 3 to 5 days in a solution of IMDM containing 20% fetal bovine serum.

In a sixth aspect, the invention features a method of treating defective, damaged or scarified heart tissue, comprising transplanting into the tissue a graft of cells chosen from the group consisting of: adult cardiomyocytes, pediatric cardiomyocytes, fetal cardiomyocytes, adult fibroblasts, fetal fibroblasts, adult smooth muscle cells, fetal smooth muscle cells, endothelial cells, and skeletal myoblasts.

In preferred embodiments of the sixth aspect of the invention, the adult cardiomyocytes may be derived from atrial tissue, cells in the graft may be adult cardiomyocytes and endothelial cells, the cells may be directly introduced into heart tissue, and the graft may be a patch comprising cells suspended on a biologically acceptable biodegradable or non-biodegradable scaffolding.

In still other preferred embodiments of the sixth aspect of the invention, the cells are transplanted into scar tissue, and at least 10%, 20%, or 30% of the scar tissue is occupied by transplanted cells four weeks after transplantation.

In another preferred embodiment of the sixth aspect of the invention, the method may comprise the steps of: (a) surgically removing defective heart tissue thereby creating an opening; and, (b) attaching the graft to the opening to form a water tight seal.

In a seventh aspect, the invention features isolated cells for transplantation into myocardial scar tissue, wherein the cells include at least one of the following cell types: adult cardiomyocytes, pediatric cardiomyocytes, adult fibroblasts, fetal fibroblasts, adult smooth muscle cells, fetal smooth muscle cells, endothelial cells, and skeletal myoblasts, wherein the cells survive in myocardial scar tissue after transplantation and improve cardiac function, relative to cardiac function of a heart having similar myocardial scar tissue that is not transplanted with cells. Cardiac function is assessed by at least one of the criteria in the group consisting of: area occupied by scar tissue; vascularization of scar tissue; blood flow to scar tissue; developed pressure, systolic pressure; end diastolic pressure; and dp/dt.

In preferred embodiments of the seventh aspect of the invention, the cells include at least two different cell types. For example, the cells may include a combination of: adult cardiomyocytes and endothelial cells; pediatric cardiomyocytes and endothelial cells; or myoblasts and endothelial cells.

In an eighth aspect, the invention features a method for testing a pharmacological agent that is intended to prevent or ameliorate cardiac damage during cardiac surgery. The method comprises exposing the pharmacological agent to isolated cells selected from the group consisting of: adult cardiomyocytes, pediatric cardiomyocytes, adult fibroblasts, fetal fibroblasts, adult smooth muscle cells, fetal smooth muscle cells, endothelial cells, and skeletal myoblasts, wherein the cells survive in myocardial scar tissue after transplantation and improve cardiac function, relative to cardiac function of a heart having similar myocardial scar tissue that is not transplanted with cells (cardiac function is assessed by at least one of the criteria in the group consisting of: area occupied by scar tissue; vascularization of scar tissue; blood flow to scar tissue; developed pressure, systolic pressure; end diastolic pressure; and dp/dt), wherein cells exposed to the pharmacological agent show a decrease or absence of cardiac damage during cardiac surgery, compared to cells not exposed to the pharmacological agent.

In a ninth aspect, the invention features a method of forming a stable cardiac graft in a mammal, including transplanting into the scar tissue of a heart, cells chosen from the group consisting of: adult cardiomyocytes; pediatric cardiomyocytes; adult fibroblasts; fetal fibroblasts; adult smooth muscle cells; fetal smooth muscle cells; 5 endothelial cells; and skeletal myoblasts, wherein the cells survive in scar tissue in a heart after transplantation into scar tissue, and wherein the cells improve cardiac function, relative to cardiac function of a heart having similar myocardial scar tissue that is not transplanted with such cells. Cardiac function is assessed by at least one of the criteria in the group consisting of: area occupied by scar tissue; vascularization of 10 scar tissue; blood flow to scar tissue; developed pressure, systolic pressure; end diastolic pressure; and dp/dt, wherein at least 10% of scar tissue is occupied by transplanted cells four weeks after transplantation.

In preferred embodiments of the ninth aspect of the invention, at least 20% or 15 at least 30% of the scar tissue may be occupied by transplanted cells four weeks after transplantation, or at least 40% or at least 50% of the scar tissue may be occupied by transplanted cells eight weeks after transplantation.

In other preferred embodiments of the ninth aspect of the invention, the cells 20 may include at least two types of cells. For example, the cells may include a combination of: adult cardiomyocytes and endothelial cells; pediatric cardiomyocytes and endothelial cells; or myoblasts and endothelial cells.

In still other preferred embodiments of the ninth aspect of the invention, growth factors are co-transplanted with the cells. The growth factors are chosen from the group consisting of: insulin-like growth factors I and II; transforming growth factor -  
β1; platelet-derived growth factor -B; basic fibroblast growth factor; and, vascular 25 endothelial growth factor.

In a tenth aspect, the invention features a method of treating defective, damaged or scarified heart tissue, including transplanting into defective, damaged or scarified heart tissue a graft of cells that includes a combination of: adult

-9-

cardiomyocytes and endothelial cells; pediatric cardiomyocytes and endothelial cells; or myoblasts and endothelial cells.

In preferred embodiments of the tenth aspect of the invention, the graft may be used for cardiomyoplasty, for closing cardiac defects, or for myocardial reconstructive surgery.

In an eleventh aspect, the invention features a therapeutic graft for implantation in mammalian myocardial tissue or scar tissue in a heart, including biodegradable or non-biodegradable scaffolding supporting cells, wherein the cells include a combination of: adult cardiomyocytes plus endothelial cells; pediatric cardiomyocytes plus endothelial cells; or myoblasts plus endothelial cells.

In various embodiments of the eleventh aspect of the invention, the scaffolding includes Dacron or polyglycolic acid polymers with or without polylactic acid polymers, or further includes an implantable pacemaker.

In another embodiment of the eleventh aspect, the cells may be transfected to deliver recombinant molecules to the myocardial tissue or scar tissue.

In still another embodiment of the eleventh aspect, the graft may include growth factors, for example: insulin-like growth factors I and II; transforming growth factor - $\beta$ 1; platelet-derived growth factor -B; basic fibroblast growth factor; and, vascular endothelial growth factor.

In yet another embodiment of the eleventh aspect, the cells may be suspended on a biodegradable mesh.

In a twelfth aspect, the invention features a therapeutic graft including transplanted cells, for use in scar tissue in a mammalian heart. The transplanted cells include: adult cardiomyocytes; adult fibroblasts; fetal fibroblasts; smooth muscle cells; endothelial cells; or skeletal myoblasts.

In a thirteenth aspect, the invention features a therapeutic graft including transplanted cells for use in myocardial tissue in a mammalian heart. The transplanted cells include: adult fibroblasts; fetal fibroblasts; smooth muscle cells; or endothelial

cells.

In a fourteenth aspect, the invention features a method of forming a stable myocardial graft in a mammal. The method includes transplanting cells into myocardial tissue in the heart of the mammal, wherein said cells include: adult fibroblasts; fetal fibroblasts; smooth muscle cells; or endothelial cells.

In a fifteenth aspect, the invention features a method of treating defective, damaged or scarified heart tissue. The method includes transplanting, into the tissue, a graft of cells including: adult cardiomyocytes; adult fibroblasts; fetal fibroblasts; smooth muscle cells; endothelial cells; or skeletal myoblasts.

In preferred embodiments of the ninth through fifteenth aspects of the invention, prior to transplantation, at least one of the cells may be genetically engineered to express a recombinant protein. The recombinant protein may be a therapeutic protein that stimulates cell growth, survival, and/or angiogenesis by endogenous cells within the heart and/or by cells transplanted into the myocardium or myocardial scar tissue, and thereby improves cardiac function. The stimulation of cell growth, survival, and/or angiogenesis or improvement in cardiac function may be by at least 5%, preferably, by at least 10%, 20%, or 30%. Examples of such recombinant proteins include: fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (e.g., PDGF- $\beta$ ), transforming growth factor- $\beta$  (TGF- $\beta$ ), insulin-like growth factor (e.g., IGF-1 and IGF-2), insulin, Bcl-2, and Bcl-X<sub>L</sub>. Preferably, at least 1%, more preferably, at least 5%, at least 10%, at least 25%, and most preferably, at least 50% of the cells express the recombinant protein.

#### BRIEF DESCRIPTION OF THE DRAWINGS

These and other features of the present invention will become more apparent in the following detailed description wherein references are made to the following figures:

Fig. 1 is a graph showing the improvement in myocardial function of scarred

-11-

hearts having smooth muscle cells transplanted into the scars.

Fig. 2 is a graph showing the amount of blood flow (represented as microsphere count) to control scar tissue and scar tissue transplanted with endothelial cells.

5 Fig. 3 is a graph showing systolic pressure of transplantation hearts and control hearts with increasing balloon volume.

Fig. 4 is a graph showing developed pressure of transplantation hearts and control hearts with increasing balloon volume.

10 Fig. 5 is a diagram showing the design of the histological study of cryoinjured hearts (top) and histological and functional studies of hearts transplanted with endothelial cells after cryo-injury (bottom).

Figs. 6A-6D are diagrams of photomicrographs of haematoxylin and eosin (H & E)-stained left ventricular free wall (LVFW): *A*, immediately after cryo-injury (200X magnification), and *B*) 1 week (100X magnification), *C*) 2 weeks (100X magnification), and *D*) 4 weeks (200X magnification) after cryo-injury.

15 Figs. 7A-7D are diagrams of photomicrographs of H & E-stained heart sections (5X magnification): *A*) 1 week, *B*) 2 weeks, *C*) 4 weeks, and *D*) 8 weeks after cryo-injury of the LVFW.

Fig. 8 is a graph showing percentages of scar tissue in the LVFW at 1 week, 2 weeks, 4 weeks, and 8 weeks after cryo-injury.

20 Figs. 9A-9D are diagrams of photomicrographs of H & E-stained heart sections (5X magnification) at 8 weeks after cryo-injury of the LVFW.

Fig. 10 is a graph showing percentages of scar tissue and transplanted cardiac tissue in the LVFW at 8 weeks after cryo-injury.

25 Fig. 11 is a diagram of a photomicrograph showing fetal rat cardiomyocytes 6 weeks after transplantation (100X magnification).

Fig. 12 is a series of graphs of systolic, diastolic, developed balloon pressures and positive dp/dt with increasing balloon volumes of control hearts and hearts transplanted immediately after myocardial injury.

-12-

Fig. 13 is a series of graphs of systolic, diastolic, developed balloon pressures and positive dp/dt with increasing balloon volumes of control hearts and hearts transplanted 2 weeks after myocardial injury.

5 Fig. 14 is a series of graphs of systolic, diastolic, developed balloon pressures and positive dp/dt with increasing balloon volumes of control hearts and hearts transplanted 4 weeks after myocardial injury.

Fig. 15 is a graph showing developed pressures at balloon volumes of 0.04, 0.1, 0.2 and 0.3 ml of the hearts transplanted with fetal cardiomyocytes at 2 and 4 weeks after myocardial injury (\* p<0.05, \*\* p<0.01).

10 Fig. 16 is a graph showing developed pressure in cryo-injured hearts containing transmural scars transplanted with medium (control), adult cardiomyocytes (CM) or adult cardiomyocytes plus vascular endothelial cells (CM + EC).

#### **DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS**

15 We have discovered methods for improving the outcome of patients having myocardial scars and other heart defects. Our discovery was made while investigating the use of grafts, comprising cellular transplants, for treating scar tissue in the heart. We transplanted cultured cells into the center of a mature ventricular scar so that there was no contact between the transplanted cells and the host cells. This approach was used to facilitate identification of the transplant. Initially, in transplanting fetal 20 cardiomyocytes into the mature scar, it was surprising to find stimulation of angiogenesis in the affected area and an improvement in heart function. Since we were previously unsuccessful in transplanting adult ventricular cardiomyocytes into myocardial scar tissue, we were surprised that adult atrial cardiomyocytes could be successfully transplanted into such scar tissue. In further studies, we have 25 transplanted autologous and allogeneic smooth muscle cells, fibroblasts, and endothelial cells into the center of a mature ventricular scar. As with our previous findings, the cell transplants formed stable grafts in the scar, improved myocardial

function, decreased myocardial remodeling, stimulated angiogenesis, salvaged myocardium, and provided a means of gene delivery. On the basis of these studies we expect that similar results can be obtained from the use of skeletal myoblasts as well.

We have also developed a novel method for culturing, passaging and storing 5 postnatal (adult or pediatric) human ventricular cardiomyocytes. Transplantation of cultured postnatal cardiomyocytes provides an approach for restoring function and blood flow to regions of the heart that are destroyed by acquired heart disease or are absent because of congenital heart disease. The postnatal cardiomyocyte cell culture method further provides a model for testing a variety of pharmacological or other 10 approaches for preventing or ameliorating cardiac damage during cardiac surgery. Therefore, this unique method offers the promise of preventing injury as well as 15 restoring heart function after cardiac injury.

The following examples will assist those skilled in the art to better understand the invention and its principles and advantages. It is intended that these examples be 15 illustrative of the invention and not limit the scope thereof.

## I) GENERAL METHODS

### A) CELL ISOLATION, CULTURE, AND IDENTIFICATION

20 1. Fetal Rat Cardiomyocyte Cultures: Fetal rat cardiomyocytes were isolated by enzymatic digestion (Li, R-K et al., *Circulation Research* 78:283-288, 1996; Li, R-K et al., *Annals of Thoracic Surgery* 62:654-661, 1996) from 18-day gestational Sprague-Dawley rat heart ventricles (Charles River Canada Inc. Quebec, Canada). Fetal rats were anesthetized with intraperitoneal injection of sodium pentobarbital (30 mg/kg) and the hearts were then excised. The heart tissues were washed with phosphate-buffered saline (NaCl 136.9 mM, KCl 2.7 mM, Na<sub>2</sub>HPO<sub>4</sub> 8.1 mM, KH<sub>2</sub>PO<sub>4</sub> 1.5 mM, pH 7.3). The tissues were minced and incubated in 10 ml phosphate buffered saline containing 0.2% trypsin, 0.1% collagenase, and 0.02% glucose for 30 minutes 25

-14-

at 37°C. The cardiomyocytes were then isolated by repetitive pipetting of the digested myocardial tissue. The cells in the supernatant were transferred to a tube containing 20 ml of cell culture medium (Iscove's modified Dulbecco's medium containing 10% fetal bovine serum, 0.1 mmole/L  $\beta$ -mercaptoethanol, 100 units/ml penicillin and 100 ug/ml streptomycin). The tube was centrifuged at 600 x g for 5 minutes at room temperature and the cell pellet was resuspended in the cell culture medium for purification by plating (see Section 10 below).

2. Adult Rat Ventricular Cardiomyocyte Cultures: Adult rats (Charles River Canada Inc. Quebec, Canada) were anesthetized with intramuscular administration of ketamine hydrochloride (22 mg/kg body weight) followed by an intraperitoneal injection of sodium pentobarbital (30 mg/kg) and the hearts were then excised. Cardiomyocytes were isolated by enzymatic digestion as described in Section 1. Adult human ventricular biopsies obtained from the operating theatre were similarly enzymatically digested.

3. Adult Rat Atrial Cardiomyocyte Cultures: Adult rats weighing 400 g (Charles River Canada Inc. Quebec, Canada) were anesthetized as in Section 2 above. The atrial appendages were ligated and removed (rats survive this procedure), after which the atrial tissue was used for cardiomyocyte isolation as described in Section 1. Adult human atrial tissue was obtained from the operating theatre and similarly enzymatically digested.

4. Fetal Rat Smooth Muscle Cells: Fetal rat smooth muscle cells were isolated from 18-day gestational Sprague-Dawley rat stomachs by enzymatic digestion (Li, R-K et al., *Journal of Tissue Culture and Methods* 14:93-100, 1992). Fetal rats (Charles River Canada Inc. Quebec, Canada) were anesthetized with pentobarbital (30 mg/kg body weight, intraperitoneal) and the stomachs were then excised. The stomachs were

-15-

washed with phosphate buffered saline, minced, and incubated in 10 ml phosphate buffered saline containing 0.2% trypsin, 0.1% collagenase, and 0.02% glucose for 30 minutes at 37°C. Smooth muscle cells were isolated by repetitive pipetting of the digested stomach tissue. The cells in the supernatant were transferred to a tube 5 containing 20 ml of cell culture medium (199 medium containing 20% fetal bovine serum, 100 units/ml penicillin and 100 ug/ml streptomycin), and centrifuged at 600 x g for 5 minutes at room temperature, after which the cells were resuspended in the cell culture medium and cultured.

10       5. Adult Rat Smooth Muscle Cells: Adult female rats (Charles River Canada Inc. Quebec, Canada) were anesthetized as described in Section 2 above. Uteri were removed after occlusion of blood vessels and incision was closed. Smooth muscle cells were isolated from uterus as described in Section 4.

15       6. Fetal Rat Fibroblasts: Fetal rat skin biopsies were obtained from anesthetized 18-day gestational Sprague-Dawley rats, and fibroblasts from fetal rat skin were isolated, purified and cultured as previously described (Mickle et al., *Journal of Molecular and Cell Cardiology* 22:1297-1304, 1990). Briefly, the tissue was washed with phosphate buffered saline, minced, and digested for 30 minutes at 37°C in 10 ml 20 phosphate buffered saline containing 0.2% trypsin, 0.1% collagenase, and 0.02% glucose. Fibroblasts were isolated by repetitive pipetting of the digested skin tissue. The cells in the supernatant were transferred into a tube containing 20 ml of cell culture medium (Dulbecco's Modified Essential Medium containing 10% fetal bovine serum, 100 units/ml penicillin and 100 ug/ml streptomycin) and centrifuged at 600 x g 25 for 5 minutes at room temperature, after which the cells were resuspended in the cell culture medium and cultured.

7. Adult Rat Fibroblasts: Skin biopsies were obtained from anesthetized adult

-16-

Sprague-Dawley rats. Fibroblasts were isolated and cultured as described in Section 6.

8. Adult Rat Endothelial Cells: Adult rat vascular endothelial cells were isolated from Sprague-Dawley rat aortas by enzymatic digestion (Mickle et al., *Journal of Molecular and Cell Cardiology* 22:1297-1304, 1990). Adult rats (Charles River Canada Inc. Quebec, Canada) were anesthetized as described in Section 2. Aortas were excised, washed with phosphate buffered saline, incubated for 30 minutes at 37°C in 10 ml phosphate buffered saline containing 0.2% trypsin, 0.1% collagenase, and 0.02% glucose, and washed with cell culture medium (199 medium containing 20% fetal bovine serum, 100 units/ml penicillin and 100 ug/ml streptomycin), after which the isolated endothelial cells were cultured.

9. Human Cell Isolation, Culturing and Storage: Human cardiomyocytes were isolated from atrial appendages and ventricular myocardial biopsies were obtained from patients undergoing corrective cardiac surgery. Human myocardium was dissected to remove connective tissue and then minced to pieces less than 1 mm<sup>3</sup> in size.

9(a). Pediatric Cardiomyocytes: Pediatric tissue was digested for 15 minutes in an enzymatic digestion solution containing 0.2% trypsin, 0.1% collagenase dissolved in phosphate-buffered saline (no calcium or EDTA was added). Culture medium containing Iscove's modified Dulbecco's medium (IMDM), 10% fetal bovine serum and 0.1 mM β-mercaptoethanol was added in a ratio of 20 volumes culture medium to 1 volume enzymatic digestion solution. The cell suspension was centrifuged at 581 g for 5 minutes, after which the supernatant was discarded. The cell and tissue pellet was resuspended in culture medium, after which the isolated cells were cultured on a dish for 5 to 8 days. Cardiomyocytes that migrated from this culture were collected by

a Pasteur pipette and cultured once again.

9(b). Adult Cardiomyocytes: In contrast to pediatric myocardium digestion, adult human myocardium was digested twice. The second digestion was necessary for the adult tissue due to the increased amount of connective tissue. After the first digestion (as described in Section 9a), the cell suspension was collected, after which the tissue was re-digested for 10 minutes and the second cell suspension was collected. The two collected suspensions were combined, and centrifuged, after which the cells were resuspended and cultured. The digested tissue fragments in the pellet were collected and cultured for no longer than 2 days (to avoid cell deterioration) and a further enzymatic digestion carried out on the remaining undigested tissue if sufficient cells were not found in the suspensions. In addition, cardiomyocytes that migrated from the cultured tissue fragments were isolated and re-cultured.

9(c). Passaging of Cultures: The cardiomyocytes were cultured in a medium containing IMDM, 10% fetal bovine serum and 0.1 mM  $\beta$ -mercaptoethanol. The subculturing enzymatic solution for cell dissociation contained 0.01% trypsin, 0.02% glucose and 0.5 mM EDTA. The cells were subcultured when the culture reached confluence (i.e. when the cell culture covered the dish surface and the cells began contacting each other). Cells that were subcultured before reaching confluence rapidly became de-differentiated; such de-differentiated cells cannot be successfully transplanted. On the other hand, if the cells were allowed to become over-confluent, enzymatic digestion yielded cell clumps that would not dissociate; we observed that cardiomyocytes in cell clumps did not divide in culture.

9(d). Storage of Cultured Cells: Primary cultures of human cardiomyocytes were dissociated from culture plates using the subculturing enzymatic digestion solution described in Section 9(c), after which culture medium was added in a ratio of 5 volumes culture medium to 1 volume digestion solution, and the cell suspension was

-18-

centrifuged at 581 g for 5 minutes. The supernatant was removed and the cell pellet was gently re-suspended in 1 mL IMDM containing 20% fetal bovine serum and 20% glycerol, transferred to a sterile cryo-vial, and placed in a Nalgene freezing container containing isopropranol in its base. Cryo-vials were stored in a -80°C freezer  
5 container for a period of time that: (a) ensured that the cells reached -80°C; and (b) prevented over-oxidation of the cells. In the present example, cryo-vials were stored for a minimum of 4 hours and no longer than 8 hours. Cryo-vials containing the cells were placed in liquid nitrogen for long term storage.

10 9(e). Thawing of Cultures: To culture the stored cells, the vials were removed from liquid nitrogen and warmed at 37°C. Although 37°C was preferred, cells were also thawed at other temperatures that allowed for rapid yet non-destructive warming. The initial plating of the cells was done in 10 ml of IMDM medium containing 20% fetal bovine serum (warming medium). Cells were cultured in warming medium for 3 to 5 days after thawing to allow the cells to attach firmly to the culture dish before  
15 switching to the usual culture medium. The warming medium must contain IMDM and 20% fetal bovine serum. For example, if the warming medium contains 10% rather than 20% fetal bovine serum, the human cardiomyocytes will not divide and will de-differentiate. De-differentiated cardiomyocytes cannot be used for transplantation.

20 Cardiomyocytes that were cryo-frozen and warmed as described were successfully subcultured and were morphologically identical to cells that had not been frozen. Cells that had been frozen and cells that had not been frozen were analyzed for mitochondrial integrity at each passage for 7 passages (over the course of one month of subculture following thawing and plating). The mitochondrial enzyme cytochrome C oxidase showed no difference in activity between frozen and unfrozen  
25 cardiomyocytes at each passage. Our finding that primary human cardiomyocytes can be stored frozen and later revived allows their "lifetime" to be extended, thus enhancing the usefulness of such cells.

-19-

9(f). Endothelial Cells: Human vascular endothelial cells were isolated as described in section 8 from saphenous vein and aorta obtained from patients undergoing coronary bypass surgery.

9(g). Smooth Muscle Cells: Human smooth muscle cells were isolated from saphenous vein after endothelial cell isolation. After endothelial cells were collected from veins as described in Section 8, the tissue was minced and incubated in 10 ml phosphate buffered saline containing 0.2% trypsin, 0.1% collagenase, and 0.02% glucose for 30 minutes at 37°C. The smooth muscle cells were isolated by repetitive pipetting of the digested tissue. The cells in the supernatant were transferred into a tube containing 20 ml of cell culture medium (199 medium containing 20% fetal bovine serum, 100 units/ml penicillin and 100 ug/ml streptomycin), centrifuged at 600 x g for 5 minutes at room temperature, resuspended in cell culture medium, and cultured.

15 9(h). Human Fibroblasts: Human fibroblasts were isolated from skin biopsies as described in Section 6.

10. Rat Cell Purification: Contaminating fibroblasts were removed from populations rat cardiomyocytes, smooth muscle cells, vascular endothelial cells by preplating (Simpson et al., *Circulation Research* 51:787-801, 1982), which takes advantage of the finding that fibroblasts attach to a cell culture dish more rapidly than do other cells. Freshly isolated cells were plated on dishes and cultured for 2 hours at 37°C, after which the culture medium containing the suspended cells (minus the fibroblasts adhering to the dishes) was transferred into another dish for further culturing.

Pure populations of cells may also be obtained by clonal dilution. The cells are seeded at low density and allowed to form individual cell colonies. Any cell not of the desired type that is adjacent to a colony of interest is killed with a sterile needle.

-20-

Desired colonies are then collected using a sterile Pasteur pipette, and transferred to new culture dishes for culturing and passaging.

Human cardiomyocytes were used without a purification step.

5           11. Cell Identification:

Cardiomyocytes: The purity of primary cultures of cardiomyocytes was assessed by immunofluorescent staining for cardiac myosin heavy chain (Rougier Bio-Tech Ltd, Quebec, Canada) (Li R-K, et al., *Cardiovascular Research* 32:362-73, 1996). The cultured cells were fixed with methanol at -20°C for 15 minutes, washed with phosphate buffered saline, incubated with a monoclonal antibody against cardiac myosin heavy chain for 45 minutes at 37°C, washed three times with phosphate buffered saline for 5 minutes each at room temperature, and then under humid and dark conditions incubated with rabbit anti-mouse IgG conjugated with fluorescein isothiocyanate for 45 minutes at 37°C. The cells were washed with phosphate buffered saline, mounted and photographed using a light and UV microscope. The purity of cardiomyocyte cultures was determined by counting the percentage of stained cells in 8 random fields/dish. Eight dishes of cardiomyocyte cultures were used in each cardiomyocyte preparation.

20           Smooth Muscle Cells: The purity of smooth muscle cell cultures was determined by immunofluorescent staining for  $\alpha$ -smooth muscle cell actin (Sigma, St. Louis, MI) as described in the previous paragraph.

Vascular Endothelial Cells: The purity of endothelial cell cultures was determined by immunofluorescent staining for factor VIII as described in the cardiomyocyte section above.

25           Fibroblasts: The purity of fibroblast cell cultures was determined by examining cell morphology with a microscope.

**B) CELL TRANSPLANTATION**

Subject animals were grouped into three categories: sham, control and transplantation. The criteria for such grouping was as follows:

5

Group	Surgical exposure	Scar generation	Cell transplantation
Sham	X		
Control	X	X	
Transplantation	X	X	X

10

1. Surgical Exposure: Sprague-Dawley rats (500 gram) were anesthetized with ketamine (22 mg/kg body weight, intramuscular) followed by an intraperitoneal injection of pentobarbital (30 mg/kg body weight). Once anaesthetized, rats were intubated and positive pressure ventilation was maintained with a Harvard ventilator (Model 683, USA). The respiratory rate was set at 60 cycles/minute with a tidal volume of 2 ml. Animals were ventilated with oxygen-supplemented room air. The heart was exposed through a 2-cm left lateral thoracotomy. The muscle layer and skin incision were surgically closed with 5-0 vicryl sutures.

2. Myocardial Injury and Myocardial Scar Generation: The hearts of the adult rats were exposed as described in the previous paragraph. A 5-mm-diameter metal probe cooled to -190°C for 2 minutes was applied to the left ventricular free wall of the heart for 20 seconds. This procedure was repeated 8 times. The muscle layer and skin incision were then surgically closed with 5-0 vicryl sutures.

The animals recovered from surgery in a warm environment, were monitored for 4 hours postoperatively and then given Penlog XL (benzathine penicillin G 150,000 U/ml and procaine penicillin G 150,000 U/ml) intramuscularly (0.25 ml/rat) every three days, and buprenorphine (0.01-0.05 mg/kg body weight) subcutaneously 8-12 hourly for the first 48 hours following surgery.

3. Transfection of the Cultured Cardiomyocytes: Freshly isolated or cultured cells were transfected by calcium phosphate coprecipitation (Shi Q-W, et al., *Journal*

-22-

of *Molecular and Cell Cardiology* 24:1221-1229, 1992) with a plasmid containing the  $\beta$ -galactosidase gene. Plasmid DNA (20 ug) dissolved in 450  $\mu$ l of sterile water and 50  $\mu$ l of 2.5 M CaCl<sub>2</sub> was slowly added to 500  $\mu$ l of aerated 2X HEPES-buffered saline (0.284 M NaCl, 0.050 M HEPES acid, and 1.48 mM Na<sub>2</sub> HPO<sub>4</sub>, pH 7.05). After 5 20 minutes at room temperature, the solution was added to a cardiomyocyte suspension (1.0 X 10<sup>6</sup> cells/6 ml of culture medium). In the control groups the same procedure was performed either without plasmid DNA or with pREP4 (a plasmid that lacks a  $\beta$ -galactosidase gene; Invitrogen, Carlsbad, CA). The cells were cultured at 37°C, 5% CO<sub>2</sub> and 95% air for 24 hours.

10 To determine the efficiency of cell transfection, cells cultured for either 24 hours or 4 weeks were washed three times with phosphate buffered saline, fixed in 2% formaldehyde and 2% glutaraldehyde in phosphate buffer (0.15 M NaCl and 0.015 M NaH<sub>2</sub>PO<sub>4</sub>, pH 7.2) at 4°C for 5 minutes, washed with phosphate buffer containing 2.0 mM MgCl<sub>2</sub>, and stained overnight at 37°C in a solution containing 1 mg/ml 5-bromo-15 4-chloro-3-indolyl-beta-galactopyranoside (X-gal), 5 mM K<sub>3</sub>Fe(CN)<sub>6</sub>, 5 mM K<sub>4</sub>Fe(CN)<sub>6</sub>·3H<sub>2</sub>O, 0.2 mM MgCl<sub>2</sub> in phosphate buffer (pH 7.2). The stained and non-stained cells in 8 random fields/dish (6 dishes from 6 preparations) were counted under the microscope to determine the percentage of cells containing  $\beta$ -galactosidase activity. Two dishes from each transplant experiment were used for a cell transfection 20 efficiency study (N (number of animals) = 6).

25 4. Cell Preparation and Transplantation: Cultured cells were washed three times with phosphate buffered saline to remove dead cells and then detached from the cell culture dish and each other with 0.05% trypsin in phosphate buffered saline for 3 minutes. After adding 10 ml of culture medium, the cell suspension was centrifuged at 580 X g for 3 minutes. The cell pellet was resuspended in culture medium at a concentration of 4 X 10<sup>6</sup> cells/ml culture medium. The volume of cell suspension was 0.25 ml for each cell transplantation.

On day 14 or 30 following myocardial scar generation (as described in Section

-23-

2), the animals (which now had mature transmural scars in their ventricles) were anesthetized as described in Section 1. The scar tissue in the heart was exposed through a midline sternotomy. The cell suspension (0.25 ml) was injected into the scar tissue of the animals of the transplant group using a tuberculin syringe. Control 5 animals were similarly injected with 0.25 ml of culture medium alone (i.e., no cells). The rats in the sham group underwent the surgical procedure without injection. Cryo-precipitate (fibrin glue) was placed on the injection sites to prevent leakage of the injected cells. The chest was closed with 5-0 vicryl sutures. Antibiotics and analgesia were given as described in Section 1. Cyclosporin A, at a dose of 5 mg/kg body 10 weight/day, was administered subcutaneously into animals of all three groups. The rats were housed in cages with filter tops.

### C) MEASUREMENT OF HEART FUNCTION

Eight weeks after myocardial injury, the heart function of sham, control and 15 transplanted animals was measured using a Langendorff preparation (Stephen SE, et al., *Annals of Thoracic Surgery* 59:1127-1133, 1995). The rats were anesthetized and heparin (200 units) was administered intravenously. The hearts were quickly isolated from rats and perfused in a Langendorff apparatus with filtered Krebs Heinseleit buffer (mmol/L NaCl 118, KCl 4.7, KH<sub>2</sub>PO<sub>4</sub> 1.2, CaCl<sub>2</sub> 2.5, MgSO<sub>4</sub> 1.2, NaHCO<sub>3</sub> 25, 20 glucose 11; pH 7.4) equilibrated with a 5% CO<sub>2</sub> and 95% O<sub>2</sub>. A latex balloon was passed into the left ventricle through the mitral valve and connected to a pressure transducer (Model p10EZ, Viggo-Spectramed, CA) and transducer amplifier and differentiator amplifier (Model 11-G4113-01, Gould Instrument System Inc., Ohio). After 30 minutes of stabilization, coronary flow in the heart was measured in triplicate 25 by timed collection in the emptying beating state. The balloon size was increased by addition of saline in 0.02 ml increments from 0.04 to 0.8 ml, or the volume at which end diastolic pressure reached to 30 mm Hg, or whichever came first. The systolic and diastolic pressures were recorded at each balloon volume and developed pressure

-24-

was calculated as the difference between the systolic and diastolic pressures.

Hearts were weighed and their sizes were measured by water displacement.

#### D) MEASUREMENT OF LEFT VENTRICULAR REMODELING

The epicardial and endocardial surface areas of the normal and scar tissue in the left ventricular free wall (LVFW) were measured by the techniques of Pfeffer et al. (Pfeffer JM, et al., *American Journal of Physiology* 260:H1406-14, 1991) and Jugdutt and Khan (Jugdutt BI, et al., *Circulation* 89:2297-307, 1994). Briefly, the hearts were fixed in distension (30 mm Hg) with 10% phosphate-buffered formalin solution and then cut into 3-mm sections. For each section, the area of normal tissue, scar tissue, and transplanted tissue in the left ventricular free wall were traced onto a transparency and quantified using computerized planimetry (Jandal Scientific Sigma Scan, USA) as described by Wu et al. (Wu TW, et al., *Cardiovascular Research* 27:736-39, 1993). The lengths of left ventricular free wall and scar tissue on both the endocardial and epicardial surfaces of each section were measured. The surface areas of the epicardial and endocardial scar tissue and left ventricular free wall were measured as:

$$(endocardial length + epicardial length) \times \text{section thickness (3 mm)}.$$

The surface area percentage of scar tissue in the left ventricular free wall (LVFW) was calculated as:

$$\frac{(epicardial scar size + endocardial scar size)}{(endocardial LVFW1 + epicardial LVFW)} \times 100$$

To calculate the percentage of the surface area in the scar tissue occupied by the transplanted tissue, the following equation was used:

$$(cardiac tissue length in the scar tissue of each section) \times (\text{section thickness (3 mm)})$$

$$\frac{x100}{(\text{total scar area})}$$

-25-

**E) HISTOLOGY AND ELECTRON MICROSCOPY OF TRANSPLANTED CELLS**

On day 30 or 45 post-transplantation, the animals were anesthetized as in Section 1 and transplant, control, and sham hearts were exposed through a midline sternotomy and quickly harvested. The animals were euthanised by exsanguination  
5 under general anesthesia.

To localize the tissue formed by transplanted cells, the transplanted and control myocardial scar tissues were fixed in 5% glacial acetic acid in methanol. The tissue was embedded in paraffin and cut into 10- $\mu$ m sections. After removal of the paraffin by immersing the sections for 3 minutes in xylene and then in 100%, 95%, 90%, 85%,  
10 and 70% ethanol for 3 minutes each, the samples were stained with haematoxylin and eosin as described by the manufacturer (Sigma Diagnostics, St. Louis, MO), and photographed.

To stain for  $\beta$ -galactosidase activity in the transplanted cardiomyocytes, the heart sections were fixed at 4°C for 12 hours in 2% formaldehyde and 2%  
15 glutaraldehyde in phosphate buffer (0.15 M NaCl and 0.015 M NaH<sub>2</sub>PO<sub>4</sub>, pH 7.2). The transplanted cardiomyocytes were localized by staining for  $\beta$ -galactosidase activity as described earlier in Section B above. The stained tissue was embedded in paraffin and cut into 10- $\mu$ m sections that were stained with haematoxylin and eosin as described above.

20 To identify cultured ventricular and atrial cardiomyocyte transplants, the transplanted heart tissue was immunofluorescently stained for cardiac myosin heavy chain. Briefly, tissue sections were washed three times with phosphate buffered saline and fixed with 2 ml 100% cold methanol at -20°C for 15 minutes. After washing three times with phosphate buffered saline and drying by draining, the tissue sections were exposed for 45 minutes at 37°C to monoclonal antibodies against cardiac myosin  
25 heavy chain (Rougier Bio-Tech, Montreal, Canada), diluted 1:20 with saline. Control tissues were incubated under the same conditions with phosphate buffered saline. The tissues were washed three times with phosphate buffered saline for 15 minutes at room

-26-

temperature with gentle shaking, after which the secondary antibody, rabbit anti-mouse IgG conjugated with fluorescein isothiocyanate at a concentration of 1:32 dilution with phosphate buffered saline, was added. The tissues were incubated with the second antibody under dark and humid conditions for 45 minutes at 37°C. After 5 washing with phosphate buffered saline, the cells in the transplant control tissues were visualized under ultraviolet light using an epi-microscope with a blue filter.

The smooth muscle cell transplants were identified by staining immuno-fluorescently using a monoclonal antibody for  $\alpha$ -smooth muscle actin as the primary antibody. Endothelial cell transplants were identified by immunofluorescent staining 10 for factor VIII, as described in the next section.

Fibroblast transplants were identified by the presence of a localized immunorejection within the ventricular scar.

15 **F) HISTOLOGICAL AND ELECTRON MICROSCOPY STUDIES OF ANGIOGENESIS IN THE GRAFT**

For immunocytochemical staining of factor VIII-related antigen in the vascular endothelial cells, tissue sections processed as in Section E above were incubated with xylene twice for 5 minutes each, 100% ethanol twice for 2 minutes each and then with 70% ethanol twice for 1 minute each. The sections were incubated with rabbit IgG 20 against factor VIII-related antigen (Dimension Lab. Inc., Ontario). The control samples were incubated with phosphate buffered saline under the same conditions. The test and control samples were incubated with goat anti-rabbit IgG conjugated with peroxidase. After washing the samples three times with phosphate buffered saline following secondary antibody staining, the samples were immersed in 25 diaminobenzidine-H<sub>2</sub>O<sub>2</sub> (2 mg/ml diaminobenzidine, 0.03% H<sub>2</sub>O<sub>2</sub> in 0.02 M phosphate buffer) solution for 15 minutes. The samples were washed with phosphate buffered saline. The stained vascular endothelial cells in the grafts (N=17) and control groups (N=14) were counted using a light microscope at 200X magnification. The result was

-27-

expressed as number of blood vessels/field area (0.8 mm<sup>2</sup>).

For electron microscopy studies, hearts were fixed in 1% glutaraldehyde in phosphate buffer, postfixed with 1% osmium tetroxide, dehydrated in graded ethanol (50%, 70%, 90%, and 100%), polymerized in propylene oxide at 60°C overnight, sectioned, and examined using a JEOL 1200 TEM electron microscope (Li R-K, et al., *Cardiovascular Research* 32:362-73, 1996).

5           G) CELL GRAFTS

Cultured cardiomyocytes, smooth muscle cells, endothelial cells, and/or fibroblasts were seeded onto biological mesh, such as a collagen membrane, and on non-biological membranes, such as non-degradable membranes (Dacron) or degradable membranes (polyglycolic acid polymers), and the mesh and cells were cultured in cell culture medium. Seven days after culture, the cell-containing mesh was fixed in 2% formaldehyde and 2% glutaraldehyde in phosphate buffer (0.15 M NaCl and 0.015 M NaH<sub>2</sub>PO<sub>4</sub>, pH 7.2) at 4°C for 12 hours, embedded in paraffin, and cut into 10-μm sections, which were stained with haematoxylin and eosin as described in Section E, and photographed.

10           H) CELL GLUING TECHNIQUE FOR CELL TRANSPLANTATION

A sufficient cardiomyocytes must be implanted into the infarcted myocardium to successfully prevent heart failure. Although this can be done by multiple syringe injections, injecting the cells, unfortunately, limits the number of cells which can be transplanted into myocardial scar tissue. We have investigated another technique to apply a large number of cells onto the infarcted myocardium. Thrombin and cryoprecipitate (fibrin glue), which are derived from human blood, clot rapidly. Our *in vitro* results showed survival and contraction of cardiomyocytes in fibrin clots. We used this fibrin glue for cell transplantation.

1. Gluing Injection Site to Prevent Transplanted Cell Leakage: The biological glue is applied onto the injection site while the injection needle is still in place. The needle is withdrawn after the glue clots. In such manner, leakage of transplanted cells, as discussed previously, is prevented.

5        2. Gluing the Cells onto the Myocardial Scar Tissue to Prevent Injection

Damage: We removed the epicardium over the scar and damaged myocardium. The transplanted cells were suspended in thrombin, and the thrombin/cell suspension was applied onto the myocardial scar tissue with cryoprecipitate (fibrin glue). The glue caused the cell suspension to adhere to the surface of both the scarred and normal myocardium, after which the pericardium was glued on top of the fibrin clot; this procedure prevented loss of the transplanted cells. We found that glued cardiomyocytes can survive on the myocardial scar tissue and permit a large number of cells to be transplanted. This technique improved heart function better than cell injection alone. The cardiomyocytes glued directly onto the myocardium without epicardium can connect with host cardiomyocytes and cardiomyocytes to contract synchronously with the host myocardium.

10        3. Gluing the Cellular Mesh onto the Myocardial Scar Tissue to Prevent Its Expansion: Cell grafts comprising biological or non-biological mesh having cells suspended thereon (as described in Section G) were glued onto the scar tissue. The pericardium was in turn glued on top of the mesh.

15        I) DATA ANALYSIS

Data are expressed as the mean  $\pm$  standard error. The Statistical Analysis System software was used for all analysis (SAS Institute, Cary, NC). Comparisons of continuous variables between more than two groups were performed by a one-way analysis of variance. If the F ratio was significant from the analysis of variance, a Duncan's multiple-range t test was employed to specify differences between the groups. Alpha for these analyses was set at  $p<0.05$ .

Function data were evaluated for the sham, control and transplant groups by an analysis of covariance using intracavitory balloon volume as the covariate and systolic, diastolic and developed pressure as dependent variables. Main effects were group, volume, and the interaction between group x volume. If there was an overall difference in the analysis of covariance, multiple pair-wise comparisons were performed to specify which groups were different. Because there were multiple pair-wise comparisons, a Bonferroni correction was performed and the critical alpha level was set at 0.01 for the analysis of covariance.

10 J) USE OF GROWTH FACTORS IN TREATING IDIOPATHIC HYPERTROPHIC CARDIOMYOPATHY (HCM)

Idiopathic hypertrophic cardiomyopathy (HCM) is a primary cardiac abnormality characterized by regional asymmetrical myocardial hypertrophy. The hypertrophic myocardium can result in obstruction of left ventricular ejection as well 15 as systolic and diastolic dysfunction and myocardial ischemia. Symptoms unresponsive to medical therapy can necessitate surgery.

HCM is described for the most part as a heterogeneous disease of the sarcomeres. At least 34 missense mutations have been described in the  $\beta$ -myosin heavy chain gene, and 7 mutations in candidate loci also exist. However, family 20 studies suggest that the autosomal dominant trait accounts for only 50% of HCM patients. The remaining HCM patients show no familial transmission and the disease occurs sporadically. Myocardial calcium kinetics and sympathetic stimulation have been studied because of diastolic functional abnormalities. However, none of these findings explains the regional myocardial hypertrophy (cardiomyocyte hypertrophy and over production of extracellular matrix proteins) observed in most HCM patients. 25 The etiology of this disease remains unknown. It is thought that growth factors may play an important role in cardiomyocyte proliferation, cell hypertrophy and the overproduction of extracellular matrix.

-30-

To investigate the involvement of growth factors in myocardial hypertrophy in HCM patients, we evaluated gene expression and cellular localization of transforming growth factor  $\beta$ 1 (TGF $\beta$ 1), insulin-like growth factors (IGF-I, -II), and platelet-derived factor-B (PDGF-B) in ventricular biopsies obtained from patients with HCM (N = 8), aortic stenosis (AS, N = 8), stable angina (SA, N = 8), and explanted hearts with ischemic cardiomyopathy (TM, N = 7).

**Methods:** Levels of TGF $\beta$ 1, IGF-I, IGF-II and PDGF-B transcripts were quantitated using multiplex RT-PCR. Glyceraldehyde 3-phosphate dehydrogenase (G3PDH) was used as an internal standard. Antibodies against TGF $\beta$ 1 and IGF-I were used to localize their peptides within the myocardium. Antisense and sense (control) cRNA probes for TGF $\beta$ 1 and IGF-I, labeled with digoxigenin, were used to localize the growth factor transcripts by *in situ* hybridization.

**Results:** mRNA levels (densitometric ratio of GF/G3PDH) of TGF $\beta$ 1 and IGF-I in HCM myocardium ( $0.75 \pm 0.05$ ,  $0.85 \pm 0.15$ , mean  $\pm$  1SE) were significantly ( $p < 0.01$  for all groups) elevated in comparison to non-HCM myocardium (AS:  $0.38 \pm 0.07$ ,  $0.29 \pm 0.06$ ; SA:  $0.32 \pm 0.04$ ,  $0.18 \pm 0.05$ ; TM:  $0.25 \pm 0.03$ ,  $0.15 \pm 0.03$ ). mRNA level of TGF $\beta$ 1 and IGF-I in the hypertrophic AS myocardium were greater ( $p = 0.02$ ,  $p = 0.05$ ) than those in the explanted myocardium (TM).

Immunohistochemical and *in situ* hybridization studies showed increased expression of TGF $\beta$ 1 and IGF-I in the HCM cardiomyocytes.

**Conclusion:** Gene expression of TGF $\beta$ 1 and IGF-I was enhanced in idiopathic hypertrophy and may be associated with its development.

## II) RESULTS

**1. Ventricular and Atrial Cardiomyocytes:** Fetal and adult mammalian ventricular cardiomyocytes and adult mammalian atrial cardiomyocytes were isolated using enzymatic digestion as described above in Sections A1-A3. After purification, the purity of the cultured ventricular and atrial cardiomyocytes was

greater than 94% (N=8) as determined by the percentage of cells that stained for cardiac myosin heavy chain. The cardiomyocytes grew *in vitro*, connected with each other and formed a tissue pattern after six days of culture. The fetal cardiac-like tissue contracted regularly and spontaneously in culture. The adult 5 cardiomyocytes did not contract in culture.

2. Smooth Muscle Cells: Fetal and adult smooth muscle cells were successfully cultured. The cells proliferated in the culture. The cultured cells were stained strongly with antibodies against  $\alpha$ -smooth muscle actin.

10

3. Vascular Endothelial Cells: Endothelial cells were isolated from blood vessel and cultured. Staining with antibody against factor VIII showed that more than 95% cells in the culture dish were endothelial cells.

15

4. Fibroblasts: Fetal and adult skin fibroblasts were isolated and cultured. The cells proliferated in the culture condition. When the culture reached confluence, the cells formed a typical fibroblast pattern: spindle-shaped cells in a wave pattern.

20

5. Cell Transfection: Twenty-four hours after transfection of freshly isolated cells, the percentage of the transfected cells with  $\beta$ -galactosidase was  $18.2 \pm 5.2\%$  (N=6). No cells stained positively in the control groups with plasmid pREP4 (N=6) and without a plasmid (N=6). After culturing for 4 weeks,  $5.4 \pm 3.1\%$  (N=6) of the transfected cells stained positively for  $\beta$ -galactosidase activity.

25

6. Myocardial Scar Tissue: Immediately after myocardial injury,  $25 \pm 3\%$  of the left ventricular free wall (LVFW) was transmurally damaged. The cardiomyocytes were fragmented. At one week, most of the necrosed

-32-

cardiomyocytes were gone and a predominantly mononuclear inflammatory infiltrate was present in the affected area. At two weeks the inflammatory infiltrate had almost disappeared and fibroblasts and collagen deposition were evident. At four and eight weeks, the scar was composed of fibrotic tissue. The tissue was less 5 cellular and lymphocytes were not observed. No cardiac muscle cells were observed in any scar tissue.

The myocardial scar of the left ventricle increased in size over the 8 week study period in the control hearts. Although the scar sizes at 1 and 2 weeks ( $13 \pm 6$  % and  $21 \pm 4$  % of left ventricular free wall) were not statistically different, the 10 scar size after 4 weeks ( $39 \pm 5$  % of left ventricular free wall) was greater ( $p<0.01$ ). At 8 weeks there was a further increase ( $p<0.01$ ) in scar size ( $55 \pm 3$  % of left ventricular free wall).

7. Optimal Time for Cell Transplantation: The fetal rat cardiomyocytes 15 transplanted into myocardial tissue immediately after myocardial damage did not survive in the affected area. The scar area ( $53 \pm 5$  %) of transplanted hearts was similar to that of the control group ( $55 \pm 3$  % of the left ventricular free wall). Cardiomyocytes transplanted at 2 weeks after myocardial damage formed cardiac 20 tissue that occupied 34% of the total scar area ( $11 \pm 3$  % of the left ventricular free wall). Similarly, cardiomyocytes transplanted at 4 weeks occupied 32% of total scar area ( $14 \pm 4$  % of left ventricular free wall). The scar sizes in the hearts that received transplants 2 weeks and 4 weeks after myocardial damage were smaller ( $p<0.01$ ) than the scar size of the control hearts. The scar size of the hearts that received transplants 2 weeks after myocardial damage was smaller ( $p<0.01$ ) than 25 that of the hearts that received transplants 4 weeks after myocardial damage.

8. Transplanted Cells in Myocardial Scar Tissue: Cells were transplanted into transmural scars two and four weeks after scar cryo-induction. Six weeks or

four weeks after ventricular cardiomyocyte transplantation (i.e., eight weeks after scar induction in all animals (N=17)), only fetal cardiomyocyte tissue had formed within the myocardial scar tissue. The cells were connected to each other and formed a cardiac tissue pattern.  $\beta$ -galactosidase activity was observed in the tissue of all three animals transplanted with cardiomyocytes transfected with the  $\beta$ -galactosidase gene. The transplanted cardiomyocytes contained sarcomeres and were connected by junctions composed of desmosomes and fascia adherens, which were not present in the cardiomyocytes immediately prior to transplantation.

5 Lymphocytic infiltration surrounded the cardiac tissue formed by transplanted fetal cardiomyocytes. In the control animals (N=14), cardiac tissue, lymphocytic infiltration, and  $\beta$ -galactosidase activity were not observed in the scar. Eight-week-old scar tissue was less cellular than four-week-old scar tissue.

10

Adult rat atrial cardiomyocytes were autotransplanted into the scar tissue of the same rat. At 6 weeks after transplantation, the transplanted cells were detected in the myocardial scar tissue by staining with an antibody against cardiac myosin heavy chain. There was no lymphocytic infiltration. No cardiac tissue was found

15 in the scar tissue of control rats.

At 6 weeks after transplantation, scars transplanted with either allo- or auto-smooth muscle cells contained smooth muscle tissue that stained positively for  $\alpha$ -smooth muscle actin. The allotransplants were infiltrated with lymphocytes,

20 indicative of immuno-rejection. In contrast, there was no lymphocytic infiltrate or signs of immunorejection in the auto-smooth muscle cell transplant.

Fig. 1 shows the improved cardiac function of scarred hearts transplanted with smooth muscle cells. Hearts were cryo-injured, after which the mature scar tissue was transplanted with allogenic smooth muscle cells. Function measurements were made four weeks after transplantation. The graph shows developed balloon pressures of sham (top line; no cryo-injury, no transplantation), control (bottom line; cryo-injury, no transplantation), and transplanted (middle

25

-34-

line) hearts with increasing balloon volumes. Developed pressures of transplanted hearts were significantly higher than control hearts ( $p=0.0001$ ), but lower than that sham of sham hearts ( $0=0.0001$ ).

At 6 weeks after transplantation, the transplanted fibroblasts proliferated in the myocardial scar tissue. The cells secreted extracellular matrix, which increased the thickness of the scar tissue. The transplanted cells also stimulated angiogenesis (see below), which survived damaged myocardial tissue in the scar tissue. There were no cardiac muscle cells in the scar tissue in control animals. The scar tissue at the left ventricular free wall of the control hearts dilated during systole, whereas scar tissue containing transplanted cells was immobile. Although the surface area of transplanted scar tissue ( $22.9 \pm 6.2 \text{ mm}^2$ ) was similar to that of control scar tissue ( $23.8 \pm 6.5 \text{ mm}^2$ ), scar thickness ( $1.9 \pm 0.9 \text{ mm}$ ,  $N=12$ ) in hearts containing transplanted cells was twice ( $p<0.01$ ) that of the control hearts ( $1.0 \pm 0.4 \text{ mm}$ ,  $N=10$ ). Consistent with the above findings, the left ventricular volume of the transplanted hearts was  $275 \pm 48 \text{ mm}^3$  ( $N=12$ ) which was less ( $p<0.01$ ) than the  $360 \pm 94 \text{ mm}^3$  volume of the control hearts ( $N=10$ ).

Although a detailed observation was not made of transplanted endothelial cells, staining with antibody against factor VIII revealed that more cells stained positively in scar tissue transplanted with endothelial cells than in the control scar tissue.

9. Angiogenesis in Myocardial Scar Tissue after Cell Transplantation: At 4 to 6 weeks after transplantation, examination by histology and electron microscopy showed that angiogenesis occurred in the transplanted fetal ventricular cardiomyocyte transplant. Significantly more arterioles and venules were found ( $p<0.01$ ) in the cardiomyocyte grafts ( $1.2 \pm 0.6 \text{ vessels}/0.8 \text{ mm}^2$ ,  $N=14$ ) than in the control myocardial scar tissue ( $0.1 \pm 0.1 \text{ vessels}/0.8 \text{ mm}^2$ ,  $N=14$ ).

Similarly, angiogenesis occurred in the atrial cell, endothelial cell, smooth

muscle cell, and fibroblast cell transplants.

10. Transplanted Cells Limited Scar Expansion: At 4 to 6 weeks after transplantation of the cells, the heart rate and coronary flow did not differ among the sham, control and transplanted animals. The control myocardial wall at the site of injury had thinned and consisted of fibrous tissue and a few blood vessels. No cardiac muscle or lymphocytes were present. The control and transplanted hearts were larger ( $p<0.01$ ) than the sham (undamaged) hearts. At 4 weeks after cryo-injury,  $36.4 \pm 4.4\%$  (mean  $\pm$  1 SE, N=5) of the left ventricular free wall in the pretransplant animals was replaced with a transmural scar. At 8 weeks, the scar tissue expanded ( $p<0.01$ ) in the control group to  $54.6 \pm 2.9\%$  (N=5) of the free wall for the fetal cardiomyocytes. The scar tissue in the transplanted animals was  $43.4 \pm 1.8\%$  (N=5) of the left ventricular free wall. This did not significantly differ from the pretransplanted animals at 4 weeks after cryo-injury and was less ( $p<0.05$ ) than the control hearts at 8-weeks after cryo-injury. The transplanted cardiomyocytes formed cardiac tissue which occupied  $36.5 \pm 3.5\%$  (N=5) of the scar tissue. The transplanted tissue visibly contracted. We were unsuccessful in measuring its contractility because of the contractions of the heart. After removing the hearts and separating the scar area, the transplanted region continued to contract when stimulated.

Similarly the atrial cell, smooth muscle cell, and fibroblast transplants limited scar expansion.

11. Improvement of Heart Function by Transplanted Cells: Ventricular function of hearts into which cells were transplanted immediately after myocardial injury was similar to that of control hearts. Analysis of covariance demonstrated no interaction between balloon volume and treatment group for developed pressures. Ventricular function of the transplanted and the control hearts when the

-36-

cardiomyocytes were transplanted at 2 weeks after myocardial injury was different because an analysis of covariance demonstrated a significant ( $p<0.05$ ) interaction between balloon volume and treatment group for developed pressures. The transplanted hearts had better ( $p<0.05$ ) function than the control hearts. Similarly cells transplanted at 4 weeks after myocardial necrosis improved ( $p<0.05$ ) myocardial function. The hearts transplanted at 2 weeks had higher ( $p<0.05$ ,  $p<0.05$ ,  $p<0.05$ ) developed pressures at balloon volumes 0.1, 0.2, and 0.3 ml than hearts transplanted at 4 weeks.

In the measurements of ventricular function in the sham-operated, the transplanted and the control hearts, an analysis of covariance demonstrated a significant ( $p<0.05$ ) interaction between balloon volume and treatment group for systolic, diastolic and developed pressures. Pairwise comparisons demonstrated a significant ( $p<0.05$ ) depression in systolic and developed pressures in control animals compared to the sham-operated normal hearts. The transplanted hearts had better ( $p<0.05$ ) function than the control hearts although both systolic pressure and developed pressure were lower ( $p<0.05$ ) than the sham-operated normal hearts. Diastolic pressures were significantly lower in both the cryo-injured controls and the transplanted hearts than sham-operated normal hearts at higher balloon volumes due to the marked dilatation resulting from myocardial scar expansion.

**12. Tissue Engineered Grafts:** Cardiomyocytes, smooth muscle cells, fibroblasts, and endothelial cells were observed in the mesh of the grafts. The tissue that formed in the mesh stained strongly with haematoxylin and eosin.

## **SUMMARY**

From the above results, it can be seen that we have successfully transplanted muscle and non-muscle cells in cardiac scar tissue. These cells formed viable tissue, altered structure of the scar, improved heart function,

stimulated angiogenesis, and expressed a gene foreign to the scar. From these results, the following conclusions are drawn:

5       I. Cultured adult atrial cardiomyocytes could be successfully transplanted into the scar. The atrial tissue could be digested and the atrial cells immediately transplanted, or the atrial tissue could be digested and the resulting atrial cells could be cultured and passaged up to five times and then transplanted. Autologous and allogeneic transplantation of cultured adult atrial cardiomyocytes formed tissue within the scar. Heart function improved and angiogenesis occurred. No 10 immunorejection occurred with auto-transplantation of the adult atrial cardiomyocytes.

15       II. Smooth muscle cells can be successfully auto- or allo-transplanted into the scar. Smooth muscle tissue formed within the scar. No immunorejection occurred with the auto-transplantation. Heart function improved and angiogenesis occurred. The cells can be freshly isolated, or cultured and passaged before transplanting.

20       III. Fibroblasts can be successfully transplanted into scar tissue. Scar thickness increased. Heart function improved, angiogenesis occurred, and host cardiomyocytes survived in the scar. The cells can be freshly isolated, or cultured and passaged before transplanting.

25       IV. The addition of cryo-precipitate to the injection site prevented leakage of the transplanted cells from the scar.

V. A plasmid containing a foreign gene to the scar tissue and heart tissue was transfected into the cultured cells to be transplanted. The cells were

successfully transplanted into the scar tissue and expressed the foreign gene.

VI. Cardiomyocytes, smooth muscle cells, skeletal muscle cells, fibroblasts, and endothelial cells can be successfully transplanted into fibrous membranes and  
5 non-degradable or biodegradable polymers to form tissue. The product of such a process would be a patch which can have various clinical and therapeutic uses.  
Such membranes may be made from Dacron or biodegradable sheets such as polyglycolic acid polymers with or without polylactic acid polymers. Such a patch can be associated with a pacemaker and be implanted close to a cardiac defect,  
10 thereby providing a means of paced cardiomyoplasty.

VII. Cell combinations could be successfully transplanted to form tissue within a scar to improve function, to stimulate angiogenesis, and to form tissue.

15 VIII. The optimal time for transplantation is immediately after the acute inflammatory response to the myocardial injury has disappeared.

IX. Adult mammalian atrial and ventricular cardiomyocytes can be successfully isolated from human myocardium, cultured, passaged and stored  
20 using the cell culture procedure described for human cardiomyocytes described in the Human Cell Isolation, Culturing and Storage section. Human cardiomyocytes can be prepared for long term storage in liquid nitrogen and thawed for culturing as described. Such cultured cells can then be used in forming grafts as discussed above.

25 X. The biological glue technique used in the cell transplantation procedure increased the number of cells transplanted in myocardial scar tissue. This invention enhanced the transplant success rate and maximized the improvement of

heart function.

Co-transplantation of growth factors such as IGF-I, IGF-II, TGF- $\beta$ 1 and PDGF-B increases the survival of transplanted cells, induces transplanted muscle hypertrophy, and stimulates angiogenesis. Based on these findings, the use of other growth factors such as fibroblast growth factor and vascular endothelial growth factor are also possible. Such growth factors can be co-transplanted either alone or in combination. These techniques can increase transplanted muscle size and survival in myocardial scar tissue and damaged myocardial tissue.

XI. Cultured cells can be employed to restore regional cardiac function and blood flow to regions in the heart damaged by acquired disease processes or absent because of congenital defects. During reconstructive surgery, the defective portion of the heart is removed and replaced with inert materials to secure a water-tight seal. Attaching a contracting tissue of myocytes to the reconstruction patch will permit the return of function to the destroyed region. Implantation of a collection of cells could restore function and improve the quality of life of the patients undergoing reconstructive surgery.

XII. Most acquired or congenital cardiac defects are closed with inert materials intended to provide a water-tight seal. Instead of an inert material, a graft consisting of a biodegradable or non-biodegradable scaffolding supporting cultured cells can be employed to close such cardiac defects. The graft would employ myocytes enhanced with genes to increase perfusion and contractility (by increasing the size and number of myocytes). In addition, endothelial cells can be applied to the blood surface of the graft to prevent intravascular clot formation in the heart. The endothelial cells could be genetically engineered so that they produce proteins that prevent clot formation on the blood surfaces. The cellular grafts will permit closure of acquired and congenital cardiac defects with

-40-

functioning tissue which may improve heart function.

XIII. Cardiac surgeons frequently remove segments of the heart which have been damaged or are defective due to congenital abnormalities. A cellular graft permits an opportunity to restore function to regions which are usually closed with inert materials. The graft may consist of myocytes grown on biodegradable scaffolding. Endothelial cells can be grown on the blood interface layer. The cells will create a functioning graft which will replace the region removed at the time of surgery. The functioning myocardial graft could restore function for patients who have suffered a myocardial infarction and require removal of the destroyed regions. The functioning graft could re-establish systematic and/or pulmonary circulation for patients with extensive congenital defects undergoing reconstructive surgery. A functioning myocardial graft offers the promise of improving the quality of life for disabled individuals.

15

### **III) EFFECT OF DONOR AGE ON CONTRACTILITY OF TRANSPLANTED RAT CARDIOMYOCYTES**

The inability of heart muscle to regenerate following myocardial necrosis is an important clinical problem. Our previous research has shown survival and contractility of transplanted fetal rat cardiomyocytes (CMs) in adult rat skeletal muscle. The experiment described below focuses on the effect of donor age on contractility of transplanted CMs.

#### **Methods:**

25 CMs were isolated from 18-day gestation, 5-, 22-, 32-, and 62-day old Sprague-Dawley rat hearts and cultured for 1 day. 2 to 5 x 10<sup>6</sup> cells in saline were injected into the skeletal muscle of one adult rat leg. The other leg (control) was injected with saline alone. Cell viability and function were assessed visually and

-41-

by ultrasound and electrocardiography (ECG).

**Results:**

In the groups with transplanted fetal (n=12) and neonatal (n=4) CMs, rhythmic contractions ( $73 \pm 12$  beats/min (n=11) and  $43 \pm 21$  beats/min (n=3)) were found only in the transplanted area. These contractions were not observed in the control legs. Contractions were not observed at sites transplanted with CMs from 22-, 32-, and 62-day donor animals (n=4 for all groups).

**Conclusion:**

Donor age is important for maintaining contractility of CMs after transplantation into skeletal muscle.

**IV) INDUCTION OF ANGIOGENESIS BY ENDOTHELIAL CELLS  
TRANSPLANTED INTO MYOCARDIAL TRANSMURAL SCARS DID  
NOT IMPROVE CARDIAC FUNCTION IN INFARCTED HEARTS.**

We speculated that artificial induction of angiogenesis might improve perfusion, alleviate angina and restore cardiac function in cases where revascularization does not occur spontaneously after myocardial infarction (e.g., in scar tissue). The present study evaluated whether allogenic and syngenic endothelial cells transplanted into myocardial scar tissue induce new blood vessel formation and whether angiogenesis (if any) induced by transplanted cells affects the function of the scarred heart. The effect of transplanted cells upon blood vessel formation in myocardial scar tissue has not been studied previously.

**Methods and Results:** Transmural scars were produced at the left ventricular free wall of adult rats hearts by cryo-injury. Two weeks later, cultured adult rat aortic endothelial cells (transplanted group) or culture media (control

-42-

group) were injected into the myocardial scars of rats immunosuppressed with cyclosporin A (25mg/kg/day). Transplanted cells were observed at transplanted sites at day 1 and 7, but not at day 14 (n=2). At 6 weeks after transplantation, the number of capillaries in the scars of the transplanted group ( $3.4 \pm 2.0$ , n=10) was greater (p<0.01) than that in the control group ( $1.0 \pm 0.6$ , n=9). Blood flow measured by radioactive  $^{57}\text{Co}$  labeled microspheres was greater (p<0.01) in the transplanted group ( $6.85 \pm 2.27\%$ , n=9) than in the control group ( $3.78 \pm 0.99\%$ , n=8). There was no difference in scar size and heart function between two groups measured by planimetry and Langendorf preparation.

**Conclusion:** Angiogenesis was induced in the scar tissue by endothelial cell transplantation. Since no myocytes were present in the scar, cardiac function did not improve. However, endothelial cell transplantation in patients with incomplete infarction may restore perfusion, relieve angina and restore function.

## **Methods**

**Experimental Animals:** All procedures performed on animals were approved by the Animal Care Committee of The Toronto Hospital. Experiments were performed according to the "Guide to the Care and Use of Experimental Animals" published by the National Institutes of Health (NIH publication 85-23, revised 1985). Sprague-Dawley rats (Charles River Canada Inc, Quebec, Canada) were used for allogenic transplantation. Male rats, weighing 330 to 360 g, were used as recipients and donors of endothelial cells. Sygenic Lewis rats (Male, 250-300 g, Charles River Canada Inc, Quebec, Canada) were used for autologous transplantation.

**Cell Isolation and Culture:** Endothelial cells from rat aorta were isolated and cultured as previously described (Mickle et al., *J. Mol. Cell. Cardiol.* 22:1297-1304, 1990). In brief, descending thoracic aortic segments were obtained from rats under general anesthesia, as described in the next section. The blood vessels were

-43-

washed with phosphate buffered saline solution (PBS; composition in mmol/L: NaCl 136.9, KCl 2.7, Na<sub>2</sub>HPO<sub>4</sub> 8.1, KH<sub>2</sub>PO<sub>4</sub> 1.5, pH 7.3) and connective tissue was removed. The aortic segment was then flushed with enzyme solution (0.1% collagenase and 0.2% trypsin in PBS) and incubated with the enzyme solution for 5 30 minutes at 37°C. After incubation, endothelial cells were isolated by flushing the inside of aortic segments with culture medium (Medium 199 containing 20% fetal bovine serum, 100U/ml of penicillin, 100 µg/ml of streptomycin, and 0.5% heparin salt) three to five times. The isolated cells were cultured at 37°C in 5% CO<sub>2</sub> and 95% air in culture medium.

10        *Cell Identification:* The purity of endothelial cell cultures was confirmed by a immunohistochemical stain using antibody against factor VIII-related antigen as previously described (Mickle et al., *J. Mol. Cell. Cardiol.* 22:1297-1304, 1990). In brief, the cultured endothelial cells were fixed in methanol for 15 minutes at -20°C. After washing three times with PBS, the cells were incubated with rabbit 15 immunoglobulin G against factor VIII-related antigen (Dimension Laboratory, Inc) at 37°C for 45 minutes. After incubation, the cells were washed three times (15 minutes per wash) with PBS, then incubated with goat anti- rabbit immunoglobulin G conjugated with peroxidase at 37°C for 45 minutes, washed three times (15 minutes per wash) with PBS, and immersed in diaminobenzidine-H<sub>2</sub>O<sub>2</sub> (2mg/ml diaminobenzidine, 0.03% H<sub>2</sub>O<sub>2</sub> in 0.02ml/l phosphate buffer) solution for 15 20 minutes. After a final wash in PBS, the samples were photographed.

25        *Quantitation of VEGF Protein Levels in Cultured Endothelial Cells and Secreted by Cultured Cells:* Purified endothelial cells were cultured in cell culture medium for 3 days. The supernatants (n=5) were collected, centrifuged at 14,000 g for 10 min. to remove cell debris, and were saved for protein quantitation. The cultured cells (n=5) were washed 3 times with PBS and collected by scraping with a cell scraper. After centrifugation at 580 g for 3 min., the cell pellets were resuspended in 1 ml of PBS and sonicated for 1 min. The samples were

centrifugated at 14,000 g for 10 min., and the supernatants were collected for protein quantitation. The protein concentration was measured using the Bio-Rad protein assay (Bio-Rad, Richmond, CA). VEGF protein levels in culture medium and endothelial cells were quantitated by chemiluminescent slot blot analysis.

5 Culture medium incubated without cells was used as a control. Forty micrograms of protein from culture medium or from cultured endothelial cells were loaded onto a 0.2 µm nitrocellulose membrane (Schleicher & Schuell Inc., Keene, NH) using the Minifold II Slot Blotting System (Schleicher & Schuell Inc., Keene, NH). Standards of VEGF (2, 5, 10, 25 ng) (Sigma, Mississauga, ONT, Canada) were

10 loaded on the same membrane. After drying at room temperature for 10 minutes, the membrane was washed twice in TTBS buffer (50 mM Tris-HCl buffer pH 7.4 and 0.1% of Tween-20) for 5 minutes. Subsequently, the membrane was treated for 60 minutes with blocking buffer (Boehringer Mannheim, GmbH, German).

15 Monoclonal antibodies against VEGF (Sigma, Mississauga, ONT) (1:3000, diluted with 0.5X blocking buffer) were added and incubated overnight at 4°C.

After washing twice with TTBS for 5 minutes each, the membrane was incubated with goat anti-mouse-HRP conjugated antibody (1:3000 dilution) (Bio-Rad Laboratories, Hercules, CA) for 60 minutes at room temperature. The membrane was again washed twice with TTBS (10 minutes per wash). VEGF proteins were

20 detected by chemiluminescence using the Boehringer Mannheim detection kit (Quebec, Canada). A densitometric analysis of the standard and sample bands was performed with a Bio-Rad image analysis system (Bio-Rad, Hercules, CA).

Standard curves of VEGF were generated and VEGF quantity in culture medium and cultured endothelial cells was calculated based on the standard curve. The

25 results (mean ± SD) are expressed as ng of VEGF/mg protein.

*Preparation of Cells for Transplantation:* Cultured endothelial cells were passaged twice before transplantation to increase the number of cells. Prior to transplantation, the cultured endothelial cells were detached from culture dish with

-45-

0.05% trypsin in PBS. After centrifugation in 580g for 3 minutes, the cell pellets were resuspended in culture medium at a concentration of  $1.0 \times 10^6$  cells/10  $\mu$ l. A 60  $\mu$ l cell suspension was used for each transplantation.

*Myocardial Scar Formation:* Rats were anesthetized by intramuscular injection of ketamine hydrochloride (20 mg/kg body weight) followed by intraperitoneal injection of sodium pentobarbital (30 mg/kg body weight). The anesthetized rats were intubated and positive pressure ventilation was performed with room air supplemented with oxygen and isoflurane (0.2-1.0%) using a Harvard ventilator. Rats were monitored by electrocardiogram during each operation.

The heart was exposed through a 2- to 3-cm left lateral thoracotomy incision. Cryo-injury was produced in the left ventricular free wall (LVFW) with a metal probe (8 X 10 mm in diameter) cooled to -190°C by immersion in liquid nitrogen. It was applied to the LVFW for one minute and this procedure was repeated ten times. The muscle and skin were closed with 3-0 silk sutures. Penlong XL (benzathine penicillin G 150,000 U/ml and procaine penicillin G 150,000 U/ml) was given intramuscularly (1ml/kg) and buprenorphine hydrochloride (0.01mg/kg) was administered after each operation. The cryoinjured rats were randomly divided into two groups: transplantation and control.

*Endothelial Cell Transplantation:* At two weeks after cryo-injury, cell transplantation was performed. Under general anesthesia, the heart was exposed through a midline sternotomy. An Endothelial cell suspension ( $6 \times 10^6$  cells in 60  $\mu$ l) was injected into the center of the scar tissue in the transplantation group using a tuberculin syringe, and the same amount of culture media was injected into the scar tissue in the control group. The chest was closed with 3-0 silk sutures and antibiotics and analgesics were administered as described above. Cyclosporine A (25 mg/kg/day) was administered subcutaneously to both transplanted and control groups.

*Identification of Transplanted Endothelial Cells:* The transplanted cells were identified in two ways.

(1) At day 1, 7, and 14 post transplantation, two rats from transplanted and control groups were sacrificed by exsanguination under general anesthesia. The hearts were fixed in with 10% phosphate-buffered formalin solution for 2 days and cut into 3-mm sections. The sections were fixed in 5% glacial acetic acid in methanol, embedded in paraffin, and cut to yield 10- $\mu$ m sections which were stained with hematoxylin and eosin as described by the manufacturer (Sigma Diagnostics, St. Louis, MO).

(2) The transplanted cells also were identified by detection of green fluorescent protein expressed by the transplanted cells. At 2 days pre-transplantation, cultured endothelial cells were lipofectamine-transfected with a plasmid encoding green fluorescent protein. The transfected cells were cultured, harvested and transplanted as described above. At end of the study, monoclonal antibodies against green fluorescent protein were used to localize the transplanted endothelial cells by avidin-biotin-peroxidase complex technique (Hsu, S.M. *Am. J. Pathol.*, 75:816-821, 1981). Briefly, sections were incubated with a solution of 3% H<sub>2</sub>O<sub>2</sub> in 70% methanol for 30 minutes to inhibit endogenous myocardial peroxidase. Nonspecific protein binding was blocked with 2% normal goat serum in 0.05 M Tris buffer (pH 7.4) for 15 minutes, primary antibodies against green fluorescent protein (Cedarlane Lab., Hornby, Ontario, Canada) were added and the samples were incubated at 37°C for 30 minutes followed by an overnight incubation at 4°C. Negative control samples were incubated in PBS (without the primary antibodies) under the same conditions. After washing with PBS (three times for 5 minutes each), a biotin-labeled secondary antibody (1:250, Vector Lab. Inc. Burlingame, CA) was added and the specimens were incubated at room temperature for 1 hour. The samples were rinsed 3 times for 5 minutes each in fresh PBS and reacted with an avidin-biotin complex conjugated with peroxidase

at room temperature for 45 minutes. Visualization was performed with a diaminobenzidine solution (0.25 mg/ml in 0.05 Tris-HCl buffer containing 0.02% H<sub>2</sub>O<sub>2</sub>) for 10 minutes. The samples were then covered with crystal mounts and photographed.

5           *Blood Flow Measurement with Radionuclide-labeled Microspheres:* At six weeks after transplantation, blood flow to the normal and scar tissue in the transplanted (n=9) and control groups (n=8) was measured using radionuclide-labeled microspheres (Pang, C.Y. *Plastic and Reconstructive Surgery* 74(4):513-521, 1984). Rats were anesthetized and heparin sodium (200 units) was 10 then administered intravenously. Hearts were excised and perfused in a Langendorf apparatus with 0.9% saline solution to wash out all blood cell remnants in the coronary vascular bed. Ten ml of 20 mEq KCl solution was injected through the coronary arteries to arrest the heart completely, and the heart was perfused with 0.9% saline solution for 10 minutes.

15           <sup>57</sup>Co-labeled microspheres (5 uCi, New England Nuclear, Boston, MA) were suspended in 2 ml of 0.9% saline containing 5% sucrose and 0.05% Tween 80. The suspension was vortexed vigorously for 2 minutes immediately before injection. The microspheres were infused over a 5 second period through a needle connected to the ascending aortic root.

20           Ventricles were dissected into normal tissue, scar tissue, and tissue in the borderline area. Each section was weighed and the radioactivity was then determined using a gamma counter at the window setting of 110 to 138 KeV. The data was expressed as counts per minute (cpm)/mg of tissue. The ratio of cpm/mg in scar and borderline tissue to normal tissue was calculated, expressed as the 25 percentage, and compared between transplanted and control hearts.

*Heart Function Measurement:* Six weeks after transplantation, heart function in transplanted (n=10) and control (n=9) groups was measured using a Langendorf preparation (Stephen, S.E. *Annals of Thoracic Surgery* 59:1127-1133,

-48-

1995). Rats were anesthetized and heparin sodium (200 units) was administered intravenously. Hearts were quickly isolated and perfused at 37°C in a Langendorf apparatus with filtered Krebs-Hanseleit buffer (mmol/L: NaCl 118, KCl 4.7, KH<sub>2</sub>PO<sub>4</sub> 1.2, CaCl<sub>2</sub> 2.5, MgSO<sub>4</sub> 1.2, NaHCO<sub>3</sub> 25, glucose 11, pH 7.4) equilibrated with 5% carbon dioxide and 95% oxygen at a pressure of 100 cm H<sub>2</sub>O. A latex balloon was inserted into the left ventricle through the mitral valve and connected to a pressure transducer (Model p10EZ; Viggo-Spectramed, Oxnard CA) and a transducer amplifier and differentiator amplifier (Model 11-G4113-01; Gould Instrument System Inc, Valley View OH).

10 After 20 minutes of stabilization, the coronary flow was measured by the timed collection in the empty beating state. The balloon size was increased in 0.02 ml increments from 0.04 to 0.6 ml by the addition of saline solution. The systolic and end-diastolic pressure and maximal and minimal dp/dt were recorded at each balloon volume. The developed pressure was calculated as the difference between  
15 the systolic and end-diastolic pressure.

*Measurement of Left Ventricular Remodeling:* The epicardial and endocardial surfaces of the normal and scar tissue in the LVFW were measured by the technique of Pfeffer (*Am. J. Physiol.* 260:H1406-14, 1991) and Jugdutt and Khan (*Circulation* 89:2297-307, 1994). Briefly, the hearts were fixed in distension (30 mmHg) with 10% phosphate-buffered formalin solution for 2 days. The atria were excised, the ventricular weight and the size of the scar on epicardial surface were measured, and ventricular volume was measured by water displacement.  
20 After that, the hearts were cut into sections of 3 mm thickness. For each section, the area of normal and scar tissue in the LVFW were traced onto a transparency and quantified using computed planimetry (Jandal Scientific Sigma-Scan, Corte Madera, CA). The lengths of LVFW and scar tissue on both the endocardial and epicardial surfaces of each section were measured. The surface areas of the endocardial and epicardial scar tissue and the LVFW were measured as the sum of  
25

-49-

the endocardial length and epicardial length times the section thickness (3mm). The surface area percentage of scar tissue in the LVFW was calculated as follows: (endocardial scar size+epicardial scar size)/(endocardial LVFW+epicardial LVFW) X 100.

5       *Measurement of Capillaries in Scar Tissue:* The heart sections were used for immunohistochemical staining of endothelial cells. The sections were incubated with xylene twice for 5 minutes each, 100% ethanol twice for 2 minutes each, and then with 70% ethanol twice for 1 minute each. The sections were incubated with rabbit immunoglobulin G against factor VIII-related antigen and 10 endothelial cells were identified as described in the *Cell Identification* section above. The stained vasculoendothelial cells in the transplanted and control groups were counted using a light microscope at 400X magnification. The result was expressed as the number of capillary vessels/field.

15      *Syngeneic endothelial cell transplantation:* To evaluate angiogenesis induced by transplanted endothelial cells in the absence of an inflammatory reaction, endothelial cells isolated from adult Lewis rat aorta were transfected and transplanted into myocardial scar tissue of syngeneic rat hearts (n=5) two weeks after the scarring procedure. The transplanted cells were identified in the scar tissue at 6 weeks after transplantation by immunohistochemical staining. The 20 number of capillaries in the scar areas of transplanted and control hearts was counted and compared. All the procedures performed on these animals were same as described above, except that cyclosporine was not administered after cell transplantation.

25      *Statistical Analysis:* Data were expressed as the mean  $\pm$  standard error. Statistical Analysis System software was used for all analysis (SAS Institute, Cary, NC). Student's t-test was used for comparison of the results. Cardiac function data were evaluated for the transplantation and control groups using intracavitory volume as the variant factor and systolic, end-diastolic, and developed pressure as

dependent variables.

### Results

Cultured endothelial cells were distinguished from fibroblasts and vascular smooth muscle cells by morphologic criteria and growth characteristics. The endothelial cells were oval-shaped, in contrast to the spindle-shape of cultured fibroblasts and vascular smooth muscle cells. Cultured endothelial cells grew in a "cobblestone" pattern whereas fibroblasts grew in a "whirling" pattern and vascular smooth muscle cells grew in a "hill and valley" pattern. In addition, cultured endothelial cells stained positively for factor VIII-related antigen. The purity of the culture to be transplanted was more than 95%.

We found that cultured vascular endothelial cells contained VEGF (0.007 and 0.005 ng/µg of cell protein, N=2). The VEGF molecules in the cultured cells were secreted into cultured medium: VEGF protein levels (0.331 and 0.229 ng/50 µl, N=2) in conditioned medium (i.e., in which cells were cultured) was greater than in medium not exposed to endothelial cells (0.143 ng/50 µl, N=1).

At one day after transplantation, two rats in the transplanted group were sacrificed in order to identify transplanted cells. A large endothelial cell cluster was observed within each scar. There was no increased capillary network around the cell clusters compared with control rats.

At one week after transplantation, there were some capillaries around the transplanted endothelial cell cluster within each scar. The size of the endothelial cell cluster was, however, much smaller than that observed one day after transplantation.

At two weeks after transplantation, there were more capillaries within the scar but the endothelial cell cluster was no longer present.

Six weeks after transplantation, the number of blood vessels in the scar tissue of the transplanted group ( $3.4 \pm 2.0$  vessels/ $0.8\text{ mm}^2$ , n=10) was significantly

-51-

greater ( $p<0.01$ ) than within control (non-transplanted) scars ( $1.0 \pm 0.6$ ,  $n=9$ ). Most of the blood vessels were capillaries without smooth muscle components. In agreement with the number of blood vessels, the blood perfusion (represented as microsphere count) in the scar tissue of transplanted hearts ( $6.85 \pm 2.27\%$  of normal myocardium) was greater ( $p<0.01$ ) than that of control hearts ( $3.78 \pm 0.99\%$ ) (Fig. 2).

In syngeneic cell transplantation, the transplanted cells also induced angiogenesis in the myocardial scar tissue. The density of capillaries in the scar tissue of the transplanted group was  $2.6 \pm 1.5$  vessels/ $0.8\text{mm}^2$ , which was significantly ( $p<0.01$ ) greater than that in the control group ( $1.1 \pm 0.6$ ). Transplanted endothelial cells were incorporated into capillaries at the transplant site.

In morphological studies of the hearts, there was no difference, between transplanted and control groups, in body weight and in the weights of the heart, left ventricle, and scar. Ventricular volume in transplanted hearts was similar to that of control hearts. The size of the scar tissue in the transplanted group was also similar to that of the control group (Table 1).

There were no statistically significant differences in systolic and developed pressures between transplanted and control hearts (Figs. 3 and 4), and no differences in coronary flow and heart rate (Table 1).

**Table 1. Hemodynamics and heart dimensions in transplantation and control groups<sup>(a,b)</sup>**

Group	Coronary flow	Heart rate	Ventricular weight	Ventricular volume	Scar size
	(ml/min)	(bpm)	(g)	(ml)	(mm <sup>2</sup> )
Transplant	20.9+/-4.36	279+/-15	1160+/-168	1.86+/-0.27	109+/-19
Control	21.9+/-3.82	289+/-19	1150+/-137	1.79+/-0.21	110+/-19

<sup>a</sup> Data are shown as the mean +/- standard error

<sup>b</sup> There were no significant differences in all parameters between two groups.

-53-

5       The transplanted endothelial cells stimulated angiogenesis, demonstrated by an increase in the number of capillaries in the scar tissue and increased blood perfusion in scar tissue as illustrated by microsphere perfusion studies. However, the induced angiogenesis in transmural scar tissue did not improve infarcted heart function.

10      There are three possible mechanisms of increased angiogenesis by endothelial transplantation: (1) formation of blood vessels by transplanted endothelial cells; (2) angiogenesis stimulated by growth factors secreted by transplanted endothelial cells; (3) angiogenesis stimulated by an inflammatory reaction induced by transplanted endothelial cells.

15      Endothelial cells are the most important component for blood vessel formation. Our *in vivo* study showed that transplanted endothelial cells become part of newly formed capillaries in syngeneic cell transplantation. These data suggested that transplanted endothelial cells are involved in blood vessel formation. However, the data obtained from allogeneic endothelial cell transplantation suggested that newly formed capillaries in the scar tissue were grown from recipient heart endothelial cells. We found transplanted cells at 1 and 7 days after transplantation, but did not observe transplanted cells after 14 days post-transplantation. Additional evidence of this conclusion is that there was no immunologic reaction around capillary vessels in the scar. If the transplanted allogenic endothelial cells become part of the newly formed capillaries, lymphocyte infiltration should have been observed around the blood vessel. These data illustrate that transplanted endothelial cells are involved in new blood vessel formation and also stimulate angiogenesis. In the latter situation, angiogenic factors secreted by transplanted cells may play an important role in this process.

20      Angiogenesis in our animal model might also be stimulated by inflammatory reactions. Although syngeneic endothelial cell transplantation has shown that angiogenesis occurs without inflammatory reaction, factors released

-54-

by inflammatory cells might play a role in blood vessel formation induced by allogenic endothelial cell transplantation. Capillary density in scar tissue subjected to allogenic cell transplantation was 1.3 time greater than that subjected to syngeneic cell transplantation. This difference in capillary density may be due to 5 lymphocyte infiltration.

Although blood flow was increased by endothelial cell transplantation in our experimental model, increased blood flow did not have any effects on left ventricular remodeling and function. We found muscle cells in the scar tissue of a few hearts but the number of the muscle cells may not be sufficient to improve 10 heart function. There were no differences in heart volume, heart weight, and scar size between transplanted and control hearts. In the analysis of function, there were no differences in heart rate, coronary flow, systolic and developed pressures between two groups.

We observed that the 2 week old scar was less mature and contained more 15 blood vessels and fibroblasts than 4 week old scar, which was firm connective tissue. In addition, we found that cardiomyocyte transplantation was most successful after the inflammatory reaction resolved and before significant scar expansion and ventricular dilatation occurred.

The finding of increased angiogenesis in transmural scars induced by 20 endothelial cell transplantation gives rise to a new technique for induction of angiogenesis. We observed an increased number of capillary vessels within the scars of rat hearts that were transplanted with endothelial cells. In contrast, we observed an increased number of arterioles and venules in scars transplanted with fetal cardiomyocytes. If endothelial cells and cardiomyocytes are co-transplanted 25 into myocardial scars and endothelial cells augment the blood flow into the transplanted area, the survival and function of transplanted cardiomyocytes might be enhanced. It would be possible to obtain ventricular cardiomyocytes from transvenous endomyocardial biopsy and endothelial cells from saphenous vein or

-55-

omental fat and culture those cells for subsequent autologous co-transplantation.

In addition to morphologic evidence of increased angiogenesis, we demonstrated that blood flow to scar tissue was increased. Because there was usually adhesion between the scar area and the chest wall from the previous two operations (scarring and transplantation), blood flow to the scar area may result from two sources, one from coronary arteries and the other from the chest wall by non-coronary collateral vessels produced by adhesion. If blood flow from chest wall adhesion is counted together with blood flow from coronary artery, it obscures the effect of angiogenesis *per se* on blood flow to the scar area.

Therefore, we injected microspheres into isolated heart preparations, although for actual blood flow estimation, injection of microspheres into left atrium or left ventricle *in vivo* may be more physiological. Because there were areas of non-transmural infarction in the periphery of the cryoinjured lesions, the left ventricular free wall was divided into three parts: normal area, transmural infarct area, and borderline area. The blood flow to the borderline areas was always between that of the normal and complete transmural infarct area.

**V) OPTIMAL TIME FOR CARDIOMYOCYTE TRANSPLANTATION  
FOR MAXIMIZING MYOCARDIAL FUNCTION AFTER LEFT  
VENTRICULAR NECROSIS**

After myocardial infarction, damaged myocardium undergoes both acute and chronic inflammatory reactions. During this process, the necrosed cardiac cells are replaced with fibrotic tissue and ventricular remodeling progresses. Ventricular pressure stretches and thins the healing area and ventricular dilatation occurs. A ventricular aneurysm may form and congestive heart failure may result. Limitation of post-infarction ventricular remodelling is important to prevent expansion and thinning of the infarct region and thinning, and progressive ventricular dilatation, which results in congestive heart failure. The addition of

cardiac tissue to replace the scar tissue may prevent infarct thinning and preserve chamber size and ventricular function. We had shown that fetal cardiomyocytes transplanted into a LVFW scar formed cardiac tissue and improved myocardial function. Transplantation was arbitrarily performed at 4 weeks after cryo-necrosis of the LVFW when ventricular dilatation was already present. However, the optimal time for cardiomyocyte transplantation to provide the best ventricular function is important. The acute inflammatory reaction could destroy the transplanted cardiomyocytes that are introduced too soon after myocardial infarction. On the other hand, cardiomyocyte transplantation after significant scar expansion may be of limited benefit. Therefore, the present study investigated the optimal time for cell transplantation after myocardial injury.

### Summary

#### *Methods:*

(1) Scar expansion studies: The rats were sacrificed at 0, 1, 2, 4, and 8 weeks after cryo-injury and the scar area was measured by planimetry (N=7 each).

(2) Transplantation studies: Fetal rat cardiomyocytes (transplant) or culture medium (control) were transplanted immediately (N=8 each), 2 weeks (N=8 each) and 4 weeks (N=12 each) after cryo-injury. At 8 weeks after cryo-injury, rat heart function was evaluated using a Langendorff preparation. Scar and transplanted cardiomyocytes were assessed histologically.

#### *Results:*

(1) A transmural injury occurred immediately after cryo-injury. An inflammatory reaction was more evident at 1 week than 2 weeks. Although the scar size did not significantly change between week 1 and 2, it expanded ( $p<0.01$ ) at 4 and 8 weeks.

(2) At 8 weeks after myocardial injury, cardiomyocytes transplanted immediately after myocardial injury were not found in the myocardial scar tissue.

-57-

Scar size and myocardial function were similar to those of the control hearts. Cardiomyocytes transplanted at 2 and 4 weeks formed cardiac tissue, which occupied 34% and 31% of total scar area, respectively, and limited ( $p<0.01$ ) scar expansion compared to control hearts. Both transplant groups had better ( $p<0.001$ ,  $<0.001$ ) heart function than the control groups. Developed pressure was greater ( $p<0.01$ ) in the hearts transplanted cells at 2 weeks than at 4 weeks.

5            *Conclusion:*

Cardiomyocyte transplantation was most successful after the inflammatory reaction resolved and before significant scar expansion and ventricular dilatation 10 occurred.

15            Material and Methods

*Experimental animals:* All procedures performed on animals were approved by the Animal Care Committee of The Toronto Hospital. Experimental animals used were male Sprague-Dawley rats (Lewis, Charles River Canada Inc. Quebec, Canada), weighing 450 grams. Cardiomyocytes obtained from 18-day gestational rat hearts were cultured prior to transplantation. All experiments were performed according to "A Guide to the Care and Use of Experimental Animals" of the Canadian Council on Animal Care and the "Guide for the Care and Use of 20 Laboratory Animals" NIH publication 85-23, revised 1985).

*Myocardial scar generation and evaluation:* Myocardial scar tissue was generated as described in the examples above. Briefly, rats were anesthetized with ketamine (22 mg/kg body weight, intramuscular) followed by an intraperitoneal injection of pentobarbital (30 mg/kg body weight). The anesthetized rats were 25 intubated and positive pressure ventilation was maintained with room air supplemented with oxygen (6 L/minute) using a Harvard ventilator (Model 683, South Natick, MA, USA). The rat heart was exposed through a two cm left lateral thoracotomy. Cryo-injury was produced at the left ventricular free wall (LVFW)

with a liquid nitrogen probe. The muscle layer and skin were closed with 5-0 vicryl sutures. The rats were monitored for 4 hours postoperatively. Penlog XL (benzathine penicillin G 150,000 U/ml and procaine penicillin G 150,000 U/ml) were given intramuscularly (0.25 ml/rat) every three days for 1 week after surgery and buprenorphine (0.01-0.05 mg/kg body weight) was administrated subcutaneously every 8 to 12 hours for the first 48 hours following surgery.

The LVFWs of 35 animals were cryo-injured. Immediately after cryo-injury and at 1, 2, 4, and 8 weeks after injury, 7 animals chosen at random were sacrificed under general anesthesia (see Fig. 5 (top) for a schematic diagram of the experimental design). The hearts were then fixed in distension (30 mm Hg) with 10% phosphate-buffered formalin solution for 24-48 hours and then cut into 3-mm sections. All sections were used for assessment of myocardial and scar sizes. For each section, the area of scar tissue in the LVFW was traced onto a transparency and quantified using computerized planimetry (Jandal Scientific Sigma Scan, Fairfield, CT., USA). Scar length was calculated as the average of endocardial scar length and epicardial scar length. Scar area was calculated as the scar length X section thickness (3mm). The total scar area in size was calculated as the sum of the scar areas for all of the tissue sections showing scars. The LVFW myocardial size was calculated using the same equation. The percentage of the LVFW occupied by the scar was calculated as scar size/LVFW size X 100.

*Histological studies:* The fixed heart sections were embedded in paraffin and cut to yield 10- $\mu$ m sections. The sections were stained with haematoxylin and eosin as described by the manufacturer (Sigma Diagnostics, St. Louis, MO).

*Cell culture and preparation for transplantation:* Cardiomyocytes from fetal rat hearts were isolated, purified and cultured as previously described (Li, R-K, et al. *J. Tissue Culture Methods* 14:93-100, 1992). Briefly, the cells were cultured for 24 hours in Iscove's modified Dulbecco's medium containing 10% fetal bovine serum, 100 U/ml penicillin and 100 ug/ml streptomycin at 37°C, 5 %

-59-

CO<sub>2</sub> and 95% air. The cultured cardiomyocytes were detached from the cell culture dish with 0.05% trypsin in phosphate-buffered saline (PBS). After centrifugation at 580 X g for 3 minutes, the cell pellet was resuspended in culture medium at a concentration of 16 X 10<sup>6</sup> cells/ml. A 0.25 ml cell suspension was used for each transplantation.

Cardiomyocyte transplantation: The LVFW of 56 adult rat hearts were cryo-injured as described above. The animals were randomly divided into 3 groups (see Fig. 5, bottom). In group one, 8 animals were transplanted with cultured cardiomyocytes (transplant) and 8 animals were transplanted with culture medium (control) immediately after myocardial injury. In group two, animals were transplanted either with cells or with culture medium (N=8 each) 2 weeks after myocardial injury. In group three, animals (N=12 each) were transplanted with either cells or culture medium 4 weeks after myocardial injury. All animals were maintained 8 weeks after the transplant procedure, after which they were sacrificed for histological and functional studies.

Under general anesthesia, the hearts were exposed through a midline sternotomy. A fetal rat cardiomyocyte suspension (4 X 10<sup>6</sup> cells in 0.25 mls) or culture medium (0.25 ml) was injected once into the center of the scar tissue of the transplanted and control animals, respectively, using a tuberculin syringe. The chest was closed with 5-0 vicryl sutures. Antibiotics and analgesics were given as described in the "Myocardial Scar Generation and Evaluation" section below. Cyclosporin A, at a dose of 5 mg/kg body weight/day, was administered subcutaneously to the control and transplanted rats. The rats were housed in cages with filter tops.

Myocardial function studies: At 8 weeks after myocardial injury, the heart function of control and transplanted animals transplanted at 0, 2, and 4 weeks after myocardial injury was measured using a Langendorff preparation (Stephen, S.E. *Annals of Thoracic Surgery* 59:1127-1133, 1995). The rats were anesthetized and

-60-

heparin (200 units) was administered intravenously. The hearts were quickly isolated from rats and perfused in a Langendorff apparatus with filtered Krebs Heinseleit buffer (mmol/L: NaCl 118, KCl 4.7, KH<sub>2</sub>PO<sub>4</sub> 1.2, CaCl<sub>2</sub> 2.5, MgSO<sub>4</sub> 1.2, NaHCO<sub>3</sub> 25, glucose 11; pH 7.4) equilibrated with a 5% CO<sub>2</sub> and 95% O<sub>2</sub>. A 5 latex balloon was passed into the left ventricle through the mitral valve and connected to a pressure transducer (Model p10EZ, Viggo-Spectramed, CA) and transducer amplifier and differentiator amplifier (Model 11-G4113-01, Gould Instrument System Inc., Ohio). After 30 minutes of stabilization, the balloon size was increased in 0.02 ml increments from 0.04 to a volume, at which end diastolic 10 pressure was 30 mm Hg or more by the addition of saline. The systolic and diastolic pressures were recorded at each balloon volume and developed pressure was calculated as the difference between the systolic and diastolic pressures.

10 *Measurement of left ventricular free wall remodeling:* After function measurements, the hearts were fixed, sectioned, and traced onto a transparency. 15 LVFW and scar sizes were quantified using computerized planimetry as described in the "Myocardial Scar Generation and Evaluation" section. The transplanted tissue size as a percentage of the scar size was similarly calculated.

20 *Histological identification of transplanted muscle cells in the scar tissue:* Fixed heart sections were embedded in paraffin, and cut into 10-μm sections. The sections were stained with hematoxylin and eosin as described in the "Histological Studies" section above.

25 Heart sections containing transplanted cells also were stained for myosin heavy chain (MHC) (Rougier Bio-Tech, Montreal, Canada). After deparaffination and rehydration, samples were incubated for 30 minutes with a solution of 3% H<sub>2</sub>O<sub>2</sub> in 70% methanol to inhibit endogenous myocardial peroxidase. Triton X-100 (0.2%) was used to treat samples for 10 minutes to enhance cell permeability. After blocking nonspecific protein binding with 2% normal goat serum in 0.05 M Tris buffer (pH 7.4) for 15 minutes, primary antibodies against MHC (1:1000)

-61-

were added and the samples were incubated at 37°C for 30 minutes followed by an overnight incubation at 4°C. Negative control samples were incubated in PBS under the same conditions. After samples were washed with PBS, a biotin-labeled secondary antibody (1:250) was added and the samples were incubated at room temperature for 1 hour. After rinsing with PBS, the samples were exposed to an avidin-biotin complex conjugated with peroxidase at room temperature for 45 minutes. Visualization was performed with a diaminobenzidine solution (0.25 mg/ml in 0.05 Tris-HCl buffer containing 0.02% H<sub>2</sub>O<sub>2</sub>) for 10 minutes. The cellular nuclei were counter-stained with hematoxylin for 1 minute. The samples 5 were covered and photographed.

10

*Data Analysis:* Data are expressed as the mean ± standard error. The Statistical Analysis System software was used for all analysis (SAS Institute, Cary, NC). Comparisons of continuous variables between more than two groups were performed by a one-way analysis of variance. If the F ratio was significant from 15 the ANOVA, a Duncan=s multiple-range t test was employed to specify differences between the groups. The critical alpha-level for these analyses was set at p<0.05.

Functional data were evaluated for the control and transplant groups by an analysis of covariance (ANCOVA) using intracavitory balloon volume as the covariate and systolic, diastolic and developed pressure as dependent variables. 20 Main effects were group, volume, and the interaction between group and volume.

## Results

*Histological and morphological changes of the hearts after myocardial injury:* Immediately after cryo-injury, 25±3% of the size of the LVFW was transmurally damaged. At this time, the cardiomyocytes were fragmented (Fig. 25 6A; magnification= 200X). At one week after cryo-injury, most of the necrosed cardiomyocytes were gone and a predominantly mononuclear inflammatory

infiltrate was present in the affected area (Fig. 6B; magnification= 100X). At two weeks after cryo-injury, the inflammatory infiltrate had almost disappeared and fibroblasts and collagen deposition were evident (Fig. 6C; magnification= 100X). At four and eight weeks, the scar was composed of fibrotic tissue (Fig. 6D; magnification= 200X). The tissue was less cellular and lymphocytes were not observed.

The myocardial scar size of the left ventricle expanded over the 8 week study period in the damaged hearts (Figs. 7 and 8). Figs. 7A-7D show photomicrographs (magnification= 5X) of H & E-stained heart sections 1 week (Fig. 7A), 2 weeks (Fig. 7B), 4 weeks (Fig. 7C), and 8 weeks (Fig. 7D) after cryo-injury of the LVFW. The size of the scar tissue (indicated by arrows) increases with time after injury.

Fig. 8 is a graph showing percentages of scar tissue in the LVFW at 1 week, 2 weeks, 4 weeks, and 8 weeks after cryo-injury. Open circles represent individual scar sizes, and closed squares represent mean scar sizes  $\pm$  SE (N=7). Although the sizes of the 1-week-old and 2-week-old scars were not statistically different from one another ( $13\pm6\%$  and  $21\pm4\%$ , respectively, of LVFW), the size of 4-week-old scars ( $39\pm5\%$  of LVFW) was significantly larger (\*\* p<0.01). At 8 weeks after myocardial injury there was a further increase in scar size ( $55\pm3\%$  of LVFW; p<0.01).

Although histological studies showed that the damage to newly-injured myocardium was transmural, some myocardium ( $12\pm5\%$  of total scar area) was observed at the endocardium one week after myocardial injury (Figs. 6 and 7). Lymphocytes surrounded the myocardium at this time. At 2 and 4 weeks, muscle tissue in the scar area ( $3\pm2\%$  and  $2\pm1.5\%$  of total scar area) decreased dramatically (p<0.01) in size. At 8 weeks, the myocardial scar became transmural and there was no myocardium in the scar tissue.

*Effect of transplanted cells on scar size:* Figs. 9(A-D) are diagrams of

-63-

photomicrographs of H & E-stained heart sections (magnification= 5X) at 8 weeks after cryo-injury of the LVFW. The control heart (Fig. 9A) was mock-transplanted with culture medium only. Experimental hearts were transplanted with cultured fetal rat cardiomyocytes immediately (Fig. 9 B), at 2 weeks (Fig. 9 C) and at 4 weeks (Fig. 9 D) after myocardial injury. Transplanted cardiac tissue was not observed in the control hearts or the hearts transplanted immediately after myocardial injury. In contrast, transplanted myocardial tissue was found in the scar tissue of hearts transplanted 2 weeks or 4 weeks after injury (indicated by arrows in Figs. 9C and 9D). Host myocardium was usually present beneath the scar when the transplant was present, but never when the transplant was absent. This observation strongly suggests that survival of transplanted cardiomyocytes limits scar expansion and enhances survival of the endogenous myocardium.

Fig. 10 is a graph showing percentages of scar tissue and transplanted cardiac tissue in the LVFW at 8 weeks after cryo-injury. Results are expressed as mean  $\pm$  SE. \*\* p<0.01. Transplantation of fetal rat cardiomyocytes immediately after cryo-injury did not reduce the scar area relative to the scar area in non-transplanted controls: the scar area (53 $\pm$ 5% of the LVFW) in hearts transplanted immediately after cryo-injury (0 weeks) was similar to that in non-transplanted controls (55 $\pm$ 3% of the LVFW). In addition, there was no cardiac tissue at the endocardial area.

Fig. 11 shows that fetal rat cardiomyocytes transplanted 2 weeks after cryo-injury to the myocardium formed new myocardial tissue within the myocardial scar tissue. The newly formed cardiac tissue (detected by staining for myosin heavy chain using the avidin-biotin-peroxidase technique) occupied 34% of the total scar area (11 $\pm$ 3% of the LVFW). Similarly cardiomyocytes transplanted at 4 weeks occupied 31% of total scar area (12 $\pm$ 2% of LVFW).

Cardiomyocytes transplanted either 2 weeks or 4 weeks after myocardial cryo-injury limited scar expansion; the scar size in both cases was smaller (p<0.01)

than the scar size in control (cryo-injured, nontransplanted) hearts (Fig. 10). The scar size in hearts transplanted at 2 weeks ( $32\pm5\%$ ) was smaller ( $p<0.01$ ) than that in hearts transplanted at 4 weeks ( $42\pm2\%$ ). In addition to the cardiac tissue formed by transplanted cardiomyocytes, recipient myocardium was also found at endocardium in both transplanted groups.

*Effect of transplanted cells on heart function:* When fetal rat cardiomyocytes were transplanted immediately after myocardial injury, ventricular function of hearts transplanted with cells was similar to that of injured, control (nontransplanted) hearts. Fig. 12 shows graphs of systolic, diastolic, developed balloon pressures and positive dp/dt with increasing balloon volumes of control and transplanted hearts. Closed circles represent control hearts, open squares represent transplanted hearts, and results are expressed as mean  $\pm$  SE ( $N=8$ ). An analysis of covariance demonstrated no association between the control group and the treatment group for developed pressures.

When the cardiomyocytes were transplanted at 2 weeks after myocardial injury, the transplanted hearts had better ( $p=0.001$ ) ventricular function than the control hearts. Fig. 13 shows systolic, diastolic, developed balloon pressures and positive dp/dt with increasing balloon volumes of control and transplanted hearts. Closed circles represent control hearts; open squares represent transplanted hearts. Results are expressed as mean  $\pm$  SE ( $N=8$ ). Similar diastolic and developed pressures were found at lower balloon volumes in the transplant group.

Cardiomyocytes transplanted at 4 weeks after myocardial injury also improved ( $p<0.001$ ) myocardial function. Fig. 14 shows systolic, diastolic, developed balloon pressures and positive dp/dt with increasing balloon volumes of control and transplanted hearts. Closed circles represent control hearts; open squares represent transplanted hearts. Results are expressed as mean  $\pm$  SE ( $N=12$ ). Systolic and developed pressures of the transplanted rat hearts were significantly greater than those of control hearts ( $p<0.01$ ).

-65-

Fig. 15 is a graph showing developed pressures at balloon volumes of 0.04, 0.1, 0.2 and 0.3 ml of the hearts transplanted with fetal cardiomyocytes at 2 and 4 weeks after myocardial injury. The results are expressed as mean  $\pm$  SE (\* p<0.05, \*\* p<0.01). Fig. 15 shows that hearts transplanted 2 weeks after cryo-injury had significantly higher developed pressures at balloon volumes 0.1 ml (p<0.05), 0.2 ml (p<0.01) and 0.3 ml (p<0.01) than hearts transplanted 4 weeks after cryo-injury.

The transplant tissue visibly contracted, but at different rates than did host myocardium. The contraction of the transplanted tissue persisted after dissection of the recipient heart, but its rate of contraction continued to be different.

In the rat, loss of necrosed ventricular tissue occurs by 2 days after cryo-injury of the myocardium. At this time there is an acute inflammatory reaction with neutrophils accumulating first in the periphery and later in the center of the necrotic region. A chronic inflammatory reaction involving macrophages and lymphocytes follows the acute reaction.

One week after cryo-injury, more than 80% of necrotic muscle fibres had disappeared. The remaining muscle fibres were surrounded by lymphocytes.

The inflammatory reaction is less intense two weeks after cryo-injury (and is absent by three weeks): two weeks after cryo-injury, the scars of the control animal hearts showed minimal or no inflammatory reaction. Two-week-old scars were less mature and contained more blood vessels and fibroblasts than 4-week-old scars, which contained firm connective tissue. Compared to one-week-old scars, there was less cardiac tissue in older scars. It is possible that progressive inflammation and lack of oxygen and nutrient supply decreased the myocardial tissue over time.

The cardiomyocytes transplanted immediately after cryo-injury did not survive in any of the animals studied. We believe the activated neutrophils and macrophages in the inflamed scar area destroyed the transplanted cells. At 8 weeks, the left ventricular chamber of the animals transplanted at the time of

-66-

cryo-necrosis was similar to that of the control scar. The chamber was dilated due to thinning of the scar. The remaining viable muscle of the left ventricle was hypertrophied. No inflammatory reaction was seen. The function of these transplanted hearts was similar to that of the control hearts.

5 All the animals transplanted with the fetal cardiomyocytes at 2 and 4 weeks post-scarring formed cardiac tissue within the scar tissue; therefore, transplantation is possible in both the immature and mature scar. Histological studies of the LVFW of the transplanted hearts showed that host myocardium was usually present beneath the scar when the transplant was present. This did not occur when  
10 the transplant was absent.

Control scar studies showed that scars were always transmural and did not have host cardiomyocytes underneath. Scar sizes and left ventricular chamber sizes of the hearts transplanted at 2 weeks were smaller than those of hearts transplanted at 4 weeks. In turn, scar sizes and left ventricular chamber sizes of the hearts transplanted at 4 weeks were smaller than those of the control hearts.  
15 Consistent with these histological findings, the myocardial function of the hearts transplanted at 2 weeks was better than that of the hearts transplanted at 4 weeks. We attributed the improved myocardial function to less ventricular dilatation and scar thinning. Compared with the sham-operated animals in our previous study, the  
20 contractile function of the hearts transplanted at 2 weeks was less efficient.

Transplantation as soon as possible after the acute inflammatory reaction in the infarcted myocardium has disappeared should minimize ventricular remodeling and optimize myocardial function.

Although the mechanism of improved heart function is unknown, a  
25 cardiomyocyte transplant forms the equivalent of a viable epicardial rim and prevents ventricular dilatation and over-stretching of the cardiomyocytes during systole. With over-stretching of the cardiomyocytes, cardiac function is diminished (Frank-Starling Law). The elastic properties of the contractile apparatus of the

transplanted cardiomyocytes may prevent host fibroblast and cardiomyocyte stretching and ventricular enlargement.

In the course of forming cardiac tissue from transplanted cardiomyocytes, angiogenesis occurred. Angiogenesis is most likely necessary to maintain the viability of the transplanted muscle cells. However, an increased blood supply in the scar could also facilitate fibroblast turnover and strengthening of the scar in response to left ventricular free wall stretch.

With the advent of thrombolysis and percutaneous transluminal coronary angioplasty (PTCA), the incidence of patchy nontransmural infarction is becoming more frequent and transmural infarction with aneurysm formation less common. If the blood flow to the viable cardiomyocytes within the ventricular scar is insufficient for contractile function, stimulation of angiogenesis in the scar tissue becomes important. With adequate blood flow, normal contractile function should return to the hibernating cardiomyocytes within the scar. Transplantation of fetal cardiomyocytes could offer significant benefits to the patients with a patchy infarction. Angiogenesis would be stimulated in the scar, increase the blood flow, and restore normal contractile function to the host's hibernating cardiomyocytes. The transplanted cardiomyocytes should also increase the contractile capacity of the scar tissue and decrease the contractile requirements of the non-affected host myocardium. Patients with angina that cannot be corrected by bypass surgery may benefit from the angiogenesis that occurs secondary to cardiomyocyte transplantation. In addition, it may be beneficial to stimulate angiogenesis with growth factors prior to autologous cardiomyocyte transplantation.

In summary, transplanted fetal cardiomyocytes form myocardial tissue within cardiac scars; this replacement myocardial tissue limits the ventricular dilatation and scar thinning that occurs after myocardial infarction. The optimal time for transplantation for improved myocardial function is after the acute inflammatory reaction and before significant ventricular dilatation has occurred.

## VI) CO-IMPLANTATION OF ENDOTHELIAL CELLS WITH ADULT CARDIOMYOCYTES IMPROVES THE FUNCTION OF INFARCTED HEARTS

5        Cardiac transmural scars were induced by cryo-injury in the left ventricular free wall (LVFW) of Sprague-Dawley rat hearts, as described in the previous examples. Three weeks after cryo-injury, the rats were divided into three groups (eight rats per group), and cardiac transmural scars were transplanted with either medium alone (i.e., no cells; negative control), adult cardiomyocytes alone, or  
10      adult cardiomyocytes plus endothelial cells. Cardiac function was assessed using a Langendorff preparation five weeks after cell transplantation (Stephen et al., *Annals of Thoracic Surgery* 59: 1127-1133, 1995).

15      Fig. 16 shows a graph of developed pressure in infarcted rat hearts injected with either medium alone (control), adult cardiomyocytes alone (CM), or adult cardiomyocytes plus endothelial cells (CM + EC). Adult cardiomyocytes injected alone formed tissue within the ventricular scar, but did not improve cardiac function, compared to hearts injected with medium alone. In contrast, injection of adult cardiomyocytes plus endothelial cells significantly improved cardiac function (p< 0.01), compared to hearts injected with medium or cardiomyocytes alone. Co-  
20      injection of endothelial cells likely stimulates angiogenesis, which enhances survival of adult cardiomyocytes.

## VII) IMPROVEMENT OF CARDIAC FUNCTION USING EX VIVO GENE THERAPY

25      Prior to their transplantation into myocardium or myocardial scar tissue, cells (e.g., cardiomyocytes, endothelial cells, or any other cells of the invention) may be genetically engineered (e.g., transfected or infected with an expression vector) to express a recombinant protein, e.g., a therapeutic protein. Expression of

-69-

the therapeutic protein by the transplanted cells stimulates cell growth, survival, and/or angiogenesis by endogenous cells within the heart and/or by cells transplanted into the myocardium or myocardial scar tissue, and thereby improves cardiac function.

5       The therapeutic protein may be a growth factor, a survival factor (e.g., an anti-apoptotic factor), or an angiogenic factor. Examples of such therapeutic proteins include, and are not limited to, fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (e.g., PDGF- $\beta$ ), transforming growth factor- $\beta$  (TGF- $\beta$ ), insulin-like growth factor (e.g., IGF-1 and 10 IGF-2), insulin, Bcl-2, and Bcl-X<sub>L</sub>. The protein (e.g., VEGF or IGF-1) may be secreted, thereby stimulating growth, survival, or angiogenesis by cells other the cell that expresses the therapeutic protein. Alternatively, the therapeutic protein may be retained intracellularly, such that it affects growth or survival of only the cell that expresses it (e.g., Bcl-2).

15      Prior to transplantation, an expression vector encoding the therapeutic protein of interest is introduced into the cells *ex vivo* (e.g., cells in a tissue culture dish). The vector may be, for example, a plasmid vector, a viral vector (e.g., an adenovirus, retrovirus, poxvirus, or herpesvirus vector), or an artificial chromosome. The vector may be introduced into the cells by various means. For 20 example, plasmid vectors may be introduced into cells by lipofection (using, for example, Lipofectamine<sup>TM</sup> (Gibco BRL, Gaithersberg, MD) or an analogous reagent), calcium phosphate- or DEAE-dextran-mediated transfection, electroporation, protoplast fusion, biolistic transformation, or other well-known methods. Viral vectors are generally introduced into cells by infection. If 25 necessary, expression vectors may be introduced into cells by other means, such as microinjection.

Expression of the vector-encoded therapeutic protein may be transcriptionally regulated by a promoter that is active in many types of cells (e.g.,

-70-

a  $\beta$ -actin promoter) or may be transcriptionally regulated by a tissue-specific promoter that is active in the type of cell being transfected. For example, a promoter from a myocardial-specific contractile protein gene (e.g., myosin heavy chain) may be used to drive expression of the therapeutic protein from a vector introduced into cardiomyocytes. Inducible promoters (e.g., the VEGF promoter, which up-regulates transcription in response to hypoxia; see, e.g., Liu et al., *Circ. Res.* 77:638-643, 1995) may also be used to drive transcription of therapeutic proteins. Expression vectors may also contain non-protein-encoding elements that affect protein expression levels, e.g., transcribed nucleic acid motifs that affect stability or translation efficiency of the encoded mRNA.

Although the invention has been described with reference to certain specific embodiments, various modifications thereof will be apparent to those skilled in the art without departing from the spirit and scope of the invention as outlined in the claims appended hereto.

15

What is claimed is:

-71-

## CLAIMS

1. Isolated cells, said cells comprising at least one of the following cell types:

adult cardiomyocytes;

pediatric cardiomyocytes;

adult fibroblasts;

fetal fibroblasts;

adult smooth muscle cells;

fetal smooth muscle cells;

endothelial cells; and

skeletal myoblasts,

10

wherein said cells survive in myocardial scar tissue after transplantation into said myocardial scar tissue, and wherein said cells improve cardiac function, relative to cardiac function of a heart having similar myocardial scar tissue that is not transplanted with said cells, wherein cardiac function is assessed by at least one of 15 the criteria in the group consisting of: area occupied by said scar tissue; vascularization of said scar tissue; blood flow to said scar tissue; developed pressure, systolic pressure; end diastolic pressure; and dp/dt.

15

2. The cells of claim 1, wherein said cells comprise at least two different 20 cell types.

20

3. The cells of claim 2, wherein said cells comprise a combination of:

- adult cardiomyocytes and endothelial cells;
- pediatric cardiomyocytes and endothelial cells; or
- myoblasts and endothelial cells.

25

4. A method of forming a stable cardiac graft in a mammal, said method comprising transplanting into the scar tissue of a heart, cells comprising at least

one of the following cell types:

adult cardiomyocytes;  
pediatric cardiomyocytes;  
adult fibroblasts;  
fetal fibroblasts;  
adult smooth muscle cells;  
fetal smooth muscle cells;  
endothelial cells; and  
skeletal myoblasts,

wherein said cells survive in scar tissue in a heart after transplantation into said scar tissue, and wherein said cells improve cardiac function, relative to cardiac function of a heart having similar myocardial scar tissue that is not transplanted with said cells, wherein cardiac function is assessed by at least one of the criteria in the group consisting of: area occupied by said scar tissue; vascularization of said scar tissue; blood flow to said scar tissue; developed pressure, systolic pressure; end diastolic pressure; and dp/dt, wherein at least 10% of said scar tissue is occupied by transplanted cells four weeks after transplantation.

5. The method of claim 4, wherein said cells include at least two different  
20 cell types.

6. The method of claim 4, wherein said cells for transplantation comprise a combination of:

adult cardiomyocytes and endothelial cells;  
25 pediatric cardiomyocytes and endothelial cells; or  
myoblasts and endothelial cells.

7. The method of claim 5, wherein growth factors are co-transplanted with

said cells.

8. The method of claim 7, wherein said growth factors are chosen from the group consisting of: insulin-like growth factors I and II; transforming growth factor - $\beta$ 1; platelet-derived growth factor -B; basic fibroblast growth factor; and, vascular endothelial growth factor.

9. The method of claim 4, wherein, prior to transplantation, at least one of said cells is genetically engineered to express a recombinant protein.

10

10. The method of claim 9, wherein said recombinant protein stimulates growth, survival, or angiogenesis in said heart.

15

11. The method of claim 9, wherein said recombinant protein is selected from the group including: fibroblast growth factor, vascular endothelial growth factor, platelet-derived growth factor- $\beta$ , transforming growth factor- $\beta$ , insulin-like growth factor-1, insulin-like growth factor-2, insulin, Bcl-2, and Bcl-X<sub>L</sub>.

20

12. A method of treating defective, damaged or scarified heart tissue, said method comprising transplanting into said defective, damaged or scarified heart tissue a graft of cells, wherein said graft of cells comprises a combination of:  
adult cardiomyocytes and endothelial cells;  
pediatric cardiomyocytes and endothelial cells; or  
myoblasts and endothelial cells.

25

13. The method of claim 12, wherein said graft is used for cardiomyoplasty.

-74-

14. The method of claim 12, wherein said graft is used for closing cardiac defects.

5        15. The method of claim 12, wherein said graft is used for myocardial reconstructive surgery.

10        16. The method of claim 12, wherein, prior to transplantation, at least one of said adult cardiomyocytes, said pediatric cardiomyocytes, said endothelial cells, or said myoblasts is genetically engineered to express a recombinant protein.

15        17. The method of claim 16, wherein said recombinant protein stimulates growth, survival, or angiogenesis in said heart tissue.

20        18. The method of claim 16, wherein said recombinant protein is selected from the group including: fibroblast growth factor, vascular endothelial growth factor, platelet-derived growth factor- $\beta$ , transforming growth factor- $\beta$ , insulin-like growth factor-1, insulin-like growth factor-2, insulin, Bcl-2, and Bcl-X<sub>L</sub>.

25        19. A therapeutic graft for implantation in mammalian myocardial tissue or scar tissue in a heart, said graft comprising biodegradable or non-biodegradable scaffolding supporting cells, wherein said cells comprise a combination of:

adult cardiomyocytes and endothelial cells;  
pediatric cardiomyocytes and endothelial cells; or  
myoblasts and endothelial cells.

20        20. The graft of claim 19, wherein said scaffolding comprises Dacron or polyglycolic acid polymers with or without polylactic acid polymers.

-75-

21. The graft of claim 19, wherein said graft further includes an implantable pacemaker.

5        22. The graft of claim 19, wherein said cells are transfected to deliver recombinant molecules to said myocardial tissue or scar tissue.

23. The graft of claim 22, further comprising growth factors.

10      24. The graft of claim 23, wherein said growth factors are chosen from the group consisting of: insulin-like growth factors I and II; transforming growth factor - $\beta$ 1; platelet-derived growth factor -B; basic fibroblast growth factor; and, vascular endothelial growth factor.

15      25. The graft of claim 19, wherein said cells are suspended on a biodegradable mesh.

26. A therapeutic graft for use in scar tissue in a mammalian heart, said graft comprising transplanted cells, wherein said cells comprise:

20            adult cardiomyocytes;  
                adult fibroblasts;  
                fetal fibroblasts;  
                smooth muscle cells;  
                endothelial cells; or  
                skeletal myoblasts.

25

27. A therapeutic graft for use in myocardial tissue in a mammalian heart, said graft comprising transplanted cells, wherein said transplanted cells comprise:

-76-

adult fibroblasts;  
fetal fibroblasts;  
smooth muscle cells; or  
endothelial cells.

5

28. A method of forming a stable myocardial graft in a mammal, said method comprising transplanting cells into myocardial tissue in the heart of said mammal, wherein said cells comprise:

adult fibroblasts;  
fetal fibroblasts;  
smooth muscle cells; or  
endothelial cells.

10

29. A method of treating defective, damaged or scarified heart tissue, said method comprising transplanting, into said tissue, a graft of cells comprising:

adult cardiomyocytes;  
adult fibroblasts;  
fetal fibroblasts;  
smooth muscle cells;  
endothelial cells; or  
skeletal myoblasts.

15

30. The method of claim 29, wherein, prior to transplantation, at least one of said cells is genetically engineered to express a recombinant protein.

20

31. The method of claim 30, wherein said recombinant protein stimulates growth, survival, or angiogenesis in said tissue.

25

-77-

32. The method of claim 31, wherein said recombinant protein is selected from the group including: fibroblast growth factor, vascular endothelial growth factor, platelet-derived growth factor- $\beta$ , transforming growth factor- $\beta$ , insulin-like growth factor-1, insulin-like growth factor-2, insulin, Bcl-2, and Bcl-X<sub>L</sub>.

1/16




FIG. 1




FIG. 2

3/16




FIG. 3




FIG. 4

5/16

## Experimental design:





FIG. 5

6/16




FIG. 6



FIG. 7

8/16




FIG. 8




FIG. 9

10/16




FIG. 10






FIG. 11







FIG. 13

14/16




FIG. 14





FIG. 15



## INTERNATIONAL SEARCH REPORT

International application No. PCT/US99/13850
---

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :C12N 15/00; A01N 63/00; A01N 43/04

US CL : 435/320.1; 424/93.1; 514/44

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/320.1; 424/93.1; 514/44; 435/357, 360, 363, 366, 374, 375

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,602,301A (Field et al) 11 February 1997, col. 1, lines 40-67 and col. 2, lines 1-35.	1-12
Y	US 5,543,318 (Smith et al) 06 August 1996, col. 2, lines 1-32.	1-23
Y	US 5,733,727A (Field et al) 31 March 1998, col. 1, lines 41-67 and col. 2, lines 1-35.	1-13

Further documents are listed in the continuation of Box C.

See patent family annex.

• Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
• "A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
• "E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
• "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
• "O" document referring to an oral disclosure, use, exhibition or other means		
• "P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

10 SEPTEMBER 1999

Date of mailing of the international search report

07 OCT 1999

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer  Jon Shuman  Telephone No. (703) 308-0196
---	--

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/US99/13850

**B. FIELDS SEARCHED**

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, DIALOG, NTIS, CA, MEDLINE, BIOSIS, BIOSCI, BIOTECH  
search terms: fetal cardiomyocyte, heart, myocardium, transplant, inject, gene therapy,  
transplant, graft, reconstructive surgery, cardiothoracic, growth factor





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/00, A01N 63/00, 43/04</b>		A1	(11) International Publication Number: <b>WO 99/66036</b> (43) International Publication Date: 23 December 1999 (23.12.99)
(21) International Application Number: <b>PCT/US99/13850</b>		(74) Agent: CLARK, Paul, T.; Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110-2214 (US).	
(22) International Filing Date: 18 June 1999 (18.06.99)			
(30) Priority Data: 09/099,994	19 June 1998 (19.06.98)	US	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US Filed on			
09/099,994 (CIP) 19 June 1998 (19.06.98)			
(71) Applicant (for all designated States except US): GENZYME CORPORATION [US/US]; One Kendall Square, Cambridge, MA 02138 (US).			
(72) Inventors; and		Published	
(75) Inventors/Applicants (for US only): MICKLE, Donald, A., G. [CA/CA]; 7 McGillivray Avenue, Toronto, Ontario M5M 2X9 (CA). LE, Ren-Ke [CA/CA]; 75 Ardgowan Crescent, Scarborough, Ontario M1V 1B4 (CA). WEISEL, Richard, D. [CA/CA]; 413 Sackville Street, Toronto, Ontario M4X 1S8 (CA).		With international search report.	
(54) Title: TRANSPLANTS FOR MYOCARDIAL SCARS			
(57) Abstract			
<p>A method is provided for forming a graft in heart tissue which comprises the transplantation of cells chosen from cardiomyocytes, fibroblasts, smooth muscle cells, endothelial cells and skeletal myoblasts. The grafts are especially useful in treating scar tissue on the heart.</p>			

\*(Referred to in PCT Gazette No. 18/2000, Section II)

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

## TRANSPLANTS FOR MYOCARDIAL SCARS

5

### FIELD OF THE INVENTION

The present invention relates to novel methods of cell transplantation into cardiac scar tissue to improve heart function, stimulate angiogenesis, and salvage myocardial tissue.

10

### BACKGROUND OF THE INVENTION

Normal cardiac contractile activity in the heart is dependent upon a healthy myocardium. The myocardium is a cellular syncytium composed primarily of interconnected heart muscle cells, the cardiomyocytes. Damage to the myocardium, such as that resulting from oxygen deprivation, results in cardiomyocyte death. Because cardiomyocytes do not regenerate within the myocardium, the damaged region of myocardium is replaced by cardiac scar tissue.

15

In contrast to myocardial tissue, cardiac scar tissue contains no cardiomyocytes. Instead, it is composed of connective tissue cells, such as fibroblasts, and non-cellular components, such as collagen and fibronectin. Cardiac scar tissue is non-contractile, and, therefore, interferes with normal cardiac function. Moreover, its lack of contractility increases the physical demands upon the remaining cardiomyocytes, which often leads to further myocardial damage and cardiac scarring.

20

Because the presence of non-contractile cardiac scar tissue places an additional physiological burden on the remaining myocardium, which often results in disease progression, there is a need for therapies that would inhibit or reverse the formation of such scar tissue. Ideally, such therapies would also allow improvement of contractile function, minimization of myocardial remodeling, stimulation of angiogenesis, salvation of damaged cardiomyocytes, rebuilding of the myocardium, and provide delivery vehicles for gene therapy. The present invention addresses these needs.

30

## SUMMARY OF THE INVENTION

It is an object of the present invention to provide cell transplantation methods for treating diseased myocardial tissue and myocardial scar tissue which overcome deficiencies in the prior art. The invention illustrates that atrial cardiomyocytes, skeletal myoblasts, smooth muscle cells, endothelial cells, and fibroblasts can be successfully transplanted into the scar tissue formed after ventricular necrosis and into tissue membranes and porous synthetic membranes. The cell grafts form tissue that survived the three month duration of the study, improved myocardial function, limited myocardial remodeling, and stimulated angiogenesis. The presence of the grafts did not induce overt cardiac arrhythmias. When auto-cell transplantation occurred, immunorejection did not occur.

In a first aspect, the invention features a method of forming a stable myocardial graft in a mammal comprising, transplanting cells into myocardial tissue or scar tissue in the heart. Cells are chosen from the group consisting of: adult cardiomyocytes, fetal cardiomyocytes, pediatric cardiomyocytes, adult fibroblasts, fetal fibroblasts, smooth muscle cells, endothelial cells, and skeletal myoblasts.

In preferred embodiments of the first aspect of the invention, cells may be chosen from adult or fetal smooth muscle cells and fibroblasts, adult cardiomyocytes and endothelial cells may be co-transplanted, adult cardiomyocytes may be derived from atrial tissue, the graft may be derived from auto-, allo- or xenotransplantation, and the graft may comprise adult cardiomyocytes derived from autotransplantation, such as cardiomyocytes derived from atrial tissue.

In another preferred embodiment of the first aspect of the invention, the cells may be directly introduced into the myocardial tissue or the scar tissue, for example, by injection, and the injection site may be sealed with a biological adhesive to prevent leakage of the cells.

In other preferred embodiments of the first aspect of the invention the cells may be suspended on a biodegradable or non-degradable mesh, or may be transfected to

deliver recombinant molecules to the myocardial tissue or the scar tissue.

In still another embodiment of the first aspect of the invention, the cells may be used in myocardial reconstructive surgery, and may be attached to the outer surface of the myocardial tissue or the scar tissue with a biological adhesive, or may be transplanted following an inflammatory response in the myocardial tissue. In addition, growth factors may be co-transplanted with the cells. Growth factors are chosen from the group consisting of: insulin-like growth factors I and II; transforming growth factor- $\beta$ 1, platelet-derived growth factor-B, basic fibroblast growth factor, and, vascular endothelial growth factor.

In yet other preferred embodiments of the first aspect of the invention, the cells are transplanted into scar tissue, and at least 10%, 20%, or 30% of the scar tissue area is occupied by transplanted cells four weeks after transplantation.

In a second aspect, the invention features a therapeutic graft for application in mammalian myocardial tissue or scar tissue in the heart, comprising transplanted cells chosen from the group consisting of: adult cardiomyocytes, pediatric cardiomyocytes, fetal cardiomyocytes, adult fibroblasts, fetal fibroblasts, adult smooth muscle cells, fetal smooth muscle cells, endothelial cells, and skeletal myoblasts.

In preferred embodiments of the second aspect of the invention, the graft may comprise adult cardiomyocytes and endothelial cells, the transplanted cells may be chosen from smooth muscle cells and fetal fibroblasts, the adult cardiomyocytes may be derived from atrial tissue, or the graft may be derived from auto-, allo- or xenotransplantation. The graft may comprise adult cardiomyocytes derived from autotransplantation and the cardiomyocytes may be derived from atrial tissue. The cells of the graft may be introduced into myocardial tissue or scar tissue by injection, and the cells may be transfected to deliver recombinant molecules to myocardial tissue or scar tissue. The graft may further comprise growth factors, for example, insulin-like growth factors I and II, transforming growth factor- $\beta$ 1, platelet-derived growth factor -B, basic fibroblast growth factor, and, vascular endothelial growth factor.

Cells of the graft also may be suspended on a mesh (e.g., a biodegradable mesh).

In a third aspect, the invention features a therapeutic graft, for implantation into mammalian myocardial tissue or scar tissue in the heart, comprising a suitable biodegradable or non-biodegradable scaffolding having cells supported thereon. The 5 cells are chosen from the group consisting of: adult cardiomyocytes, pediatric cardiomyocytes, fetal cardiomyocytes, adult fibroblasts, fetal fibroblasts, smooth muscle cells (e.g., adult smooth muscle cells or fetal smooth muscle cells), endothelial cells, and skeletal myoblasts.

In preferred embodiments of the third aspect of the invention, adult 10 cardiomyocytes may be derived from atrial tissue, and the graft may comprise adult cardiomyocytes and adult endothelial cells. The graft may be used in cardiomyoplasty. The scaffolding of the graft may comprise Dacron or polyglycolic acid polymers with or without polylactic acid polymers, the cellular material may consist of cardiomyocytes, smooth muscle cells or endothelial cells, and the graft may further include an implantable pacemaker.

Grafts according to the third aspect of the invention may be used for closing cardiac defects, and for myocardial reconstructive surgery.

In a fourth aspect, the invention features a method of culturing cardiomyocytes from pediatric mammalian myocardial tissue comprising: a) comminuting said 20 myocardial tissue; b) digesting said tissue for 15 minutes in a digesting solution containing 0.2% trypsin and 0.1% collagenase dissolved in phosphate buffered saline and separating the digested tissue solution from the remaining myocardial tissue; c) adding to the digested tissue solution a culture medium comprising Iscove's modified Dulbecco's medium (IMDM), 10% fetal bovine serum, and 0.1mM  $\beta$ -mercaptoethanol; culture medium being added in a ratio of 20 volumes of culture 25 medium to 1 volume of digesting solution; d) centrifuging the resulting solution at 581 x g for 5 minutes and discarding the supernatant; e) re-suspending the pellet in fresh culture medium; f) culturing the suspension in 10% fetal bovine serum and 0.1 mM  $\beta$ -

mercaptoethanol; and, g) isolating cardiomyocytes from the culture.

In preferred embodiments of the fourth aspect of the invention the method may further include passaging cardiomyocytes by sub-culturing with a sub-culturing enzyme solution comprising 0.01% trypsin, 0.02% glucose, and 0.5 mM EDTA. The method of the fourth aspect may further include storing the cardiomyocytes by a) dissociating cultured cardiomyocytes from the culture plate using sub-culturing enzyme solution; b) adding culture medium in a ratio of 5 volumes of culture medium to 1 volume of sub-culturing enzyme solution; c) centrifuging the solution at 581 x g for 5 minutes; d) discarding the supernatant and re-suspending the pellet in 1 mL IMDM containing 20% fetal bovine serum and 20% glycerol; and, e) freezing and storing the resulting suspension in liquid nitrogen. The method may further include thawing the frozen sample at 37° C and culturing the cardiomyocytes for 3 to 5 days in a solution of IMDM containing 20% fetal bovine serum.

In a fifth aspect, the invention features a method of culturing cardiomyocytes from adult mammalian myocardial tissue comprising: a) comminuting said myocardial tissue; b) digesting the tissue for 15 minutes in a digesting solution containing 0.2% trypsin and 0.1% collagenase dissolved in phosphate buffered saline; c) separating the digested tissue solution and digesting the remaining tissue with fresh digesting solution for 10 minutes; d) combining both digested tissue solutions from steps (b) and (c) and adding a culture medium comprising Iscove's modified Dulbecco's medium (IMDM, containing 10% fetal bovine serum, and, 0.1mM  $\beta$ -mercaptoethanol) in a ratio of 20 volumes of culture medium to 1 volume of said digesting solution; e) centrifuging the resulting solution at 581 x g for 5 minutes and discarding the supernatant; f) re-suspending the pellet in fresh culture medium; g) culturing the suspension in 10% fetal bovine serum and 0.1 mM  $\beta$ -mercaptoethanol; and, h) isolating cardiomyocytes from the culture.

In a preferred embodiment of the fifth aspect of the invention, the method may further include passaging the cardiomyocytes using sub-culturing enzyme solution

comprising 0.01% trypsin, 0.02% glucose, and 0.5 mM EDTA.

The method of the fifth aspect also may further include storing cardiomyocytes by a) dissociating cultured cardiomyocytes from the culture plate using sub-culturing enzyme solution; b) adding culture medium in a ratio of 5 volumes of culture medium to 1 volume of sub-culturing enzyme solution; c) centrifuging the solution at 581 x g for 5 minutes; d) discarding the supernatant and re-suspending the pellet in 1 mL IMDM containing 20% fetal bovine serum and 20% glycerol; and, e) freezing and storing the resulting suspension in liquid nitrogen.

In another embodiment of the fifth aspect, the method may further include thawing the frozen sample at 37° C and culturing the cardiomyocytes for 3 to 5 days in a solution of IMDM containing 20% fetal bovine serum.

In a sixth aspect, the invention features a method of treating defective, damaged or scarified heart tissue, comprising transplanting into the tissue a graft of cells chosen from the group consisting of: adult cardiomyocytes, pediatric cardiomyocytes, fetal cardiomyocytes, adult fibroblasts, fetal fibroblasts, adult smooth muscle cells, fetal smooth muscle cells, endothelial cells, and skeletal myoblasts.

In preferred embodiments of the sixth aspect of the invention, the adult cardiomyocytes may be derived from atrial tissue, cells in the graft may be adult cardiomyocytes and endothelial cells, the cells may be directly introduced into heart tissue, and the graft may be a patch comprising cells suspended on a biologically acceptable biodegradable or non-biodegradable scaffolding.

In still other preferred embodiments of the sixth aspect of the invention, the cells are transplanted into scar tissue, and at least 10%, 20%, or 30% of the scar tissue is occupied by transplanted cells four weeks after transplantation.

In another preferred embodiment of the sixth aspect of the invention, the method may comprise the steps of: (a) surgically removing defective heart tissue thereby creating an opening; and, (b) attaching the graft to the opening to form a water tight seal.

In a seventh aspect, the invention features isolated cells for transplantation into myocardial scar tissue, wherein the cells include at least one of the following cell types: adult cardiomyocytes, pediatric cardiomyocytes, adult fibroblasts, fetal fibroblasts, adult smooth muscle cells, fetal smooth muscle cells, endothelial cells, and skeletal myoblasts, wherein the cells survive in myocardial scar tissue after transplantation and improve cardiac function, relative to cardiac function of a heart having similar myocardial scar tissue that is not transplanted with cells. Cardiac function is assessed by at least one of the criteria in the group consisting of: area occupied by scar tissue; vascularization of scar tissue; blood flow to scar tissue; developed pressure, systolic pressure; end diastolic pressure; and dp/dt.

10 In preferred embodiments of the seventh aspect of the invention, the cells include at least two different cell types. For example, the cells may include a

combination of: adult cardiomyocytes and endothelial cells; pediatric cardiomyocytes and endothelial cells; or myoblasts and endothelial cells.

15 In an eighth aspect, the invention features a method for testing a pharmacological agent that is intended to prevent or ameliorate cardiac damage during cardiac surgery. The method comprises exposing the pharmacological agent to isolated cells selected from the group consisting of: adult cardiomyocytes, pediatric cardiomyocytes, adult fibroblasts, fetal fibroblasts, adult smooth muscle cells, fetal smooth muscle cells, endothelial cells, and skeletal myoblasts, wherein the cells survive in myocardial scar tissue after transplantation and improve cardiac function, relative to cardiac function of a heart having similar myocardial scar tissue that is not transplanted with cells (cardiac function is assessed by at least one of the criteria in the group consisting of: area occupied by scar tissue; vascularization of scar tissue; blood flow to scar tissue; developed pressure, systolic pressure; end diastolic pressure; and dp/dt), wherein cells exposed to the pharmacological agent show a decrease or absence of cardiac damage during cardiac surgery, compared to cells not exposed to the pharmacological agent.

In a ninth aspect, the invention features a method of forming a stable cardiac graft in a mammal, including transplanting into the scar tissue of a heart, cells chosen from the group consisting of: adult cardiomyocytes; pediatric cardiomyocytes; adult fibroblasts; fetal fibroblasts; adult smooth muscle cells; fetal smooth muscle cells; endothelial cells; and skeletal myoblasts, wherein the cells survive in scar tissue in a heart after transplantation into scar tissue, and wherein the cells improve cardiac function, relative to cardiac function of a heart having similar myocardial scar tissue that is not transplanted with such cells. Cardiac function is assessed by at least one of the criteria in the group consisting of: area occupied by scar tissue; vascularization of scar tissue; blood flow to scar tissue; developed pressure, systolic pressure; end diastolic pressure; and dp/dt, wherein at least 10% of scar tissue is occupied by transplanted cells four weeks after transplantation.

In preferred embodiments of the ninth aspect of the invention, at least 20% or at least 30% of the scar tissue may be occupied by transplanted cells four weeks after transplantation, or at least 40% or at least 50% of the scar tissue may be occupied by transplanted cells eight weeks after transplantation.

In other preferred embodiments of the ninth aspect of the invention, the cells may include at least two types of cells. For example, the cells may include a combination of: adult cardiomyocytes and endothelial cells; pediatric cardiomyocytes and endothelial cells; or myoblasts and endothelial cells.

In still other preferred embodiments of the ninth aspect of the invention, growth factors are co-transplanted with the cells. The growth factors are chosen from the group consisting of: insulin-like growth factors I and II; transforming growth factor - $\beta$ 1; platelet-derived growth factor -B; basic fibroblast growth factor; and, vascular endothelial growth factor.

In a tenth aspect, the invention features a method of treating defective, damaged or scarified heart tissue, including transplanting into defective, damaged or scarified heart tissue a graft of cells that includes a combination of: adult

-9-

cardiomyocytes and endothelial cells; pediatric cardiomyocytes and endothelial cells; or myoblasts and endothelial cells.

In preferred embodiments of the tenth aspect of the invention, the graft may be used for cardiomyoplasty, for closing cardiac defects, or for myocardial reconstructive surgery.

In an eleventh aspect, the invention features a therapeutic graft for implantation in mammalian myocardial tissue or scar tissue in a heart, including biodegradable or non-biodegradable scaffolding supporting cells, wherein the cells include a combination of: adult cardiomyocytes plus endothelial cells; pediatric cardiomyocytes plus endothelial cells; or myoblasts plus endothelial cells.

In various embodiments of the eleventh aspect of the invention, the scaffolding includes Dacron or polyglycolic acid polymers with or without polylactic acid polymers, or further includes an implantable pacemaker.

In another embodiment of the eleventh aspect, the cells may be transfected to deliver recombinant molecules to the myocardial tissue or scar tissue.

In still another embodiment of the eleventh aspect, the graft may include growth factors, for example: insulin-like growth factors I and II; transforming growth factor - $\beta$ 1; platelet-derived growth factor -B; basic fibroblast growth factor; and, vascular endothelial growth factor.

In yet another embodiment of the eleventh aspect, the cells may be suspended on a biodegradable mesh.

In a twelfth aspect, the invention features a therapeutic graft including transplanted cells, for use in scar tissue in a mammalian heart. The transplanted cells include: adult cardiomyocytes; adult fibroblasts; fetal fibroblasts; smooth muscle cells; endothelial cells; or skeletal myoblasts.

In a thirteenth aspect, the invention features a therapeutic graft including transplanted cells for use in myocardial tissue in a mammalian heart. The transplanted cells include: adult fibroblasts; fetal fibroblasts; smooth muscle cells; or endothelial

-10-

cells.

In a fourteenth aspect, the invention features a method of forming a stable myocardial graft in a mammal. The method includes transplanting cells into myocardial tissue in the heart of the mammal, wherein said cells include: adult fibroblasts; fetal fibroblasts; smooth muscle cells; or endothelial cells.

In a fifteenth aspect, the invention features a method of treating defective, damaged or scarified heart tissue. The method includes transplanting, into the tissue, a graft of cells including: adult cardiomyocytes; adult fibroblasts; fetal fibroblasts; smooth muscle cells; endothelial cells; or skeletal myoblasts.

In preferred embodiments of the ninth through fifteenth aspects of the invention, prior to transplantation, at least one of the cells may be genetically engineered to express a recombinant protein. The recombinant protein may be a therapeutic protein that stimulates cell growth, survival, and/or angiogenesis by endogenous cells within the heart and/or by cells transplanted into the myocardium or myocardial scar tissue, and thereby improves cardiac function. The stimulation of cell growth, survival, and/or angiogenesis or improvement in cardiac function may be by at least 5%, preferably, by at least 10%, 20%, or 30%. Examples of such recombinant proteins include: fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (e.g., PDGF- $\beta$ ), transforming growth factor- $\beta$  (TGF- $\beta$ ), insulin-like growth factor (e.g., IGF-1 and IGF-2), insulin, Bcl-2, and Bcl-X<sub>L</sub>. Preferably, at least 1%, more preferably, at least 5%, at least 10%, at least 25%, and most preferably, at least 50% of the cells express the recombinant protein.

#### BRIEF DESCRIPTION OF THE DRAWINGS

These and other features of the present invention will become more apparent in the following detailed description wherein references are made to the following figures:

Fig. 1 is a graph showing the improvement in myocardial function of scarred

-11-

hearts having smooth muscle cells transplanted into the scars.

Fig. 2 is a graph showing the amount of blood flow (represented as microsphere count) to control scar tissue and scar tissue transplanted with endothelial cells.

Fig. 3 is a graph showing systolic pressure of transplantation hearts and control hearts with increasing balloon volume.

Fig. 4 is a graph showing developed pressure of transplantation hearts and control hearts with increasing balloon volume.

Fig. 5 is a diagram showing the design of the histological study of cryoinjured hearts (top) and histological and functional studies of hearts transplanted with endothelial cells after cryo-injury (bottom).

Figs. 6A-6D are diagrams of photomicrographs of haematoxylin and eosin (H & E)-stained left ventricular free wall (LVFW): *A*, immediately after cryo-injury (200X magnification), and *B*) 1 week (100X magnification), *C*) 2 weeks (100X magnification), and *D*) 4 weeks (200X magnification) after cryo-injury.

Figs. 7A-7D are diagrams of photomicrographs of H & E-stained heart sections (5X magnification): *A*) 1 week, *B*) 2 weeks, *C*) 4 weeks, and *D*) 8 weeks after cryo-injury of the LVFW.

Fig. 8 is a graph showing percentages of scar tissue in the LVFW at 1 week, 2 weeks, 4 weeks, and 8 weeks after cryo-injury.

Figs. 9A-9D are diagrams of photomicrographs of H & E-stained heart sections (5X magnification) at 8 weeks after cryo-injury of the LVFW.

Fig. 10 is a graph showing percentages of scar tissue and transplanted cardiac tissue in the LVFW at 8 weeks after cryo-injury.

Fig. 11 is a diagram of a photomicrograph showing fetal rat cardiomyocytes 6 weeks after transplantation (100X magnification).

Fig. 12 is a series of graphs of systolic, diastolic, developed balloon pressures and positive dp/dt with increasing balloon volumes of control hearts and hearts transplanted immediately after myocardial injury.

-12-

Fig. 13 is a series of graphs of systolic, diastolic, developed balloon pressures and positive dp/dt with increasing balloon volumes of control hearts and hearts transplanted 2 weeks after myocardial injury.

5 Fig. 14 is a series of graphs of systolic, diastolic, developed balloon pressures and positive dp/dt with increasing balloon volumes of control hearts and hearts transplanted 4 weeks after myocardial injury.

10 Fig. 15 is a graph showing developed pressures at balloon volumes of 0.04, 0.1, 0.2 and 0.3 ml of the hearts transplanted with fetal cardiomyocytes at 2 and 4 weeks after myocardial injury (\* p<0.05, \*\* p<0.01).

15 Fig. 16 is a graph showing developed pressure in cryo-injured hearts containing transmural scars transplanted with medium (control), adult cardiomyocytes (CM) or adult cardiomyocytes plus vascular endothelial cells (CM + EC).

#### **DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS**

15 We have discovered methods for improving the outcome of patients having myocardial scars and other heart defects. Our discovery was made while investigating the use of grafts, comprising cellular transplants, for treating scar tissue in the heart. We transplanted cultured cells into the center of a mature ventricular scar so that there 20 was no contact between the transplanted cells and the host cells. This approach was used to facilitate identification of the transplant. Initially, in transplanting fetal cardiomyocytes into the mature scar, it was surprising to find stimulation of angiogenesis in the affected area and an improvement in heart function. Since we were previously unsuccessful in transplanting adult ventricular cardiomyocytes into 25 myocardial scar tissue, we were surprised that adult atrial cardiomyocytes could be successfully transplanted into such scar tissue. In further studies, we have transplanted autologous and allogeneic smooth muscle cells, fibroblasts, and endothelial cells into the center of a mature ventricular scar. As with our previous findings, the cell transplants formed stable grafts in the scar, improved myocardial

function, decreased myocardial remodeling, stimulated angiogenesis, salvaged myocardium, and provided a means of gene delivery. On the basis of these studies we expect that similar results can be obtained from the use of skeletal myoblasts as well.

We have also developed a novel method for culturing, passaging and storing postnatal (adult or pediatric) human ventricular cardiomyocytes. Transplantation of cultured postnatal cardiomyocytes provides an approach for restoring function and blood flow to regions of the heart that are destroyed by acquired heart disease or are absent because of congenital heart disease. The postnatal cardiomyocyte cell culture method further provides a model for testing a variety of pharmacological or other approaches for preventing or ameliorating cardiac damage during cardiac surgery. Therefore, this unique method offers the promise of preventing injury as well as restoring heart function after cardiac injury.

The following examples will assist those skilled in the art to better understand the invention and its principles and advantages. It is intended that these examples be illustrative of the invention and not limit the scope thereof.

## I) GENERAL METHODS

### A) CELL ISOLATION, CULTURE, AND IDENTIFICATION

20        1. Fetal Rat Cardiomyocyte Cultures: Fetal rat cardiomyocytes were isolated by enzymatic digestion (Li, R-K et al., *Circulation Research* 78:283-288, 1996; Li, R-K et al., *Annals of Thoracic Surgery* 62:654-661, 1996) from 18-day gestational Sprague-Dawley rat heart ventricles (Charles River Canada Inc. Quebec, Canada). Fetal rats were anesthetized with intraperitoneal injection of sodium pentobarbital (30 mg/kg) and the hearts were then excised. The heart tissues were washed with phosphate-buffered saline (NaCl 136.9 mM, KCl 2.7 mM, Na<sub>2</sub>HPO<sub>4</sub> 8.1 mM, KH<sub>2</sub>PO<sub>4</sub> 1.5 mM, pH 7.3). The tissues were minced and incubated in 10 ml phosphate buffered saline containing 0.2% trypsin, 0.1% collagenase, and 0.02% glucose for 30 minutes

-14-

at 37°C. The cardiomyocytes were then isolated by repetitive pipetting of the digested myocardial tissue. The cells in the supernatant were transferred to a tube containing 20 ml of cell culture medium (Iscove's modified Dulbecco's medium containing 10% fetal bovine serum, 0.1 mmole/L β-mercaptoethanol, 100 units/ml penicillin and 100 ug/ml streptomycin). The tube was centrifuged at 600 x g for 5 minutes at room temperature and the cell pellet was resuspended in the cell culture medium for purification by plating (see Section 10 below).

2. Adult Rat Ventricular Cardiomyocyte Cultures: Adult rats (Charles River Canada Inc. Quebec, Canada) were anesthetized with intramuscular administration of ketamine hydrochloride (22 mg/kg body weight) followed by an intraperitoneal injection of sodium pentobarbital (30 mg/kg) and the hearts were then excised. Cardiomyocytes were isolated by enzymatic digestion as described in Section 1. Adult human ventricular biopsies obtained from the operating theatre were similarly enzymatically digested.

3. Adult Rat Atrial Cardiomyocyte Cultures: Adult rats weighing 400 g (Charles River Canada Inc. Quebec, Canada) were anesthetized as in Section 2 above. The atrial appendages were ligated and removed (rats survive this procedure), after which the atrial tissue was used for cardiomyocyte isolation as described in Section 1. Adult human atrial tissue was obtained from the operating theatre and similarly enzymatically digested.

4. Fetal Rat Smooth Muscle Cells: Fetal rat smooth muscle cells were isolated from 18-day gestational Sprague-Dawley rat stomachs by enzymatic digestion (Li, R-K et al., *Journal of Tissue Culture and Methods* 14:93-100, 1992). Fetal rats (Charles River Canada Inc. Quebec, Canada) were anesthetized with pentobarbital (30 mg/kg body weight, intraperitoneal) and the stomachs were then excised. The stomachs were

-15-

washed with phosphate buffered saline, minced, and incubated in 10 ml phosphate buffered saline containing 0.2% trypsin, 0.1% collagenase, and 0.02% glucose for 30 minutes at 37°C. Smooth muscle cells were isolated by repetitive pipetting of the digested stomach tissue. The cells in the supernatant were transferred to a tube 5 containing 20 ml of cell culture medium (199 medium containing 20% fetal bovine serum, 100 units/ml penicillin and 100 ug/ml streptomycin), and centrifuged at 600 x g for 5 minutes at room temperature, after which the cells were resuspended in the cell culture medium and cultured.

10       5. Adult Rat Smooth Muscle Cells: Adult female rats (Charles River Canada Inc. Quebec, Canada) were anesthetized as described in Section 2 above. Uteri were removed after occlusion of blood vessels and incision was closed. Smooth muscle cells were isolated from uterus as described in Section 4.

15       6. Fetal Rat Fibroblasts: Fetal rat skin biopsies were obtained from anesthetized 18-day gestational Sprague-Dawley rats, and fibroblasts from fetal rat skin were isolated, purified and cultured as previously described (Mickle et al., *Journal of Molecular and Cell Cardiology* 22:1297-1304, 1990). Briefly, the tissue was washed with phosphate buffered saline, minced, and digested for 30 minutes at 37°C in 10 ml 20 phosphate buffered saline containing 0.2% trypsin, 0.1% collagenase, and 0.02% glucose. Fibroblasts were isolated by repetitive pipetting of the digested skin tissue. The cells in the supernatant were transferred into a tube containing 20 ml of cell culture medium (Dulbecco's Modified Essential Medium containing 10% fetal bovine serum, 100 units/ml penicillin and 100 ug/ml streptomycin) and centrifuged at 600 x g 25 for 5 minutes at room temperature, after which the cells were resuspended in the cell culture medium and cultured.

7. Adult Rat Fibroblasts: Skin biopsies were obtained from anesthetized adult

Sprague-Dawley rats. Fibroblasts were isolated and cultured as described in Section 6.

8. Adult Rat Endothelial Cells: Adult rat vascular endothelial cells were isolated from Sprague-Dawley rat aortas by enzymatic digestion (Mickle et al., *Journal of Molecular and Cell Cardiology* 22:1297-1304, 1990). Adult rats (Charles River Canada Inc. Quebec, Canada) were anesthetized as described in Section 2. Aortas were excised, washed with phosphate buffered saline, incubated for 30 minutes at 37°C in 10 ml phosphate buffered saline containing 0.2% trypsin, 0.1% collagenase, and 0.02% glucose, and washed with cell culture medium (199 medium containing 20% fetal bovine serum, 100 units/ml penicillin and 100 ug/ml streptomycin), after which the isolated endothelial cells were cultured.

9. Human Cell Isolation, Culturing and Storage: Human cardiomyocytes were isolated from atrial appendages and ventricular myocardial biopsies were obtained from patients undergoing corrective cardiac surgery. Human myocardium was dissected to remove connective tissue and then minced to pieces less than 1 mm<sup>3</sup> in size.

9(a). Pediatric Cardiomyocytes: Pediatric tissue was digested for 15 minutes in an enzymatic digestion solution containing 0.2% trypsin, 0.1% collagenase dissolved in phosphate-buffered saline (no calcium or EDTA was added). Culture medium containing Iscove's modified Dulbecco's medium (IMDM), 10% fetal bovine serum and 0.1 mM β-mercaptoethanol was added in a ratio of 20 volumes culture medium to 1 volume enzymatic digestion solution. The cell suspension was centrifuged at 581 g for 5 minutes, after which the supernatant was discarded. The cell and tissue pellet was resuspended in culture medium, after which the isolated cells were cultured on a dish for 5 to 8 days. Cardiomyocytes that migrated from this culture were collected by

a Pasteur pipette and cultured once again.

5           9(b). Adult Cardiomyocytes: In contrast to pediatric myocardium digestion, adult human myocardium was digested twice. The second digestion was necessary for the adult tissue due to the increased amount of connective tissue. After the first digestion (as described in Section 9a), the cell suspension was collected, after which the tissue was re-digested for 10 minutes and the second cell suspension was collected. The two collected suspensions were combined, and centrifuged, after which the cells were resuspended and cultured. The digested tissue fragments in the pellet were 10 collected and cultured for no longer than 2 days (to avoid cell deterioration) and a further enzymatic digestion carried out on the remaining undigested tissue if sufficient cells were not found in the suspensions. In addition, cardiomyocytes that migrated from the cultured tissue fragments were isolated and re-cultured.

15           9(c). Passaging of Cultures: The cardiomyocytes were cultured in a medium containing IMDM, 10% fetal bovine serum and 0.1 mM  $\beta$ -mercaptoethanol. The subculturing enzymatic solution for cell dissociation contained 0.01% trypsin, 0.02% glucose and 0.5 mM EDTA. The cells were subcultured when the culture reached confluence (i.e. when the cell culture covered the dish surface and the cells began 20 contacting each other). Cells that were subcultured before reaching confluency rapidly became de-differentiated; such de-differentiated cells cannot be successfully transplanted. On the other hand, if the cells were allowed to become over-confluent, enzymatic digestion yielded cell clumps that would not dissociate; we observed that cardiomyocytes in cell clumps did not divide in culture.

25           9(d). Storage of Cultured Cells: Primary cultures of human cardiomyocytes were dissociated from culture plates using the subculturing enzymatic digestion solution described in Section 9(c), after which culture medium was added in a ratio of 5 volumes culture medium to 1 volume digestion solution, and the cell suspension was

centrifuged at 581 g for 5 minutes. The supernatant was removed and the cell pellet was gently re-suspended in 1 mL IMDM containing 20% fetal bovine serum and 20% glycerol, transferred to a sterile cryo-vial, and placed in a Nalgene freezing container containing isopropranol in its base. Cryo-vials were stored in a -80°C freezer container for a period of time that: (a) ensured that the cells reached -80°C; and (b) prevented over-oxidation of the cells. In the present example, cryo-vials were stored for a minimum of 4 hours and no longer than 8 hours. Cryo-vials containing the cells were placed in liquid nitrogen for long term storage.

9(e). Thawing of Cultures: To culture the stored cells, the vials were removed from liquid nitrogen and warmed at 37°C. Although 37°C was preferred, cells were also thawed at other temperatures that allowed for rapid yet non-destructive warming. The initial plating of the cells was done in 10 ml of IMDM medium containing 20% fetal bovine serum (warming medium). Cells were cultured in warming medium for 3 to 5 days after thawing to allow the cells to attach firmly to the culture dish before switching to the usual culture medium. The warming medium must contain IMDM and 20% fetal bovine serum. For example, if the warming medium contains 10% rather than 20% fetal bovine serum, the human cardiomyocytes will not divide and will de-differentiate. De-differentiated cardiomyocytes cannot be used for transplantation.

Cardiomyocytes that were cryo-frozen and warmed as described were successfully subcultured and were morphologically identical to cells that had not been frozen. Cells that had been frozen and cells that had not been frozen were analyzed for mitochondrial integrity at each passage for 7 passages (over the course of one month of subculture following thawing and plating). The mitochondrial enzyme cytochrome C oxidase showed no difference in activity between frozen and unfrozen cardiomyocytes at each passage. Our finding that primary human cardiomyocytes can be stored frozen and later revived allows their "lifetime" to be extended, thus enhancing the usefulness of such cells.

-19-

9(f). Endothelial Cells: Human vascular endothelial cells were isolated as described in section 8 from saphenous vein and aorta obtained from patients undergoing coronary bypass surgery.

9(g). Smooth Muscle Cells: Human smooth muscle cells were isolated from saphenous vein after endothelial cell isolation. After endothelial cells were collected from veins as described in Section 8, the tissue was minced and incubated in 10 ml phosphate buffered saline containing 0.2% trypsin, 0.1% collagenase, and 0.02% glucose for 30 minutes at 37°C. The smooth muscle cells were isolated by repetitive pipetting of the digested tissue. The cells in the supernatant were transferred into a tube containing 20 ml of cell culture medium (199 medium containing 20% fetal bovine serum, 100 units/ml penicillin and 100 ug/ml streptomycin), centrifuged at 600 x g for 5 minutes at room temperature, resuspended in cell culture medium, and cultured.

15 9(h). Human Fibroblasts: Human fibroblasts were isolated from skin biopsies as described in Section 6.

10. Rat Cell Purification: Contaminating fibroblasts were removed from populations rat cardiomyocytes, smooth muscle cells, vascular endothelial cells by preplating (Simpson et al., *Circulation Research* 51:787-801, 1982), which takes advantage of the finding that fibroblasts attach to a cell culture dish more rapidly than do other cells. Freshly isolated cells were plated on dishes and cultured for 2 hours at 37°C, after which the culture medium containing the suspended cells (minus the fibroblasts adhering to the dishes) was transferred into another dish for further culturing.

Pure populations of cells may also be obtained by clonal dilution. The cells are seeded at low density and allowed to form individual cell colonies. Any cell not of the desired type that is adjacent to a colony of interest is killed with a sterile needle.

-20-

Desired colonies are then collected using a sterile Pasteur pipette, and transferred to new culture dishes for culturing and passaging.

Human cardiomyocytes were used without a purification step.

5        **11. Cell Identification:**

Cardiomyocytes: The purity of primary cultures of cardiomyocytes was assessed by immunofluorescent staining for cardiac myosin heavy chain (Rougier Bio-Tech Ltd, Quebec, Canada) (Li R-K, et al., *Cardiovascular Research* 32:362-73, 1996). The cultured cells were fixed with methanol at -20°C for 15 minutes, washed with phosphate buffered saline, incubated with a monoclonal antibody against cardiac myosin heavy chain for 45 minutes at 37°C, washed three times with phosphate buffered saline for 5 minutes each at room temperature, and then under humid and dark conditions incubated with rabbit anti-mouse IgG conjugated with fluorescein isothiocyanate for 45 minutes at 37°C. The cells were washed with phosphate buffered saline, mounted and photographed using a light and UV microscope. The purity of cardiomyocyte cultures was determined by counting the percentage of stained cells in 8 random fields/dish. Eight dishes of cardiomyocyte cultures were used in each cardiomyocyte preparation.

Smooth Muscle Cells: The purity of smooth muscle cell cultures was determined by immunofluorescent staining for  $\alpha$ -smooth muscle cell actin (Sigma, St. Louis, MI) as described in the previous paragraph.

Vascular Endothelial Cells: The purity of endothelial cell cultures was determined by immunofluorescent staining for factor VIII as described in the cardiomyocyte section above.

Fibroblasts: The purity of fibroblast cell cultures was determined by examining cell morphology with a microscope.

-21-

**B) CELL TRANSPLANTATION**

Subject animals were grouped into three categories: sham, control and transplantation. The criteria for such grouping was as follows:

5

Group	Surgical exposure	Scar generation	Cell transplantation
Sham	X		
Control	X	X	
Transplantation	X	X	X

10

1. Surgical Exposure: Sprague-Dawley rats (500 gram) were anesthetized with ketamine (22 mg/kg body weight, intramuscular) followed by an intraperitoneal injection of pentobarbital (30 mg/kg body weight). Once anaesthetized, rats were intubated and positive pressure ventilation was maintained with a Harvard ventilator (Model 683, USA). The respiratory rate was set at 60 cycles/minute with a tidal volume of 2 ml. Animals were ventilated with oxygen-supplemented room air. The heart was exposed through a 2-cm left lateral thoracotomy. The muscle layer and skin incision were surgically closed with 5-0 vicryl sutures.

15

2. Myocardial Injury and Myocardial Scar Generation: The hearts of the adult rats were exposed as described in the previous paragraph. A 5-mm-diameter metal probe cooled to -190°C for 2 minutes was applied to the left ventricular free wall of the heart for 20 seconds. This procedure was repeated 8 times. The muscle layer and skin incision were then surgically closed with 5-0 vicryl sutures.

20

The animals recovered from surgery in a warm environment, were monitored for 4 hours postoperatively and then given Penlog XL (benzathine penicillin G 150,000 U/ml and procaine penicillin G 150,000 U/ml) intramuscularly (0.25 ml/rat) every three days, and buprenorphine (0.01-0.05 mg/kg body weight) subcutaneously 8-12 hourly for the first 48 hours following surgery.

25

3. Transfection of the Cultured Cardiomyocytes: Freshly isolated or cultured cells were transfected by calcium phosphate coprecipitation (Shi Q-W, et al., *Journal*

30

-22-

of Molecular and Cell Cardiology 24:1221-1229, 1992) with a plasmid containing the  $\beta$ -galactosidase gene. Plasmid DNA (20  $\mu$ g) dissolved in 450  $\mu$ l of sterile water and 50  $\mu$ l of 2.5 M CaCl<sub>2</sub> was slowly added to 500  $\mu$ l of aerated 2X HEPES-buffered saline (0.284 M NaCl, 0.050 M HEPES acid, and 1.48 mM Na<sub>2</sub>HPO<sub>4</sub>, pH 7.05). After 5 20 minutes at room temperature, the solution was added to a cardiomyocyte suspension (1.0 X 10<sup>6</sup> cells/6 ml of culture medium). In the control groups the same procedure was performed either without plasmid DNA or with pREP4 (a plasmid that lacks a  $\beta$ -galactosidase gene; Invitrogen, Carlsbad, CA). The cells were cultured at 37°C, 5% CO<sub>2</sub> and 95% air for 24 hours.

10 To determine the efficiency of cell transfection, cells cultured for either 24 hours or 4 weeks were washed three times with phosphate buffered saline, fixed in 2% formaldehyde and 2% glutaraldehyde in phosphate buffer (0.15 M NaCl and 0.015 M NaH<sub>2</sub>PO<sub>4</sub>, pH 7.2) at 4°C for 5 minutes, washed with phosphate buffer containing 2.0 mM MgCl<sub>2</sub>, and stained overnight at 37°C in a solution containing 1 mg/ml 5-bromo-15 4-chloro-3-indolyl-beta-galactopyranoside (X-gal), 5 mM K<sub>3</sub>Fe(CN)<sub>6</sub>, 5 mM K<sub>4</sub>Fe(CN)<sub>6</sub>·3H<sub>2</sub>O, 0.2 mM MgCl<sub>2</sub> in phosphate buffer (pH 7.2). The stained and non-stained cells in 8 random fields/dish (6 dishes from 6 preparations) were counted under the microscope to determine the percentage of cells containing  $\beta$ -galactosidase activity. Two dishes from each transplant experiment were used for a cell transfection 20 efficiency study (N (number of animals) = 6).

4. Cell Preparation and Transplantation: Cultured cells were washed three times with phosphate buffered saline to remove dead cells and then detached from the cell culture dish and each other with 0.05% trypsin in phosphate buffered saline for 3 minutes. After adding 10 ml of culture medium, the cell suspension was centrifuged 25 at 580 X g for 3 minutes. The cell pellet was resuspended in culture medium at a concentration of 4 X 10<sup>6</sup> cells/ml culture medium. The volume of cell suspension was 0.25 ml for each cell transplantation.

On day 14 or 30 following myocardial scar generation (as described in Section

-23-

2), the animals (which now had mature transmural scars in their ventricles) were anesthetized as described in Section 1. The scar tissue in the heart was exposed through a midline sternotomy. The cell suspension (0.25 ml) was injected into the scar tissue of the animals of the transplant group using a tuberculin syringe. Control 5 animals were similarly injected with 0.25 ml of culture medium alone (i.e., no cells). The rats in the sham group underwent the surgical procedure without injection. Cryo-precipitate (fibrin glue) was placed on the injection sites to prevent leakage of the injected cells. The chest was closed with 5-0 vicryl sutures. Antibiotics and analgesia were given as described in Section 1. Cyclosporin A, at a dose of 5 mg/kg body 10 weight/day, was administered subcutaneously into animals of all three groups. The rats were housed in cages with filter tops.

### C) MEASUREMENT OF HEART FUNCTION

Eight weeks after myocardial injury, the heart function of sham, control and 15 transplanted animals was measured using a Langendorff preparation (Stephen SE, et al., *Annals of Thoracic Surgery* 59:1127-1133, 1995). The rats were anesthetized and heparin (200 units) was administered intravenously. The hearts were quickly isolated from rats and perfused in a Langendorff apparatus with filtered Krebs Heinseleit buffer (mmol/L NaCl 118, KCl 4.7, KH<sub>2</sub>PO<sub>4</sub> 1.2, CaCl<sub>2</sub> 2.5, MgSO<sub>4</sub> 1.2, NaHCO<sub>3</sub> 25, 20 glucose 11; pH 7.4) equilibrated with a 5% CO<sub>2</sub> and 95% O<sub>2</sub>. A latex balloon was passed into the left ventricle through the mitral valve and connected to a pressure transducer (Model p10EZ, Viggo-Spectramed, CA) and transducer amplifier and differentiator amplifier (Model 11-G4113-01, Gould Instrument System Inc., Ohio). After 30 minutes of stabilization, coronary flow in the heart was measured in triplicate 25 by timed collection in the emptying beating state. The balloon size was increased by addition of saline in 0.02 ml increments from 0.04 to 0.8 ml, or the volume at which end diastolic pressure reached to 30 mm Hg, or whichever came first. The systolic and diastolic pressures were recorded at each balloon volume and developed pressure

-24-

was calculated as the difference between the systolic and diastolic pressures.

Hearts were weighed and their sizes were measured by water displacement.

#### D) MEASUREMENT OF LEFT VENTRICULAR REMODELING

The epicardial and endocardial surface areas of the normal and scar tissue in the left ventricular free wall (LVFW) were measured by the techniques of Pfeffer et al. (Pfeffer JM, et al., *American Journal of Physiology* 260:H1406-14, 1991) and Jugdutt and Khan (Jugdutt BI, et al., *Circulation* 89:2297-307, 1994). Briefly, the hearts were fixed in distension (30 mm Hg) with 10% phosphate-buffered formalin solution and then cut into 3-mm sections. For each section, the area of normal tissue, scar tissue, and transplanted tissue in the left ventricular free wall were traced onto a transparency and quantified using computerized planimetry (Jandal Scientific Sigma Scan, USA) as described by Wu et al. (Wu TW, et al., *Cardiovascular Research* 27:736-39, 1993). The lengths of left ventricular free wall and scar tissue on both the endocardial and epicardial surfaces of each section were measured. The surface areas of the epicardial and endocardial scar tissue and left ventricular free wall were measured as:

$$(endocardial length + epicardial length) \times \text{section thickness (3 mm)}.$$

The surface area percentage of scar tissue in the left ventricular free wall (LVFW) was calculated as:

$$\frac{(epicardial scar size + endocardial scar size)}{(endocardial LVFW1 + epicardial LVFW)} \times 100$$

To calculate the percentage of the surface area in the scar tissue occupied by the transplanted tissue, the following equation was used:

$$\frac{(cardiac tissue length in the scar tissue of each section) \times (\text{section thickness (3 mm)})}{(\text{total scar area})} \times 100$$

-25-

**E) HISTOLOGY AND ELECTRON MICROSCOPY OF TRANSPLANTED CELLS**

On day 30 or 45 post-transplantation, the animals were anesthetized as in Section 1 and transplant, control, and sham hearts were exposed through a midline sternotomy and quickly harvested. The animals were euthanised by exsanguination under general anesthesia.

To localize the tissue formed by transplanted cells, the transplanted and control myocardial scar tissues were fixed in 5% glacial acetic acid in methanol. The tissue was embedded in paraffin and cut into 10- $\mu$ m sections. After removal of the paraffin by immersing the sections for 3 minutes in xylene and then in 100%, 95%, 90%, 85%, and 70% ethanol for 3 minutes each, the samples were stained with haematoxylin and eosin as described by the manufacturer (Sigma Diagnostics, St. Louis, MO), and photographed.

To stain for  $\beta$ -galactosidase activity in the transplanted cardiomyocytes, the heart sections were fixed at 4°C for 12 hours in 2% formaldehyde and 2% glutaraldehyde in phosphate buffer (0.15 M NaCl and 0.015 M NaH<sub>2</sub>PO<sub>4</sub>, pH 7.2). The transplanted cardiomyocytes were localized by staining for  $\beta$ -galactosidase activity as described earlier in Section B above. The stained tissue was embedded in paraffin and cut into 10- $\mu$ m sections that were stained with haematoxylin and eosin as described above.

To identify cultured ventricular and atrial cardiomyocyte transplants, the transplanted heart tissue was immunofluorescently stained for cardiac myosin heavy chain. Briefly, tissue sections were washed three times with phosphate buffered saline and fixed with 2 ml 100% cold methanol at -20°C for 15 minutes. After washing three times with phosphate buffered saline and drying by draining, the tissue sections were exposed for 45 minutes at 37°C to monoclonal antibodies against cardiac myosin heavy chain (Rougier Bio-Tech, Montreal, Canada), diluted 1:20 with saline. Control tissues were incubated under the same conditions with phosphate buffered saline. The tissues were washed three times with phosphate buffered saline for 15 minutes at room

-26-

temperature with gentle shaking, after which the secondary antibody, rabbit anti-mouse IgG conjugated with fluorescein isothiocyanate at a concentration of 1:32 dilution with phosphate buffered saline, was added. The tissues were incubated with the second antibody under dark and humid conditions for 45 minutes at 37°C. After 5 washing with phosphate buffered saline, the cells in the transplant control tissues were visualized under ultraviolet light using an epi-microscope with a blue filter.

The smooth muscle cell transplants were identified by staining immuno-fluorescently using a monoclonal antibody for  $\alpha$ -smooth muscle actin as the primary antibody. Endothelial cell transplants were identified by immunofluorescent staining 10 for factor VIII, as described in the next section.

Fibroblast transplants were identified by the presence of a localized immunorejection within the ventricular scar.

15 **F) HISTOLOGICAL AND ELECTRON MICROSCOPY STUDIES OF ANGIOGENESIS IN THE GRAFT**

For immunocytochemical staining of factor VIII-related antigen in the vascular endothelial cells, tissue sections processed as in Section E above were incubated with xylene twice for 5 minutes each, 100% ethanol twice for 2 minutes each and then with 70% ethanol twice for 1 minute each. The sections were incubated with rabbit IgG 20 against factor VIII-related antigen (Dimension Lab. Inc., Ontario). The control samples were incubated with phosphate buffered saline under the same conditions. The test and control samples were incubated with goat anti-rabbit IgG conjugated with peroxidase. After washing the samples three times with phosphate buffered saline following secondary antibody staining, the samples were immersed in 25 diaminobenzidine-H<sub>2</sub>O<sub>2</sub> (2 mg/ml diaminobenzidine, 0.03% H<sub>2</sub>O<sub>2</sub> in 0.02 M phosphate buffer) solution for 15 minutes. The samples were washed with phosphate buffered saline. The stained vascular endothelial cells in the grafts (N=17) and control groups (N=14) were counted using a light microscope at 200X magnification. The result was

-27-

expressed as number of blood vessels/field area (0.8 mm<sup>2</sup>).

For electron microscopy studies, hearts were fixed in 1% glutaraldehyde in phosphate buffer, postfixed with 1% osmium tetroxide, dehydrated in graded ethanol (50%, 70%, 90%, and 100%), polymerized in propylene oxide at 60°C overnight, sectioned, and examined using a JEOL 1200 TEM electron microscope (Li R-K, et al., *Cardiovascular Research* 32:362-73, 1996).  
5

#### G) CELL GRAFTS

Cultured cardiomyocytes, smooth muscle cells, endothelial cells, and/or fibroblasts were seeded onto biological mesh, such as a collagen membrane, and on non-biological membranes, such as non-degradable membranes (Dacron) or degradable membranes (polyglycolic acid polymers), and the mesh and cells were cultured in cell culture medium. Seven days after culture, the cell-containing mesh was fixed in 2% formaldehyde and 2% glutaraldehyde in phosphate buffer (0.15 M NaCl and 0.015 M NaH<sub>2</sub>PO<sub>4</sub>, pH 7.2) at 4°C for 12 hours, embedded in paraffin, and 10  
15 cut into 10-μm sections, which were stained with haematoxylin and eosin as described in Section E, and photographed.

#### H) CELL GLUING TECHNIQUE FOR CELL TRANSPLANTATION

A sufficient cardiomyocytes must be implanted into the infarcted myocardium to successfully prevent heart failure. Although this can be done by multiple syringe injections, injecting the cells, unfortunately, limits the number of cells which can be transplanted into myocardial scar tissue. We have investigated another technique to apply a large number of cells onto the infarcted myocardium. Thrombin and 20 cryoprecipitate (fibrin glue), which are derived from human blood, clot rapidly. Our *in vitro* results showed survival and contraction of cardiomyocytes in fibrin clots. We 25 used this fibrin glue for cell transplantation.

-28-

1. Gluing Injection Site to Prevent Transplanted Cell Leakage: The biological glue is applied onto the injection site while the injection needle is still in place. The needle is withdrawn after the glue clots. In such manner, leakage of transplanted cells, as discussed previously, is prevented.

5        2. Gluing the Cells onto the Myocardial Scar Tissue to Prevent Injection

Damage: We removed the epicardium over the scar and damaged myocardium. The transplanted cells were suspended in thrombin, and the thrombin/cell suspension was applied onto the myocardial scar tissue with cryoprecipitate (fibrin glue). The glue caused the cell suspension to adhere to the surface of both the scarred and normal myocardium, after which the pericardium was glued on top of the fibrin clot; this procedure prevented loss of the transplanted cells. We found that glued cardiomyocytes can survive on the myocardial scar tissue and permit a large number of cells to be transplanted. This technique improved heart function better than cell injection alone. The cardiomyocytes glued directly onto the myocardium without epicardium can connect with host cardiomyocytes and cardiomyocytes to contract synchronously with the host myocardium.

10        3. Gluing the Cellular Mesh onto the Myocardial Scar Tissue to Prevent Its Expansion: Cell grafts comprising biological or non-biological mesh having cells suspended thereon (as described in Section G) were glued onto the scar tissue. The pericardium was in turn glued on top of the mesh.

15        I) DATA ANALYSIS

20        Data are expressed as the mean  $\pm$  standard error. The Statistical Analysis System software was used for all analysis (SAS Institute, Cary, NC). Comparisons of continuous variables between more than two groups were performed by a one-way analysis of variance. If the F ratio was significant from the analysis of variance, a Duncan's multiple-range t test was employed to specify differences between the groups. Alpha for these analyses was set at p<0.05.

-29-

Function data were evaluated for the sham, control and transplant groups by an analysis of covariance using intracavitory balloon volume as the covariate and systolic, diastolic and developed pressure as dependent variables. Main effects were group, volume, and the interaction between group x volume. If there was an overall difference in the analysis of covariance, multiple pair-wise comparisons were performed to specify which groups were different. Because there were multiple pairwise comparisons, a Bonferroni correction was performed and the critical alpha level was set at 0.01 for the analysis of covariance.

10 J) USE OF GROWTH FACTORS IN TREATING IDIOPATHIC HYPERTROPHIC CARDIOMYOPATHY (HCM)

Idiopathic hypertrophic cardiomyopathy (HCM) is a primary cardiac abnormality characterized by regional asymmetrical myocardial hypertrophy. The hypertrophic myocardium can result in obstruction of left ventricular ejection as well 15 as systolic and diastolic dysfunction and myocardial ischemia. Symptoms unresponsive to medical therapy can necessitate surgery.

HCM is described for the most part as a heterogeneous disease of the sarcomeres. At least 34 missense mutations have been described in the  $\beta$ -myosin heavy chain gene, and 7 mutations in candidate loci also exist. However, family 20 studies suggest that the autosomal dominant trait accounts for only 50% of HCM patients. The remaining HCM patients show no familial transmission and the disease occurs sporadically. Myocardial calcium kinetics and sympathetic stimulation have been studied because of diastolic functional abnormalities. However, none of these findings explains the regional myocardial hypertrophy (cardiomyocyte hypertrophy and over production of extracellular matrix proteins) observed in most HCM patients. The etiology of this disease remains unknown. It is thought that growth factors may 25 play an important role in cardiomyocyte proliferation, cell hypertrophy and the overproduction of extracellular matrix.

-30-

To investigate the involvement of growth factors in myocardial hypertrophy in HCM patients, we evaluated gene expression and cellular localization of transforming growth factor  $\beta$ 1 (TGF $\beta$ 1), insulin-like growth factors (IGF-I, -II), and platelet-derived factor-B (PDGF-B) in ventricular biopsies obtained from patients with HCM (N = 8), aortic stenosis (AS, N = 8), stable angina (SA, N = 8), and explanted hearts with ischemic cardiomyopathy (TM, N = 7).

**Methods:** Levels of TGF $\beta$ 1, IGF-I, IGF-II and PDGF-B transcripts were quantitated using multiplex RT-PCR. Glyceraldehyde 3-phosphate dehydrogenase (G3PDH) was used as an internal standard. Antibodies against TGF $\beta$ 1 and IGF-I were used to localize their peptides within the myocardium. Antisense and sense (control) cRNA probes for TGF $\beta$ 1 and IGF-I, labeled with digoxigenin, were used to localize the growth factor transcripts by *in situ* hybridization.

**Results:** mRNA levels (densitometric ratio of GF/G3PDH) of TGF $\beta$ 1 and IGF-I in HCM myocardium ( $0.75 \pm 0.05$ ,  $0.85 \pm 0.15$ , mean  $\pm$  1SE) were significantly (p < 0.01 for all groups) elevated in comparison to non-HCM myocardium (AS:  $0.38 \pm 0.07$ ,  $0.29 \pm 0.06$ ; SA:  $0.32 \pm 0.04$ ,  $0.18 \pm 0.05$ ; TM:  $0.25 \pm 0.03$ ,  $0.15 \pm 0.03$ ). mRNA level of TGF $\beta$ 1 and IGF-I in the hypertrophic AS myocardium were greater (p = 0.02, p = 0.05) than those in the explanted myocardium (TM). Immunohistochemical and *in situ* hybridization studies showed increased expression of TGF $\beta$ 1 and IGF-I in the HCM cardiomyocytes.

**Conclusion:** Gene expression of TGF $\beta$ 1 and IGF-I was enhanced in idiopathic hypertrophy and may be associated with its development.

## II) RESULTS

**1. Ventricular and Atrial Cardiomyocytes:** Fetal and adult mammalian ventricular cardiomyocytes and adult mammalian atrial cardiomyocytes were isolated using enzymatic digestion as described above in Sections A1-A3. After purification, the purity of the cultured ventricular and atrial cardiomyocytes was

-31-

greater than 94% (N=8) as determined by the percentage of cells that stained for cardiac myosin heavy chain. The cardiomyocytes grew *in vitro*, connected with each other and formed a tissue pattern after six days of culture. The fetal cardiac-like tissue contracted regularly and spontaneously in culture. The adult 5 cardiomyocytes did not contract in culture.

2. Smooth Muscle Cells: Fetal and adult smooth muscle cells were successfully cultured. The cells proliferated in the culture. The cultured cells were stained strongly with antibodies against  $\alpha$ -smooth muscle actin.

10

3. Vascular Endothelial Cells: Endothelial cells were isolated from blood vessel and cultured. Staining with antibody against factor VIII showed that more than 95% cells in the culture dish were endothelial cells.

15

4. Fibroblasts: Fetal and adult skin fibroblasts were isolated and cultured. The cells proliferated in the culture condition. When the culture reached confluency, the cells formed a typical fibroblast pattern: spindle-shaped cells in a wave pattern.

20

5. Cell Transfection: Twenty-four hours after transfection of freshly isolated cells, the percentage of the transfected cells with  $\beta$ -galactosidase was  $18.2 \pm 5.2\%$  (N=6). No cells stained positively in the control groups with plasmid pREP4 (N=6) and without a plasmid (N=6). After culturing for 4 weeks,  $5.4 \pm 3.1\%$  (N=6) of the transfected cells stained positively for  $\beta$ -galactosidase activity.

25

6. Myocardial Scar Tissue: Immediately after myocardial injury,  $25 \pm 3\%$  of the left ventricular free wall (LVFW) was transmurally damaged. The cardiomyocytes were fragmented. At one week, most of the necrosed

cardiomyocytes were gone and a predominantly mononuclear inflammatory infiltrate was present in the affected area. At two weeks the inflammatory infiltrate had almost disappeared and fibroblasts and collagen deposition were evident. At four and eight weeks, the scar was composed of fibrotic tissue. The tissue was less 5 cellular and lymphocytes were not observed. No cardiac muscle cells were observed in any scar tissue.

The myocardial scar of the left ventricle increased in size over the 8 week study period in the control hearts. Although the scar sizes at 1 and 2 weeks ( $13 \pm 6$  % and  $21 \pm 4$  % of left ventricular free wall) were not statistically different, the 10 scar size after 4 weeks ( $39 \pm 5$  % of left ventricular free wall) was greater ( $p<0.01$ ). At 8 weeks there was a further increase ( $p<0.01$ ) in scar size ( $55 \pm 3$  % of left ventricular free wall).

15 7.Optimal Time for Cell Transplantation: The fetal rat cardiomyocytes transplanted into myocardial tissue immediately after myocardial damage did not survive in the affected area. The scar area ( $53 \pm 5$  %) of transplanted hearts was similar to that of the control group ( $55 \pm 3$  % of the left ventricular free wall). Cardiomyocytes transplanted at 2 weeks after myocardial damage formed cardiac 20 tissue that occupied 34% of the total scar area ( $11 \pm 3$  % of the left ventricular free wall). Similarly, cardiomyocytes transplanted at 4 weeks occupied 32% of total scar area ( $14 \pm 4$  % of left ventricular free wall). The scar sizes in the hearts that received transplants 2 weeks and 4 weeks after myocardial damage were smaller 25 ( $p<0.01$ ) than the scar size of the control hearts. The scar size of the hearts that received transplants 2 weeks after myocardial damage was smaller ( $p<0.01$ ) than that of the hearts that received transplants 4 weeks after myocardial damage.

8.Transplanted Cells in Myocardial Scar Tissue: Cells were transplanted into transmural scars two and four weeks after scar cryo-induction. Six weeks or

-33-

four weeks after ventricular cardiomyocyte transplantation (i.e., eight weeks after scar induction in all animals (N=17)), only fetal cardiomyocyte tissue had formed within the myocardial scar tissue. The cells were connected to each other and formed a cardiac tissue pattern.  $\beta$ -galactosidase activity was observed in the tissue of all three animals transplanted with cardiomyocytes transfected with the  $\beta$ -galactosidase gene. The transplanted cardiomyocytes contained sarcomeres and were connected by junctions composed of desmosomes and fascia adherens, which were not present in the cardiomyocytes immediately prior to transplantation.

5 Lymphocytic infiltration surrounded the cardiac tissue formed by transplanted fetal cardiomyocytes. In the control animals (N=14), cardiac tissue, lymphocytic infiltration, and  $\beta$ -galactosidase activity were not observed in the scar. Eight-

10 week-old scar tissue was less cellular than four-week-old scar tissue.

Adult rat atrial cardiomyocytes were autotransplanted into the scar tissue of the same rat. At 6 weeks after transplantation, the transplanted cells were detected in the myocardial scar tissue by staining with an antibody against cardiac myosin heavy chain. There was no lymphocytic infiltration. No cardiac tissue was found

15 in the scar tissue of control rats.

At 6 weeks after transplantation, scars transplanted with either allo- or auto-smooth muscle cells contained smooth muscle tissue that stained positively for  $\alpha$ -smooth muscle actin. The allotransplants were infiltrated with lymphocytes,

20 indicative of immuno-rejection. In contrast, there was no lymphocytic infiltrate or signs of immunorejection in the auto-smooth muscle cell transplant.

Fig. 1 shows the improved cardiac function of scarred hearts transplanted with smooth muscle cells. Hearts were cryo-injured, after which the mature scar tissue was transplanted with allogenic smooth muscle cells. Function

25 measurements were made four weeks after transplantation. The graph shows developed balloon pressures of sham (top line; no cryo-injury, no transplantation), control (bottom line; cryo-injury, no transplantation), and transplanted (middle

-34-

line) hearts with increasing balloon volumes. Developed pressures of transplanted hearts were significantly higher than control hearts ( $p=0.0001$ ), but lower than that sham of sham hearts ( $0=0.0001$ ).

At 6 weeks after transplantation, the transplanted fibroblasts proliferated in the myocardial scar tissue. The cells secreted extracellular matrix, which increased the thickness of the scar tissue. The transplanted cells also stimulated angiogenesis (see below), which survived damaged myocardial tissue in the scar tissue. There were no cardiac muscle cells in the scar tissue in control animals. The scar tissue at the left ventricular free wall of the control hearts dilated during systole, whereas scar tissue containing transplanted cells was immobile. Although the surface area of transplanted scar tissue ( $22.9 \pm 6.2 \text{ mm}^2$ ) was similar to that of control scar tissue ( $23.8 \pm 6.5 \text{ mm}^2$ ), scar thickness ( $1.9 \pm 0.9 \text{ mm}$ ,  $N=12$ ) in hearts containing transplanted cells was twice ( $p<0.01$ ) that of the control hearts ( $1.0 \pm 0.4 \text{ mm}$ ,  $N=10$ ). Consistent with the above findings, the left ventricular volume of the transplanted hearts was  $275 \pm 48 \text{ mm}^3$  ( $N=12$ ) which was less ( $p<0.01$ ) than the  $360 \pm 94 \text{ mm}^3$  volume of the control hearts ( $N=10$ ).

Although a detailed observation was not made of transplanted endothelial cells, staining with antibody against factor VIII revealed that more cells stained positively in scar tissue transplanted with endothelial cells than in the control scar tissue.

**9. Angiogenesis in Myocardial Scar Tissue after Cell Transplantation:** At 4 to 6 weeks after transplantation, examination by histology and electron microscopy showed that angiogenesis occurred in the transplanted fetal ventricular cardiomyocyte transplant. Significantly more arterioles and venules were found ( $p<0.01$ ) in the cardiomyocyte grafts ( $1.2 \pm 0.6 \text{ vessels}/0.8 \text{ mm}^2$ ,  $N=14$ ) than in the control myocardial scar tissue ( $0.1 \pm 0.1 \text{ vessels}/0.8 \text{ mm}^2$ ,  $N=14$ ).

Similarly, angiogenesis occurred in the atrial cell, endothelial cell, smooth

muscle cell, and fibroblast cell transplants.

10. Transplanted Cells Limited Scar Expansion: At 4 to 6 weeks after transplantation of the cells, the heart rate and coronary flow did not differ among the sham, control and transplanted animals. The control myocardial wall at the site of injury had thinned and consisted of fibrous tissue and a few blood vessels. No cardiac muscle or lymphocytes were present. The control and transplanted hearts were larger ( $p<0.01$ ) than the sham (undamaged) hearts. At 4 weeks after cryo-injury,  $36.4 \pm 4.4\%$  (mean  $\pm$  1 SE, N=5) of the left ventricular free wall in the pretransplant animals was replaced with a transmural scar. At 8 weeks, the scar tissue expanded ( $p<0.01$ ) in the control group to  $54.6 \pm 2.9\%$  (N=5) of the free wall for the fetal cardiomyocytes. The scar tissue in the transplanted animals was  $43.4 \pm 1.8\%$  (N=5) of the left ventricular free wall. This did not significantly differ from the pretransplanted animals at 4 weeks after cryo-injury and was less ( $p<0.05$ ) than the control hearts at 8-weeks after cryo-injury. The transplanted cardiomyocytes formed cardiac tissue which occupied  $36.5 \pm 3.5\%$  (N=5) of the scar tissue. The transplanted tissue visibly contracted. We were unsuccessful in measuring its contractility because of the contractions of the heart. After removing the hearts and separating the scar area, the transplanted region continued to contract when stimulated.

Similarly the atrial cell, smooth muscle cell, and fibroblast transplants limited scar expansion.

11. Improvement of Heart Function by Transplanted Cells: Ventricular function of hearts into which cells were transplanted immediately after myocardial injury was similar to that of control hearts. Analysis of covariance demonstrated no interaction between balloon volume and treatment group for developed pressures. Ventricular function of the transplanted and the control hearts when the

-36-

cardiomyocytes were transplanted at 2 weeks after myocardial injury was different because an analysis of covariance demonstrated a significant ( $p<0.05$ ) interaction between balloon volume and treatment group for developed pressures. The transplanted hearts had better ( $p<0.05$ ) function than the control hearts. Similarly 5 cells transplanted at 4 weeks after myocardial necrosis improved ( $p<0.05$ ) myocardial function. The hearts transplanted at 2 weeks had higher ( $p<0.05$ ,  $p<0.05$ ,  $p<0.05$ ) developed pressures at balloon volumes 0.1, 0.2, and 0.3 ml than hearts transplanted at 4 weeks.

In the measurements of ventricular function in the sham-operated, the 10 transplanted and the control hearts, an analysis of covariance demonstrated a significant ( $p<0.05$ ) interaction between balloon volume and treatment group for systolic, diastolic and developed pressures. Pairwise comparisons demonstrated a significant ( $p<0.05$ ) depression in systolic and developed pressures in control animals compared to the sham-operated normal hearts. The transplanted hearts 15 had better ( $p<0.05$ ) function than the control hearts although both systolic pressure and developed pressure were lower ( $p<0.05$ ) than the sham-operated normal hearts. Diastolic pressures were significantly lower in both the cryo-injured controls and the transplanted hearts than sham-operated normal hearts at higher balloon volumes due to the marked dilatation resulting from myocardial scar expansion.

20

12. Tissue Engineered Grafts: Cardiomyocytes, smooth muscle cells, fibroblasts, and endothelial cells were observed in the mesh of the grafts. The tissue that formed in the mesh stained strongly with haematoxylin and eosin.

25

## SUMMARY

From the above results, it can be seen that we have successfully transplanted muscle and non-muscle cells in cardiac scar tissue. These cells formed viable tissue, altered structure of the scar, improved heart function,

stimulated angiogenesis, and expressed a gene foreign to the scar. From these results, the following conclusions are drawn:

5       I. Cultured adult atrial cardiomyocytes could be successfully transplanted into the scar. The atrial tissue could be digested and the atrial cells immediately transplanted, or the atrial tissue could be digested and the resulting atrial cells could be cultured and passaged up to five times and then transplanted. Autologous and allogeneic transplantation of cultured adult atrial cardiomyocytes formed tissue within the scar. Heart function improved and angiogenesis occurred. No 10 immunorejection occurred with auto-transplantation of the adult atrial cardiomyocytes.

15       II. Smooth muscle cells can be successfully auto- or allo-transplanted into the scar. Smooth muscle tissue formed within the scar. No immunorejection occurred with the auto-transplantation. Heart function improved and angiogenesis occurred. The cells can be freshly isolated, or cultured and passaged before transplanting.

20       III. Fibroblasts can be successfully transplanted into scar tissue. Scar thickness increased. Heart function improved, angiogenesis occurred, and host cardiomyocytes survived in the scar. The cells can be freshly isolated, or cultured and passaged before transplanting.

25       IV. The addition of cryo-precipitate to the injection site prevented leakage of the transplanted cells from the scar.

V. A plasmid containing a foreign gene to the scar tissue and heart tissue was transfected into the cultured cells to be transplanted. The cells were

successfully transplanted into the scar tissue and expressed the foreign gene.

VI. Cardiomyocytes, smooth muscle cells, skeletal muscle cells, fibroblasts, and endothelial cells can be successfully transplanted into fibrous membranes and  
5 non-degradable or biodegradable polymers to form tissue. The product of such a process would be a patch which can have various clinical and therapeutic uses.  
Such membranes may be made from Dacron or biodegradable sheets such as polyglycolic acid polymers with or without polylactic acid polymers. Such a patch can be associated with a pacemaker and be implanted close to a cardiac defect,  
10 thereby providing a means of paced cardiomyoplasty.

VII. Cell combinations could be successfully transplanted to form tissue within a scar to improve function, to stimulate angiogenesis, and to form tissue.

15 VIII. The optimal time for transplantation is immediately after the acute inflammatory response to the myocardial injury has disappeared.

IX. Adult mammalian atrial and ventricular cardiomyocytes can be successfully isolated from human myocardium, cultured, passaged and stored  
20 using the cell culture procedure described for human cardiomyocytes described in the Human Cell Isolation, Culturing and Storage section. Human cardiomyocytes can be prepared for long term storage in liquid nitrogen and thawed for culturing as described. Such cultured cells can then be used in forming grafts as discussed above.

25 X. The biological glue technique used in the cell transplantation procedure increased the number of cells transplanted in myocardial scar tissue. This invention enhanced the transplant success rate and maximized the improvement of

heart function.

Co-transplantation of growth factors such as IGF-I, IGF-II, TGF- $\beta$ 1 and PDGF-B increases the survival of transplanted cells, induces transplanted muscle hypertrophy, and stimulates angiogenesis. Based on these findings, the use of other growth factors such as fibroblast growth factor and vascular endothelial growth factor are also possible. Such growth factors can be co-transplanted either alone or in combination. These techniques can increase transplanted muscle size and survival in myocardial scar tissue and damaged myocardial tissue.

10 XI. Cultured cells can be employed to restore regional cardiac function and blood flow to regions in the heart damaged by acquired disease processes or absent because of congenital defects. During reconstructive surgery, the defective portion of the heart is removed and replaced with inert materials to secure a water-tight seal. Attaching a contracting tissue of myocytes to the reconstruction patch will permit the return of function to the destroyed region. Implantation of a collection 15 of cells could restore function and improve the quality of life of the patients undergoing reconstructive surgery.

20 XII. Most acquired or congenital cardiac defects are closed with inert materials intended to provide a water-tight seal. Instead of an inert material, a graft consisting of a biodegradable or non-biodegradable scaffolding supporting cultured cells can be employed to close such cardiac defects. The graft would employ myocytes enhanced with genes to increase perfusion and contractility (by increasing the size and number of myocytes). In addition, endothelial cells can be 25 applied to the blood surface of the graft to prevent intravascular clot formation in the heart. The endothelial cells could be genetically engineered so that they produce proteins that prevent clot formation on the blood surfaces. The cellular grafts will permit closure of acquired and congenital cardiac defects with

-40-

functioning tissue which may improve heart function.

XIII. Cardiac surgeons frequently remove segments of the heart which have been damaged or are defective due to congenital abnormalities. A cellular graft permits an opportunity to restore function to regions which are usually closed with inert materials. The graft may consist of myocytes grown on biodegradable scaffolding. Endothelial cells can be grown on the blood interface layer. The cells will create a functioning graft which will replace the region removed at the time of surgery. The functioning myocardial graft could restore function for patients who have suffered a myocardial infarction and require removal of the destroyed regions. The functioning graft could re-establish systematic and/or pulmonary circulation for patients with extensive congenital defects undergoing reconstructive surgery. A functioning myocardial graft offers the promise of improving the quality of life for disabled individuals.

15

### **III) EFFECT OF DONOR AGE ON CONTRACTILITY OF TRANSPLANTED RAT CARDIOMYOCYTES**

The inability of heart muscle to regenerate following myocardial necrosis is an important clinical problem. Our previous research has shown survival and contractility of transplanted fetal rat cardiomyocytes (CMs) in adult rat skeletal muscle. The experiment described below focuses on the effect of donor age on contractility of transplanted CMs.

#### **Methods:**

25 CMs were isolated from 18-day gestation, 5-, 22-, 32-, and 62-day old Sprague-Dawley rat hearts and cultured for 1 day. 2 to 5 x 10<sup>6</sup> cells in saline were injected into the skeletal muscle of one adult rat leg. The other leg (control) was injected with saline alone. Cell viability and function were assessed visually and

-41-

by ultrasound and electrocardiography (ECG).

**Results:**

In the groups with transplanted fetal (n=12) and neonatal (n=4) CMs,  
5 rhythmic contractions ( $73 \pm 12$  beats/min (n=11) and  $43 \pm 21$  beats/min (n=3))  
were found only in the transplanted area. These contractions were not observed in  
the control legs. Contractions were not observed at sites transplanted with CMs  
from 22-, 32-, and 62-day donor animals (n=4 for all groups).

10 **Conclusion:**

Donor age is important for maintaining contractility of CMs after  
transplantation into skeletal muscle.

IV) INDUCTION OF ANGIOGENESIS BY ENDOTHELIAL CELLS  
15 TRANSPLANTED INTO MYOCARDIAL TRANSMURAL SCARS DID  
NOT IMPROVE CARDIAC FUNCTION IN INFARCTED HEARTS.

We speculated that artificial induction of angiogenesis might improve  
perfusion, alleviate angina and restore cardiac function in cases where  
revascularization does not occur spontaneously after myocardial infarction (e.g., in  
20 scar tissue). The present study evaluated whether allogenic and syngenic  
endothelial cells transplanted into myocardial scar tissue induce new blood vessel  
formation and whether angiogenesis (if any) induced by transplanted cells affects  
the function of the scarred heart. The effect of transplanted cells upon blood vessel  
formation in myocardial scar tissue has not been studied previously.

25 **Methods and Results:** Transmural scars were produced at the left  
ventricular free wall of adult rats hearts by cryo-injury. Two weeks later, cultured  
adult rat aortic endothelial cells (transplanted group) or culture media (control

-42-

group) were injected into the myocardial scars of rats immunosuppressed with cyclosporin A (25mg/kg/day). Transplanted cells were observed at transplanted sites at day 1 and 7, but not at day 14 (n=2). At 6 weeks after transplantation, the number of capillaries in the scars of the transplanted group ( $3.4 \pm 2.0$ , n=10) was greater (p<0.01) than that in the control group ( $1.0 \pm 0.6$ , n=9). Blood flow measured by radioactive  $^{57}\text{Co}$  labeled microspheres was greater (p<0.01) in the transplanted group ( $6.85 \pm 2.27\%$ , n=9) than in the control group ( $3.78 \pm 0.99\%$ , n=8). There was no difference in scar size and heart function between two groups measured by planimetry and Langendorf preparation.

**Conclusion:** Angiogenesis was induced in the scar tissue by endothelial cell transplantation. Since no myocytes were present in the scar, cardiac function did not improve. However, endothelial cell transplantation in patients with incomplete infarction may restore perfusion, relieve angina and restore function.

**15      Methods**

**Experimental Animals:** All procedures performed on animals were approved by the Animal Care Committee of The Toronto Hospital. Experiments were performed according to the "Guide to the Care and Use of Experimental Animals" published by the National Institutes of Health (NIH publication 85-23, revised 20 1985). Sprague-Dawley rats (Charles River Canada Inc, Quebec, Canada) were used for allogenic transplantation. Male rats, weighing 330 to 360 g, were used as recipients and donors of endothelial cells. Sygenic Lewis rats (Male, 250-300 g, Charles River Canada Inc, Quebec, Canada) were used for autologous transplantation.

**25      *Cell Isolation and Culture:*** Endothelial cells from rat aorta were isolated and cultured as previously described (Mickle et al., *J. Mol. Cell. Cardiol.* 22:1297-1304, 1990). In brief, descending thoracic aortic segments were obtained from rats under general anesthesia, as described in the next section. The blood vessels were

washed with phosphate buffered saline solution (PBS; composition in mmol/L: NaCl 136.9, KCl 2.7, Na<sub>2</sub>HPO<sub>4</sub> 8.1, KH<sub>2</sub>PO<sub>4</sub> 1.5, pH 7.3) and connective tissue was removed. The aortic segment was then flushed with enzyme solution (0.1% collagenase and 0.2% trypsin in PBS) and incubated with the enzyme solution for 5 30 minutes at 37°C. After incubation, endothelial cells were isolated by flushing the inside of aortic segments with culture medium (Medium 199 containing 20% fetal bovine serum, 100U/ml of penicillin, 100 µg/ml of streptomycin, and 0.5% heparin salt) three to five times. The isolated cells were cultured at 37°C in 5% CO<sub>2</sub> and 95% air in culture medium.

10        *Cell Identification:* The purity of endothelial cell cultures was confirmed by a immunohistochemical stain using antibody against factor VIII-related antigen as previously described (Mickle et al., *J. Mol. Cell. Cardiol.* 22:1297-1304, 1990). In brief, the cultured endothelial cells were fixed in methanol for 15 minutes at -20°C. After washing three times with PBS, the cells were incubated with rabbit 15 immunoglobulin G against factor VIII-related antigen (Dimension Laboratory, Inc) at 37°C for 45 minutes. After incubation, the cells were washed three times (15 minutes per wash) with PBS, then incubated with goat anti- rabbit immunoglobulin G conjugated with peroxidase at 37°C for 45 minutes, washed three times (15 minutes per wash) with PBS, and immersed in diaminobenzidine-H<sub>2</sub>O<sub>2</sub> (2mg/ml diaminobenzidine, 0.03% H<sub>2</sub>O<sub>2</sub> in 0.02ml/l phosphate buffer) solution for 15 20 minutes. After a final wash in PBS, the samples were photographed.

25        *Quantitation of VEGF Protein Levels in Cultured Endothelial Cells and Secreted by Cultured Cells:* Purified endothelial cells were cultured in cell culture medium for 3 days. The supernatants (n=5) were collected, centrifuged at 14,000 g for 10 min. to remove cell debris, and were saved for protein quantitation. The cultured cells (n=5) were washed 3 times with PBS and collected by scraping with a cell scraper. After centrifugation at 580 g for 3 min., the cell pellets were resuspended in 1 ml of PBS and sonicated for 1 min. The samples were

centrifugated at 14,000 g for 10 min., and the supernatants were collected for protein quantitation. The protein concentration was measured using the Bio-Rad protein assay (Bio-Rad, Richmond, CA). VEGF protein levels in culture medium and endothelial cells were quantitated by chemiluminescent slot blot analysis.

5 Culture medium incubated without cells was used as a control. Forty micrograms of protein from culture medium or from cultured endothelial cells were loaded onto a 0.2 µm nitrocellulose membrane (Schleicher & Schuell Inc., Keene, NH) using the Minifold II Slot Blotting System (Schleicher & Schuell Inc., Keene, NH). Standards of VEGF (2, 5, 10, 25 ng) (Sigma, Mississauga, ONT, Canada) were loaded on the same membrane. After drying at room temperature for 10 minutes, the membrane was washed twice in TTBS buffer (50 mM Tris-HCl buffer pH 7.4 and 0.1% of Tween-20) for 5 minutes. Subsequently, the membrane was treated for 10 minutes with blocking buffer (Boehringer Mannheim, GmbH, German).

10 Monoclonal antibodies against VEGF (Sigma, Mississauga, ONT) (1:3000, diluted with 0.5X blocking buffer) were added and incubated overnight at 4°C.

15 After washing twice with TTBS for 5 minutes each, the membrane was incubated with goat anti-mouse-HRP conjugated antibody (1:3000 dilution) (Bio-Rad Laboratories, Hercules, CA) for 60 minutes at room temperature. The membrane was again washed twice with TTBS (10 minutes per wash). VEGF proteins were 20 detected by chemiluminescence using the Boehringer Mannheim detection kit (Quebec, Canada). A densitometric analysis of the standard and sample bands was performed with a Bio-Rad image analysis system (Bio-Rad, Hercules, CA).

25 Standard curves of VEGF were generated and VEGF quantity in culture medium and cultured endothelial cells was calculated based on the standard curve. The results (mean ± SD) are expressed as ng of VEGF/mg protein.

*Preparation of Cells for Transplantation:* Cultured endothelial cells were passaged twice before transplantation to increase the number of cells. Prior to transplantation, the cultured endothelial cells were detached from culture dish with

-45-

0.05% trypsin in PBS. After centrifugation in 580g for 3 minutes, the cell pellets were resuspended in culture medium at a concentration of  $1.0 \times 10^6$  cells/10  $\mu$ l. A 60  $\mu$ l cell suspension was used for each transplantation.

*5 Myocardial Scar Formation:* Rats were anesthetized by intramuscular injection of ketamine hydrochloride (20 mg/kg body weight) followed by intraperitoneal injection of sodium pentobarbital (30 mg/kg body weight). The anesthetized rats were intubated and positive pressure ventilation was performed with room air supplemented with oxygen and isoflurane (0.2-1.0%) using a Harvard ventilator. Rats were monitored by electrocardiogram during each 10 operation.

The heart was exposed through a 2- to 3-cm left lateral thoracotomy incision. Cryo-injury was produced in the left ventricular free wall (LVFW) with a metal probe (8 X 10 mm in diameter) cooled to -190°C by immersion in liquid nitrogen. It was applied to the LVFW for one minute and this procedure was 15 repeated ten times. The muscle and skin were closed with 3-0 silk sutures. Penlong XL (benzathine penicillin G 150,000 U/ml and procaine penicillin G 150,000 U/ml) was given intramuscularly (1ml/kg) and buprenorphine hydrochloride (0.01mg/kg) was administered after each operation. The cryoinjured rats were randomly divided into two groups: transplantation and control.

*20 Endothelial Cell Transplantation:* At two weeks after cryo-injury, cell transplantation was performed. Under general anesthesia, the heart was exposed through a midline sternotomy. An Endothelial cell suspension ( $6 \times 10^6$  cells in 60  $\mu$ l) was injected into the center of the scar tissue in the transplantation group using a tuberculin syringe, and the same amount of culture media was injected into the 25 scar tissue in the control group. The chest was closed with 3-0 silk sutures and antibiotics and analgesics were administered as described above. Cyclosporine A (25 mg/kg/day) was administered subcutaneously to both transplanted and control groups.

*Identification of Transplanted Endothelial Cells:* The transplanted cells were identified in two ways.

(1) At day 1, 7, and 14 post transplantation, two rats from transplanted and control groups were sacrificed by exsanguination under general anesthesia. The hearts were fixed in with 10% phosphate-buffered formalin solution for 2 days and cut into 3-mm sections. The sections were fixed in 5% glacial acetic acid in methanol, embedded in paraffin, and cut to yield 10- $\mu$ m sections which were stained with hematoxylin and eosin as described by the manufacturer (Sigma Diagnostics, St. Louis, MO).

(2) The transplanted cells also were identified by detection of green fluorescent protein expressed by the transplanted cells. At 2 days pre-transplantation, cultured endothelial cells were lipofectamine-transfected with a plasmid encoding green fluorescent protein. The transfected cells were cultured, harvested and transplanted as described above. At end of the study, monoclonal antibodies against green fluorescent protein were used to localize the transplanted endothelial cells by avidin-biotin-peroxidase complex technique (Hsu, S.M. *Am. J. Pathol.*, 75:816-821, 1981). Briefly, sections were incubated with a solution of 3% H<sub>2</sub>O<sub>2</sub> in 70% methanol for 30 minutes to inhibit endogenous myocardial peroxidase. Nonspecific protein binding was blocked with 2% normal goat serum in 0.05 M Tris buffer (pH 7.4) for 15 minutes, primary antibodies against green fluorescent protein (Cedarlane Lab., Hornby, Ontario, Canada) were added and the samples were incubated at 37°C for 30 minutes followed by an overnight incubation at 4°C. Negative control samples were incubated in PBS (without the primary antibodies) under the same conditions. After washing with PBS (three times for 5 minutes each), a biotin-labeled secondary antibody (1:250, Vector Lab. Inc. Burlingame, CA) was added and the specimens were incubated at room temperature for 1 hour. The samples were rinsed 3 times for 5 minutes each in fresh PBS and reacted with an avidin-biotin complex conjugated with peroxidase

at room temperature for 45 minutes. Visualization was performed with a diaminobenzidine solution (0.25 mg/ml in 0.05 Tris-HCl buffer containing 0.02% H<sub>2</sub>O<sub>2</sub>) for 10 minutes. The samples were then covered with crystal mounts and photographed.

5           *Blood Flow Measurement with Radionuclide-labeled Microspheres:* At six weeks after transplantation, blood flow to the normal and scar tissue in the transplanted (n=9) and control groups (n=8) was measured using radionuclide-labeled microspheres (Pang, C.Y. *Plastic and Reconstructive Surgery* 74(4):513-521, 1984). Rats were anesthetized and heparin sodium (200 units) was 10 then administered intravenously. Hearts were excised and perfused in a Langendorf apparatus with 0.9% saline solution to wash out all blood cell remnants in the coronary vascular bed. Ten ml of 20 mEq KCl solution was injected through the coronary arteries to arrest the heart completely, and the heart was perfused with 0.9% saline solution for 10 minutes.

15           <sup>57</sup>Co-labeled microspheres (5 uCi, New England Nuclear, Boston, MA) were suspended in 2 ml of 0.9% saline containing 5% sucrose and 0.05% Tween 80. The suspension was vortexed vigorously for 2 minutes immediately before injection. The microspheres were infused over a 5 second period through a needle connected to the ascending aortic root.

20           Ventricles were dissected into normal tissue, scar tissue, and tissue in the borderline area. Each section was weighed and the radioactivity was then determined using a gamma counter at the window setting of 110 to 138 KeV. The data was expressed as counts per minute (cpm)/mg of tissue. The ratio of cpm/mg in scar and borderline tissue to normal tissue was calculated, expressed as the percentage, and compared between transplanted and control hearts.

25           *Heart Function Measurement:* Six weeks after transplantation, heart function in transplanted (n=10) and control (n=9) groups was measured using a Langendorf preparation (Stephen, S.E. *Annals of Thoracic Surgery* 59:1127-1133,

-48-

1995). Rats were anesthetized and heparin sodium (200 units) was administered intravenously. Hearts were quickly isolated and perfused at 37°C in a Langendorf apparatus with filtered Krebs-Hanseleit buffer (mmol/L: NaCl 118, KCl 4.7, KH<sub>2</sub>PO<sub>4</sub> 1.2, CaCl<sub>2</sub> 2.5, MgSO<sub>4</sub> 1.2, NaHCO<sub>3</sub> 25, glucose 11, pH 7.4) equilibrated with 5% carbon dioxide and 95% oxygen at a pressure of 100 cm H<sub>2</sub>O. A latex balloon was inserted into the left ventricle through the mitral valve and connected to a pressure transducer (Model p10EZ; Viggo-Spectramed, Oxnard CA) and a transducer amplifier and differentiator amplifier (Model 11-G4113-01; Gould Instrument System Inc, Valley View OH).

After 20 minutes of stabilization, the coronary flow was measured by the timed collection in the empty beating state. The balloon size was increased in 0.02 ml increments from 0.04 to 0.6 ml by the addition of saline solution. The systolic and end-diastolic pressure and maximal and minimal dp/dt were recorded at each balloon volume. The developed pressure was calculated as the difference between the systolic and end-diastolic pressure.

*Measurement of Left Ventricular Remodeling:* The epicardial and endocardial surfaces of the normal and scar tissue in the LVFW were measured by the technique of Pfeffer (*Am. J. Physiol.* 260:H1406-14, 1991) and Jugdutt and Khan (*Circulation* 89:2297-307, 1994). Briefly, the hearts were fixed in distension (30 mmHg) with 10% phosphate-buffered formalin solution for 2 days. The atria were excised, the ventricular weight and the size of the scar on epicardial surface were measured, and ventricular volume was measured by water displacement.

After that, the hearts were cut into sections of 3 mm thickness. For each section, the area of normal and scar tissue in the LVFW were traced onto a transparency and quantified using computed planimetry (Jandal Scientific Sigma-Scan, Corte Madera, CA). The lengths of LVFW and scar tissue on both the endocardial and epicardial surfaces of each section were measured. The surface areas of the endocardial and epicardial scar tissue and the LVFW were measured as the sum of

-49-

the endocardial length and epicardial length times the section thickness (3mm). The surface area percentage of scar tissue in the LVFW was calculated as follows: (endocardial scar size+epicardial scar size)/(endocardial LVFW+epicardial LVFW) X 100.

5       *Measurement of Capillaries in Scar Tissue:* The heart sections were used for immunohistochemical staining of endothelial cells. The sections were incubated with xylene twice for 5 minutes each, 100% ethanol twice for 2 minutes each, and then with 70% ethanol twice for 1 minute each. The sections were incubated with rabbit immunoglobulin G against factor VIII-related antigen and 10 endothelial cells were identified as described in the *Cell Identification* section above. The stained vasculoendothelial cells in the transplanted and control groups were counted using a light microscope at 400X magnification. The result was expressed as the number of capillary vessels/field.

15      *Syngeneic endothelial cell transplantation:* To evaluate angiogenesis induced by transplanted endothelial cells in the absence of an inflammatory reaction, endothelial cells isolated from adult Lewis rat aorta were transfected and transplanted into myocardial scar tissue of syngeneic rat hearts (n=5) two weeks after the scarring procedure. The transplanted cells were identified in the scar tissue at 6 weeks after transplantation by immunohistochemical staining. The 20 number of capillaries in the scar areas of transplanted and control hearts was counted and compared. All the procedures performed on these animals were same as described above, except that cyclosporine was not administered after cell transplantation.

25      *Statistical Analysis:* Data were expressed as the mean ± standard error. Statistical Analysis System software was used for all analysis (SAS Institute, Cary, NC). Student's t-test was used for comparison of the results. Cardiac function data were evaluated for the transplantation and control groups using intracavitory volume as the variant factor and systolic, end-diastolic, and developed pressure as

dependent variables.

## Results

Cultured endothelial cells were distinguished from fibroblasts and vascular smooth muscle cells by morphologic criteria and growth characteristics. The endothelial cells were oval-shaped, in contrast to the spindle-shape of cultured fibroblasts and vascular smooth muscle cells. Cultured endothelial cells grew in a "cobblestone" pattern whereas fibroblasts grew in a "whirling" pattern and vascular smooth muscle cells grew in a "hill and valley" pattern. In addition, cultured endothelial cells stained positively for factor VIII-related antigen. The purity of the culture to be transplanted was more than 95%.

We found that cultured vascular endothelial cells contained VEGF (0.007 and 0.005 ng/ $\mu$ g of cell protein, N=2). The VEGF molecules in the cultured cells were secreted into cultured medium: VEGF protein levels (0.331 and 0.229 ng/50  $\mu$ l, N=2) in conditioned medium (i.e., in which cells were cultured) was greater than in medium not exposed to endothelial cells (0.143 ng/50  $\mu$ l, N=1).

At one day after transplantation, two rats in the transplanted group were sacrificed in order to identify transplanted cells. A large endothelial cell cluster was observed within each scar. There was no increased capillary network around the cell clusters compared with control rats.

At one week after transplantation, there were some capillaries around the transplanted endothelial cell cluster within each scar. The size of the endothelial cell cluster was, however, much smaller than that observed one day after transplantation.

At two weeks after transplantation, there were more capillaries within the scar but the endothelial cell cluster was no longer present.

Six weeks after transplantation, the number of blood vessels in the scar tissue of the transplanted group ( $3.4 \pm 2.0$  vessels/ $0.8\text{ mm}^2$ , n=10) was significantly

-51-

greater ( $p<0.01$ ) than within control (non-transplanted) scars ( $1.0 \pm 0.6$ ,  $n=9$ ). Most of the blood vessels were capillaries without smooth muscle components. In agreement with the number of blood vessels, the blood perfusion (represented as microsphere count) in the scar tissue of transplanted hearts ( $6.85 \pm 2.27\%$  of normal myocardium) was greater ( $p<0.01$ ) than that of control hearts ( $3.78 \pm 0.99\%$ ) (Fig. 2).

In syngeneic cell transplantation, the transplanted cells also induced angiogenesis in the myocardial scar tissue. The density of capillaries in the scar tissue of the transplanted group was  $2.6 \pm 1.5$  vessels/ $0.8\text{mm}^2$ , which was significantly ( $p<0.01$ ) greater than that in the control group ( $1.1 \pm 0.6$ ).

Transplanted endothelial cells were incorporated into capillaries at the transplant site.

In morphological studies of the hearts, there was no difference, between transplanted and control groups, in body weight and in the weights of the heart, left ventricle, and scar. Ventricular volume in transplanted hearts was similar to that of control hearts. The size of the scar tissue in the transplanted group was also similar to that of the control group (Table 1).

There were no statistically significant differences in systolic and developed pressures between transplanted and control hearts (Figs. 3 and 4), and no differences in coronary flow and heart rate (Table 1).

-52-

**Table 1. Hemodynamics and heart dimensions in transplantation and control groups<sup>(a,b)</sup>**

Group	Coronary flow (ml/min)	Heart rate (bpm)	Ventricular weight (g)	Ventricular volume (ml)	Scar size (mm <sup>2</sup> )
Transplant	20.9+/-4.36	279+/-15	1160+/-168	1.86+/-0.27	109+/-19
Control	21.9+/-3.82	289+/-19	1150+/-137	1.79+/-0.21	110+/-19

<sup>a</sup> Data are shown as the mean +/- standard error<sup>b</sup> There were no significant differences in all parameters between two groups.

-53-

The transplanted endothelial cells stimulated angiogenesis, demonstrated by an increase in the number of capillaries in the scar tissue and increased blood perfusion in scar tissue as illustrated by microsphere perfusion studies. However, the induced angiogenesis in transmural scar tissue did not improve infarcted heart function.

There are three possible mechanisms of increased angiogenesis by endothelial transplantation: (1) formation of blood vessels by transplanted endothelial cells; (2) angiogenesis stimulated by growth factors secreted by transplanted endothelial cells; (3) angiogenesis stimulated by an inflammatory reaction induced by transplanted endothelial cells.

Endothelial cells are the most important component for blood vessel formation. Our *in vivo* study showed that transplanted endothelial cells become part of newly formed capillaries in syngeneic cell transplantation. These data suggested that transplanted endothelial cells are involved in blood vessel formation. However, the data obtained from allogeneic endothelial cell transplantation suggested that newly formed capillaries in the scar tissue were grown from recipient heart endothelial cells. We found transplanted cells at 1 and 7 days after transplantation, but did not observe transplanted cells after 14 days post-transplantation. Additional evidence of this conclusion is that there was no immunologic reaction around capillary vessels in the scar. If the transplanted allogenic endothelial cells become part of the newly formed capillaries, lymphocyte infiltration should have been observed around the blood vessel. These data illustrate that transplanted endothelial cells are involved in new blood vessel formation and also stimulate angiogenesis. In the latter situation, angiogenic factors secreted by transplanted cells may play an important role in this process.

Angiogenesis in our animal model might also be stimulated by inflammatory reactions. Although syngeneic endothelial cell transplantation has shown that angiogenesis occurs without inflammatory reaction, factors released

-54-

by inflammatory cells might play a role in blood vessel formation induced by allogenic endothelial cell transplantation. Capillary density in scar tissue subjected to allogenic cell transplantation was 1.3 time greater than that subjected to syngeneic cell transplantation. This difference in capillary density may be due to 5 lymphocyte infiltration.

Although blood flow was increased by endothelial cell transplantation in our experimental model, increased blood flow did not have any effects on left ventricular remodeling and function. We found muscle cells in the scar tissue of a few hearts but the number of the muscle cells may not be sufficient to improve 10 heart function. There were no differences in heart volume, heart weight, and scar size between transplanted and control hearts. In the analysis of function, there were no differences in heart rate, coronary flow, systolic and developed pressures between two groups.

We observed that the 2 week old scar was less mature and contained more 15 blood vessels and fibroblasts than 4 week old scar, which was firm connective tissue. In addition, we found that cardiomyocyte transplantation was most successful after the inflammatory reaction resolved and before significant scar expansion and ventricular dilatation occurred.

The finding of increased angiogenesis in transmural scars induced by 20 endothelial cell transplantation gives rise to a new technique for induction of angiogenesis. We observed an increased number of capillary vessels within the scars of rat hearts that were transplanted with endothelial cells. In contrast, we observed an increased number of arterioles and venules in scars transplanted with fetal cardiomyocytes. If endothelial cells and cardiomyocytes are co-transplanted 25 into myocardial scars and endothelial cells augment the blood flow into the transplanted area, the survival and function of transplanted cardiomyocytes might be enhanced. It would be possible to obtain ventricular cardiomyocytes from transvenous endomyocardial biopsy and endothelial cells from saphenous vein or

omental fat and culture those cells for subsequent autologous co-transplantation.

In addition to morphologic evidence of increased angiogenesis, we demonstrated that blood flow to scar tissue was increased. Because there was usually adhesion between the scar area and the chest wall from the previous two operations (scarring and transplantation), blood flow to the scar area may result from two sources, one from coronary arteries and the other from the chest wall by non-coronary collateral vessels produced by adhesion. If blood flow from chest wall adhesion is counted together with blood flow from coronary artery, it obscures the effect of angiogenesis *per se* on blood flow to the scar area.

Therefore, we injected microspheres into isolated heart preparations, although for actual blood flow estimation, injection of microspheres into left atrium or left ventricle *in vivo* may be more physiological. Because there were areas of non-transmural infarction in the periphery of the cryoinjured lesions, the left ventricular free wall was divided into three parts: normal area, transmural infarct area, and borderline area. The blood flow to the borderline areas was always between that of the normal and complete transmural infarct area.

## V) OPTIMAL TIME FOR CARDIOMYOCYTE TRANSPLANTATION FOR MAXIMIZING MYOCARDIAL FUNCTION AFTER LEFT VENTRICULAR NECROSIS

After myocardial infarction, damaged myocardium undergoes both acute and chronic inflammatory reactions. During this process, the necrosed cardiac cells are replaced with fibrotic tissue and ventricular remodeling progresses. Ventricular pressure stretches and thins the healing area and ventricular dilatation occurs. A ventricular aneurysm may form and congestive heart failure may result. Limitation of post-infarction ventricular remodelling is important to prevent expansion and thinning of the infarct region and thinning, and progressive ventricular dilatation, which results in congestive heart failure. The addition of

cardiac tissue to replace the scar tissue may prevent infarct thinning and preserve chamber size and ventricular function. We had shown that fetal cardiomyocytes transplanted into a LVFW scar formed cardiac tissue and improved myocardial function. Transplantation was arbitrarily performed at 4 weeks after cryo-necrosis of the LVFW when ventricular dilatation was already present. However, the optimal time for cardiomyocyte transplantation to provide the best ventricular function is important. The acute inflammatory reaction could destroy the transplanted cardiomyocytes that are introduced too soon after myocardial infarction. On the other hand, cardiomyocyte transplantation after significant scar expansion may be of limited benefit. Therefore, the present study investigated the optimal time for cell transplantation after myocardial injury.

### Summary

#### *Methods:*

(1) Scar expansion studies: The rats were sacrificed at 0, 1, 2, 4, and 8 weeks after cryo-injury and the scar area was measured by planimetry (N=7 each).

(2) Transplantation studies: Fetal rat cardiomyocytes (transplant) or culture medium (control) were transplanted immediately (N=8 each), 2 weeks (N=8 each) and 4 weeks (N=12 each) after cryo-injury. At 8 weeks after cryo-injury, rat heart function was evaluated using a Langendorff preparation. Scar and transplanted cardiomyocytes were assessed histologically.

#### *Results:*

(1) A transmural injury occurred immediately after cryo-injury. An inflammatory reaction was more evident at 1 week than 2 weeks. Although the scar size did not significantly change between week 1 and 2, it expanded ( $p<0.01$ ) at 4 and 8 weeks.

(2) At 8 weeks after myocardial injury, cardiomyocytes transplanted immediately after myocardial injury were not found in the myocardial scar tissue.

-57-

Scar size and myocardial function were similar to those of the control hearts. Cardiomyocytes transplanted at 2 and 4 weeks formed cardiac tissue, which occupied 34% and 31% of total scar area, respectively, and limited ( $p<0.01$ ) scar expansion compared to control hearts. Both transplant groups had better ( $p<0.001$ ,  $<0.001$ ) heart function than the control groups. Developed pressure was greater ( $p<0.01$ ) in the hearts transplanted cells at 2 weeks than at 4 weeks.

5           *Conclusion:*

10           Cardiomyocyte transplantation was most successful after the inflammatory reaction resolved and before significant scar expansion and ventricular dilatation occurred.

Material and Methods

15           *Experimental animals:* All procedures performed on animals were approved by the Animal Care Committee of The Toronto Hospital. Experimental animals used were male Sprague-Dawley rats (Lewis, Charles River Canada Inc. Quebec, Canada), weighing 450 grams. Cardiomyocytes obtained from 18-day gestational rat hearts were cultured prior to transplantation. All experiments were performed according to "A Guide to the Care and Use of Experimental Animals" of the Canadian Council on Animal Care and the "Guide for the Care and Use of 20 Laboratory Animals" NIH publication 85-23, revised 1985).

25           *Myocardial scar generation and evaluation:* Myocardial scar tissue was generated as described in the examples above. Briefly, rats were anesthetized with ketamine (22 mg/kg body weight, intramuscular) followed by an intraperitoneal injection of pentobarbital (30 mg/kg body weight). The anesthetized rats were intubated and positive pressure ventilation was maintained with room air supplemented with oxygen (6 L/minute) using a Harvard ventilator (Model 683, South Natick, MA, USA). The rat heart was exposed through a two cm left lateral thoracotomy. Cryo-injury was produced at the left ventricular free wall (LVFW)

-58-

with a liquid nitrogen probe. The muscle layer and skin were closed with 5-0 vicryl sutures. The rats were monitored for 4 hours postoperatively. Penlog XL (benzathine penicillin G 150,000 U/ml and procaine penicillin G 150,000 U/ml) were given intramuscularly (0.25 ml/rat) every three days for 1 week after surgery and buprenorphine (0.01-0.05 mg/kg body weight) was administrated 5 subcutaneously every 8 to 12 hours for the first 48 hours following surgery.

The LVFWs of 35 animals were cryo-injured. Immediately after cryo-injury and at 1, 2, 4, and 8 weeks after injury, 7 animals chosen at random were sacrificed under general anesthesia (see Fig. 5 (top) for a schematic diagram of the 10 experimental design). The hearts were then fixed in distension (30 mm Hg) with 10% phosphate-buffered formalin solution for 24-48 hours and then cut into 3-mm sections. All sections were used for assessment of myocardial and scar sizes. For each section, the area of scar tissue in the LVFW was traced onto a transparency and quantified using computerized planimetry (Jandal Scientific Sigma Scan, 15 Fairfield, CT., USA). Scar length was calculated as the average of endocardial scar length and epicardial scar length. Scar area was calculated as the scar length X section thickness (3mm). The total scar area in size was calculated as the sum of the scar areas for all of the tissue sections showing scars. The LVFW myocardial size was calculated using the same equation. The percentage of the LVFW 20 size occupied by the scar was calculated as scar size/LVFW size X 100.

*Histological studies:* The fixed heart sections were embedded in paraffin and cut to yield 10- $\mu$ m sections. The sections were stained with haematoxylin and eosin as described by the manufacturer (Sigma Diagnostics, St. Louis, MO).

*Cell culture and preparation for transplantation:* Cardiomyocytes from 25 fetal rat hearts were isolated, purified and cultured as previously described (Li, R-K, et al. *J. Tissue Culture Methods* 14:93-100, 1992). Briefly, the cells were cultured for 24 hours in Iscove's modified Dulbecco's medium containing 10% fetal bovine serum, 100 U/ml penicillin and 100 ug/ml streptomycin at 37°C, 5%

-59-

CO<sub>2</sub> and 95% air. The cultured cardiomyocytes were detached from the cell culture dish with 0.05% trypsin in phosphate-buffered saline (PBS). After centrifugation at 580 X g for 3 minutes, the cell pellet was resuspended in culture medium at a concentration of 16 X 10<sup>6</sup> cells/ml. A 0.25 ml cell suspension was used for each transplantation.

Cardiomyocyte transplantation: The LVFW of 56 adult rat hearts were cryo-injured as described above. The animals were randomly divided into 3 groups (see Fig. 5, bottom). In group one, 8 animals were transplanted with cultured cardiomyocytes (transplant) and 8 animals were transplanted with culture medium (control) immediately after myocardial injury. In group two, animals were transplanted either with cells or with culture medium (N=8 each) 2 weeks after myocardial injury. In group three, animals (N=12 each) were transplanted with either cells or culture medium 4 weeks after myocardial injury. All animals were maintained 8 weeks after the transplant procedure, after which they were sacrificed for histological and functional studies.

Under general anesthesia, the hearts were exposed through a midline sternotomy. A fetal rat cardiomyocyte suspension (4 X 10<sup>6</sup> cells in 0.25 mls) or culture medium (0.25 ml) was injected once into the center of the scar tissue of the transplanted and control animals, respectively, using a tuberculin syringe. The chest was closed with 5-0 vicryl sutures. Antibiotics and analgesics were given as described in the "Myocardial Scar Generation and Evaluation" section below. Cyclosporin A, at a dose of 5 mg/kg body weight/day, was administered subcutaneously to the control and transplanted rats. The rats were housed in cages with filter tops.

Myocardial function studies: At 8 weeks after myocardial injury, the heart function of control and transplanted animals transplanted at 0, 2, and 4 weeks after myocardial injury was measured using a Langendorff preparation (Stephen, S.E. *Annals of Thoracic Surgery* 59:1127-1133, 1995). The rats were anesthetized and

-60-

heparin (200 units) was administered intravenously. The hearts were quickly isolated from rats and perfused in a Langendorff apparatus with filtered Krebs Heinseleit buffer (mmol/L: NaCl 118, KCl 4.7, KH<sub>2</sub>PO<sub>4</sub> 1.2, CaCl<sub>2</sub> 2.5, MgSO<sub>4</sub> 1.2, NaHCO<sub>3</sub> 25, glucose 11; pH 7.4) equilibrated with a 5% CO<sub>2</sub> and 95% O<sub>2</sub>. A 5 latex balloon was passed into the left ventricle through the mitral valve and connected to a pressure transducer (Model p10EZ, Viggo-Spectramed, CA) and transducer amplifier and differentiator amplifier (Model 11-G4113-01, Gould Instrument System Inc., Ohio). After 30 minutes of stabilization, the balloon size was increased in 0.02 ml increments from 0.04 to a volume, at which end diastolic 10 pressure was 30 mm Hg or more by the addition of saline. The systolic and diastolic pressures were recorded at each balloon volume and developed pressure was calculated as the difference between the systolic and diastolic pressures.

15 *Measurement of left ventricular free wall remodeling:* After function measurements, the hearts were fixed, sectioned, and traced onto a transparency. LVFW and scar sizes were quantified using computerized planimetry as described in the "Myocardial Scar Generation and Evaluation" section. The transplanted tissue size as a percentage of the scar size was similarly calculated.

20 *Histological identification of transplanted muscle cells in the scar tissue:* Fixed heart sections were embedded in paraffin, and cut into 10-μm sections. The sections were stained with hematoxylin and eosin as described in the "Histological Studies" section above.

25 Heart sections containing transplanted cells also were stained for myosin heavy chain (MHC) (Rougier Bio-Tech, Montreal, Canada). After deparaffination and rehydration, samples were incubated for 30 minutes with a solution of 3% H<sub>2</sub>O<sub>2</sub> in 70% methanol to inhibit endogenous myocardial peroxidase. Triton X-100 (0.2%) was used to treat samples for 10 minutes to enhance cell permeability. After blocking nonspecific protein binding with 2% normal goat serum in 0.05 M Tris buffer (pH 7.4) for 15 minutes, primary antibodies against MHC (1:1000)

-61-

were added and the samples were incubated at 37°C for 30 minutes followed by an overnight incubation at 4°C. Negative control samples were incubated in PBS under the same conditions. After samples were washed with PBS, a biotin-labeled secondary antibody (1:250) was added and the samples were incubated at room temperature for 1 hour. After rinsing with PBS, the samples were exposed to an avidin-biotin complex conjugated with peroxidase at room temperature for 45 minutes. Visualization was performed with a diaminobenzidine solution (0.25 mg/ml in 0.05 Tris-HCl buffer containing 0.02% H<sub>2</sub>O<sub>2</sub>) for 10 minutes. The cellular nuclei were counter-stained with hematoxylin for 1 minute. The samples 5 were covered and photographed.  
10

*Data Analysis:* Data are expressed as the mean ± standard error. The Statistical Analysis System software was used for all analysis (SAS Institute, Cary, NC). Comparisons of continuous variables between more than two groups were performed by a one-way analysis of variance. If the F ratio was significant from 15 the ANOVA, a Duncan=s multiple-range t test was employed to specify differences between the groups. The critical alpha-level for these analyses was set at p<0.05.

Functional data were evaluated for the control and transplant groups by an analysis of covariance (ANCOVA) using intracavitory balloon volume as the covariate and systolic, diastolic and developed pressure as dependent variables.  
20 Main effects were group, volume, and the interaction between group and volume.

## Results

*Histological and morphological changes of the hearts after myocardial injury:* Immediately after cryo-injury, 25±3% of the size of the LVFW was transmurally damaged. At this time, the cardiomyocytes were fragmented (Fig. 25 6A; magnification= 200X). At one week after cryo-injury, most of the necrosed cardiomyocytes were gone and a predominantly mononuclear inflammatory

-62-

infiltrate was present in the affected area (Fig. 6B; magnification= 100X). At two weeks after cryo-injury, the inflammatory infiltrate had almost disappeared and fibroblasts and collagen deposition were evident (Fig. 6C; magnification= 100X). At four and eight weeks, the scar was composed of fibrotic tissue (Fig. 6D; magnification= 200X). The tissue was less cellular and lymphocytes were not observed.

The myocardial scar size of the left ventricle expanded over the 8 week study period in the damaged hearts (Figs. 7 and 8). Figs. 7A-7D show photomicrographs (magnification= 5X) of H & E-stained heart sections 1 week (Fig. 7A), 2 weeks (Fig. 7B), 4 weeks (Fig. 7C), and 8 weeks (Fig. 7D) after cryo-injury of the LVFW. The size of the scar tissue (indicated by arrows) increases with time after injury.

Fig. 8 is a graph showing percentages of scar tissue in the LVFW at 1 week, 2 weeks, 4 weeks, and 8 weeks after cryo-injury. Open circles represent individual scar sizes, and closed squares represent mean scar sizes  $\pm$  SE ( $N=7$ ). Although the sizes of the 1-week-old and 2-week-old scars were not statistically different from one another ( $13\pm6\%$  and  $21\pm4\%$ , respectively, of LVFW), the size of 4-week-old scars ( $39\pm5\%$  of LVFW) was significantly larger ( \*\*  $p<0.01$  ). At 8 weeks after myocardial injury there was a further increase in scar size ( $55\pm3\%$  of LVFW;  $p<0.01$  ).

Although histological studies showed that the damage to newly-injured myocardium was transmural, some myocardium ( $12\pm5\%$  of total scar area) was observed at the endocardium one week after myocardial injury (Figs. 6 and 7). Lymphocytes surrounded the myocardium at this time. At 2 and 4 weeks, muscle tissue in the scar area ( $3\pm2\%$  and  $2\pm1.5\%$  of total scar area) decreased dramatically ( $p<0.01$ ) in size. At 8 weeks, the myocardial scar became transmural and there was no myocardium in the scar tissue.

*Effect of transplanted cells on scar size:* Figs. 9(A-D) are diagrams of

-63-

photomicrographs of H & E-stained heart sections (magnification= 5X) at 8 weeks after cryo-injury of the LVFW. The control heart (Fig. 9A) was mock-transplanted with culture medium only. Experimental hearts were transplanted with cultured fetal rat cardiomyocytes immediately (Fig. 9 B), at 2 weeks (Fig. 9 C) and at 4 weeks (Fig. 9 D) after myocardial injury. Transplanted cardiac tissue was not observed in the control hearts or the hearts transplanted immediately after myocardial injury. In contrast, transplanted myocardial tissue was found in the scar tissue of hearts transplanted 2 weeks or 4 weeks after injury (indicated by arrows in Figs. 9C and 9D). Host myocardium was usually present beneath the scar when the transplant was present, but never when the transplant was absent. This observation strongly suggests that survival of transplanted cardiomyocytes limits scar expansion and enhances survival of the endogenous myocardium.

Fig. 10 is a graph showing percentages of scar tissue and transplanted cardiac tissue in the LVFW at 8 weeks after cryo-injury. Results are expressed as mean  $\pm$  SE. \*\* p<0.01. Transplantation of fetal rat cardiomyocytes immediately after cryo-injury did not reduce the scar area relative to the scar area in non-transplanted controls: the scar area (53 $\pm$ 5% of the LVFW) in hearts transplanted immediately after cryo-injury (0 weeks) was similar to that in non-transplanted controls (55 $\pm$ 3% of the LVFW). In addition, there was no cardiac tissue at the endocardial area.

Fig. 11 shows that fetal rat cardiomyocytes transplanted 2 weeks after cryo-injury to the myocardium formed new myocardial tissue within the myocardial scar tissue. The newly formed cardiac tissue (detected by staining for myosin heavy chain using the avidin-biotin-peroxidase technique) occupied 34% of the total scar area (11 $\pm$ 3% of the LVFW). Similarly cardiomyocytes transplanted at 4 weeks occupied 31% of total scar area (12 $\pm$ 2% of LVFW).

Cardiomyocytes transplanted either 2 weeks or 4 weeks after myocardial cryo-injury limited scar expansion; the scar size in both cases was smaller (p<0.01)

-64-

than the scar size in control (cryo-injured, nontransplanted) hearts (Fig. 10). The scar size in hearts transplanted at 2 weeks ( $32\pm 5\%$ ) was smaller ( $p<0.01$ ) than that in hearts transplanted at 4 weeks ( $42\pm 2\%$ ). In addition to the cardiac tissue formed by transplanted cardiomyocytes, recipient myocardium was also found at 5 endocardium in both transplanted groups.

*Effect of transplanted cells on heart function:* When fetal rat cardiomyocytes were transplanted immediately after myocardial injury, ventricular function of hearts transplanted with cells was similar to that of injured, control (nontransplanted) hearts. Fig. 12 shows graphs of systolic, diastolic, developed 10 balloon pressures and positive dp/dt with increasing balloon volumes of control and transplanted hearts. Closed circles represent control hearts, open squares represent transplanted hearts, and results are expressed as mean  $\pm$  SE ( $N=8$ ). An analysis of covariance demonstrated no association between the control group and the treatment group for developed pressures.

When the cardiomyocytes were transplanted at 2 weeks after myocardial 15 injury, the transplanted hearts had better ( $p=0.001$ ) ventricular function than the control hearts. Fig. 13 shows systolic, diastolic, developed balloon pressures and positive dp/dt with increasing balloon volumes of control and transplanted hearts. Closed circles represent control hearts; open squares represent transplanted hearts. 20 Results are expressed as mean  $\pm$  SE ( $N=8$ ). Similar diastolic and developed pressures were found at lower balloon volumes in the transplant group.

Cardiomyocytes transplanted at 4 weeks after myocardial injury also improved ( $p<0.001$ ) myocardial function. Fig. 14 shows systolic, diastolic, developed balloon pressures and positive dp/dt with increasing balloon volumes of 25 control and transplanted hearts. Closed circles represent control hearts; open squares represent transplanted hearts. Results are expressed as mean  $\pm$  SE ( $N=12$ ). Systolic and developed pressures of the transplanted rat hearts were significantly greater than those of control hearts ( $p<0.01$ ).

-65-

Fig. 15 is a graph showing developed pressures at balloon volumes of 0.04, 0.1, 0.2 and 0.3 ml of the hearts transplanted with fetal cardiomyocytes at 2 and 4 weeks after myocardial injury. The results are expressed as mean  $\pm$  SE (\* p<0.05, \*\* p<0.01). Fig. 15 shows that hearts transplanted 2 weeks after cryo-injury had significantly higher developed pressures at balloon volumes 0.1 ml (p<0.05), 0.2 ml (p<0.01) and 0.3 ml (p<0.01) than hearts transplanted 4 weeks after cryo-injury.

The transplant tissue visibly contracted, but at different rates than did host myocardium. The contraction of the transplanted tissue persisted after dissection of the recipient heart, but its rate of contraction continued to be different.

In the rat, loss of necrosed ventricular tissue occurs by 2 days after cryo-injury of the myocardium. At this time there is an acute inflammatory reaction with neutrophils accumulating first in the periphery and later in the center of the necrotic region. A chronic inflammatory reaction involving macrophages and lymphocytes follows the acute reaction.

One week after cryo-injury, more than 80% of necrotic muscle fibres had disappeared. The remaining muscle fibres were surrounded by lymphocytes.

The inflammatory reaction is less intense two weeks after cryo-injury (and is absent by three weeks): two weeks after cryo-injury, the scars of the control animal hearts showed minimal or no inflammatory reaction. Two-week-old scars were less mature and contained more blood vessels and fibroblasts than 4-week-old scars, which contained firm connective tissue. Compared to one-week-old scars, there was less cardiac tissue in older scars. It is possible that progressive inflammation and lack of oxygen and nutrient supply decreased the myocardial tissue over time.

The cardiomyocytes transplanted immediately after cryo-injury did not survive in any of the animals studied. We believe the activated neutrophils and macrophages in the inflamed scar area destroyed the transplanted cells. At 8 weeks, the left ventricular chamber of the animals transplanted at the time of

-66-

cryo-necrosis was similar to that of the control scar. The chamber was dilated due to thinning of the scar. The remaining viable muscle of the left ventricle was hypertrophied. No inflammatory reaction was seen. The function of these transplanted hearts was similar to that of the control hearts.

5 All the animals transplanted with the fetal cardiomyocytes at 2 and 4 weeks post-scarring formed cardiac tissue within the scar tissue; therefore, transplantation is possible in both the immature and mature scar. Histological studies of the LVFW of the transplanted hearts showed that host myocardium was usually present beneath the scar when the transplant was present. This did not occur when  
10 the transplant was absent.

Control scar studies showed that scars were always transmural and did not have host cardiomyocytes underneath. Scar sizes and left ventricular chamber sizes of the hearts transplanted at 2 weeks were smaller than those of hearts transplanted at 4 weeks. In turn, scar sizes and left ventricular chamber sizes of the hearts transplanted at 4 weeks were smaller than those of the control hearts.  
15 Consistent with these histological findings, the myocardial function of the hearts transplanted at 2 weeks was better than that of the hearts transplanted at 4 weeks. We attributed the improved myocardial function to less ventricular dilatation and scar thinning. Compared with the sham-operated animals in our previous study, the  
20 contractile function of the hearts transplanted at 2 weeks was less efficient. Transplantation as soon as possible after the acute inflammatory reaction in the infarcted myocardium has disappeared should minimize ventricular remodeling and optimize myocardial function.

Although the mechanism of improved heart function is unknown, a  
25 cardiomyocyte transplant forms the equivalent of a viable epicardial rim and prevents ventricular dilatation and over-stretching of the cardiomyocytes during systole. With over-stretching of the cardiomyocytes, cardiac function is diminished (Frank-Starling Law). The elastic properties of the contractile apparatus of the

transplanted cardiomyocytes may prevent host fibroblast and cardiomyocyte stretching and ventricular enlargement.

In the course of forming cardiac tissue from transplanted cardiomyocytes, angiogenesis occurred. Angiogenesis is most likely necessary to maintain the viability of the transplanted muscle cells. However, an increased blood supply in the scar could also facilitate fibroblast turnover and strengthening of the scar in response to left ventricular free wall stretch.

With the advent of thrombolysis and percutaneous transluminal coronary angioplasty (PTCA), the incidence of patchy nontransmural infarction is becoming more frequent and transmural infarction with aneurysm formation less common. If the blood flow to the viable cardiomyocytes within the ventricular scar is insufficient for contractile function, stimulation of angiogenesis in the scar tissue becomes important. With adequate blood flow, normal contractile function should return to the hibernating cardiomyocytes within the scar. Transplantation of fetal cardiomyocytes could offer significant benefits to the patients with a patchy infarction. Angiogenesis would be stimulated in the scar, increase the blood flow, and restore normal contractile function to the host's hibernating cardiomyocytes. The transplanted cardiomyocytes should also increase the contractile capacity of the scar tissue and decrease the contractile requirements of the non-affected host myocardium. Patients with angina that cannot be corrected by bypass surgery may benefit from the angiogenesis that occurs secondary to cardiomyocyte transplantation. In addition, it may be beneficial to stimulate angiogenesis with growth factors prior to autologous cardiomyocyte transplantation.

In summary, transplanted fetal cardiomyocytes form myocardial tissue within cardiac scars; this replacement myocardial tissue limits the ventricular dilatation and scar thinning that occurs after myocardial infarction. The optimal time for transplantation for improved myocardial function is after the acute inflammatory reaction and before significant ventricular dilatation has occurred.

## VI) CO-IMPLANTATION OF ENDOTHELIAL CELLS WITH ADULT CARDIOMYOCYTES IMPROVES THE FUNCTION OF INFARCTED HEARTS

5        Cardiac transmural scars were induced by cryo-injury in the left ventricular free wall (LVFW) of Sprague-Dawley rat hearts, as described in the previous examples. Three weeks after cryo-injury, the rats were divided into three groups (eight rats per group), and cardiac transmural scars were transplanted with either medium alone (i.e., no cells; negative control), adult cardiomyocytes alone, or  
10      adult cardiomyocytes plus endothelial cells. Cardiac function was assessed using a Langendorff preparation five weeks after cell transplantation (Stephen et al., *Annals of Thoracic Surgery* 59: 1127-1133, 1995).

15       Fig. 16 shows a graph of developed pressure in infarcted rat hearts injected with either medium alone (control), adult cardiomyocytes alone (CM), or adult cardiomyocytes plus endothelial cells (CM + EC). Adult cardiomyocytes injected alone formed tissue within the ventricular scar, but did not improve cardiac function, compared to hearts injected with medium alone. In contrast, injection of adult cardiomyocytes plus endothelial cells significantly improved cardiac function (p< 0.01), compared to hearts injected with medium or cardiomyocytes alone. Co-  
20      injection of endothelial cells likely stimulates angiogenesis, which enhances survival of adult cardiomyocytes.

## VII) IMPROVEMENT OF CARDIAC FUNCTION USING *EX VIVO* GENE THERAPY

25       Prior to their transplantation into myocardium or myocardial scar tissue, cells (e.g., cardiomyocytes, endothelial cells, or any other cells of the invention) may be genetically engineered (e.g., transfected or infected with an expression vector) to express a recombinant protein, e.g., a therapeutic protein. Expression of

the therapeutic protein by the transplanted cells stimulates cell growth, survival, and/or angiogenesis by endogenous cells within the heart and/or by cells transplanted into the myocardium or myocardial scar tissue, and thereby improves cardiac function.

5        The therapeutic protein may be a growth factor, a survival factor (e.g., an anti-apoptotic factor), or an angiogenic factor. Examples of such therapeutic proteins include, and are not limited to, fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor (e.g., PDGF- $\beta$ ), transforming growth factor- $\beta$  (TGF- $\beta$ ), insulin-like growth factor (e.g., IGF-1 and 10 IGF-2), insulin, Bcl-2, and Bcl-X<sub>L</sub>. The protein (e.g., VEGF or IGF-1) may be secreted, thereby stimulating growth, survival, or angiogenesis by cells other the cell that expresses the therapeutic protein. Alternatively, the therapeutic protein may be retained intracellularly, such that it affects growth or survival of only the cell that expresses it (e.g., Bcl-2).

15      Prior to transplantation, an expression vector encoding the therapeutic protein of interest is introduced into the cells *ex vivo* (e.g., cells in a tissue culture dish). The vector may be, for example, a plasmid vector, a viral vector (e.g., an adenovirus, retrovirus, poxvirus, or herpesvirus vector), or an artificial chromosome. The vector may be introduced into the cells by various means. For 20 example, plasmid vectors may be introduced into cells by lipofection (using, for example, Lipofectamine<sup>TM</sup> (Gibco BRL, Gaithersberg, MD) or an analogous reagent), calcium phosphate- or DEAE-dextran-mediated transfection, electroporation, protoplast fusion, biolistic transformation, or other well-known methods. Viral vectors are generally introduced into cells by infection. If 25 necessary, expression vectors may be introduced into cells by other means, such as microinjection.

Expression of the vector-encoded therapeutic protein may be transcriptionally regulated by a promoter that is active in many types of cells (e.g.,

-70-

a  $\beta$ -actin promoter) or may be transcriptionally regulated by a tissue-specific promoter that is active in the type of cell being transfected. For example, a promoter from a myocardial-specific contractile protein gene (e.g., myosin heavy chain) may be used to drive expression of the therapeutic protein from a vector introduced into cardiomyocytes. Inducible promoters (e.g., the VEGF promoter, which up-regulates transcription in response to hypoxia; see, e.g., Liu et al., *Circ. Res.* 77:638-643, 1995) may also be used to drive transcription of therapeutic proteins. Expression vectors may also contain non-protein-encoding elements that affect protein expression levels, e.g., transcribed nucleic acid motifs that affect stability or translation efficiency of the encoded mRNA.

10 Although the invention has been described with reference to certain specific embodiments, various modifications thereof will be apparent to those skilled in the art without departing from the spirit and scope of the invention as outlined in the claims appended hereto.

15

What is claimed is:

**CLAIMS**

1. Isolated cells, said cells comprising at least one of the following cell types:

adult cardiomyocytes;

pediatric cardiomyocytes;

adult fibroblasts;

fetal fibroblasts;

adult smooth muscle cells;

fetal smooth muscle cells;

endothelial cells; and

skeletal myoblasts,

10

wherein said cells survive in myocardial scar tissue after transplantation into said myocardial scar tissue, and wherein said cells improve cardiac function, relative to cardiac function of a heart having similar myocardial scar tissue that is not transplanted with said cells, wherein cardiac function is assessed by at least one of the criteria in the group consisting of: area occupied by said scar tissue; vascularization of said scar tissue; blood flow to said scar tissue; developed pressure, systolic pressure; end diastolic pressure; and dp/dt.

15

2. The cells of claim 1, wherein said cells comprise at least two different cell types.

20

3. The cells of claim 2, wherein said cells comprise a combination of:

adult cardiomyocytes and endothelial cells;

pediatric cardiomyocytes and endothelial cells; or

myoblasts and endothelial cells.

25

4. A method of forming a stable cardiac graft in a mammal, said method comprising transplanting into the scar tissue of a heart, cells comprising at least

one of the following cell types:

- adult cardiomyocytes;
- pediatric cardiomyocytes;
- adult fibroblasts;
- 5 fetal fibroblasts;
- adult smooth muscle cells;
- fetal smooth muscle cells;
- endothelial cells; and
- skeletal myoblasts,

10 wherein said cells survive in scar tissue in a heart after transplantation into said scar tissue, and wherein said cells improve cardiac function, relative to cardiac function of a heart having similar myocardial scar tissue that is not transplanted with said cells, wherein cardiac function is assessed by at least one of the criteria in the group consisting of: area occupied by said scar tissue; vascularization of said scar tissue; blood flow to said scar tissue; developed pressure, systolic pressure; end 15 diastolic pressure; and dp/dt, wherein at least 10% of said scar tissue is occupied by transplanted cells four weeks after transplantation.

20 5. The method of claim 4, wherein said cells include at least two different cell types.

6. The method of claim 4, wherein said cells for transplantation comprise a combination of:

25 adult cardiomyocytes and endothelial cells;  
pediatric cardiomyocytes and endothelial cells; or  
myoblasts and endothelial cells.

7. The method of claim 5, wherein growth factors are co-transplanted with

said cells.

8. The method of claim 7, wherein said growth factors are chosen from the group consisting of: insulin-like growth factors I and II; transforming growth factor - $\beta$ 1; platelet-derived growth factor -B; basic fibroblast growth factor; and, vascular endothelial growth factor.

9. The method of claim 4, wherein, prior to transplantation, at least one of said cells is genetically engineered to express a recombinant protein.

10

10. The method of claim 9, wherein said recombinant protein stimulates growth, survival, or angiogenesis in said heart.

15

11. The method of claim 9, wherein said recombinant protein is selected from the group including: fibroblast growth factor, vascular endothelial growth factor, platelet-derived growth factor- $\beta$ , transforming growth factor- $\beta$ , insulin-like growth factor-1, insulin-like growth factor-2, insulin, Bcl-2, and Bcl-X<sub>L</sub>.

20

12. A method of treating defective, damaged or scarified heart tissue, said method comprising transplanting into said defective, damaged or scarified heart tissue a graft of cells, wherein said graft of cells comprises a combination of:  
adult cardiomyocytes and endothelial cells;  
pediatric cardiomyocytes and endothelial cells; or  
myoblasts and endothelial cells.

25

13. The method of claim 12, wherein said graft is used for cardiomyoplasty.

-74-

14. The method of claim 12, wherein said graft is used for closing cardiac defects.

5        15. The method of claim 12, wherein said graft is used for myocardial reconstructive surgery.

10        16. The method of claim 12, wherein, prior to transplantation, at least one of said adult cardiomyocytes, said pediatric cardiomyocytes, said endothelial cells, or said myoblasts is genetically engineered to express a recombinant protein.

15        17. The method of claim 16, wherein said recombinant protein stimulates growth, survival, or angiogenesis in said heart tissue.

19        18. The method of claim 16, wherein said recombinant protein is selected from the group including: fibroblast growth factor, vascular endothelial growth factor, platelet-derived growth factor- $\beta$ , transforming growth factor- $\beta$ , insulin-like growth factor-1, insulin-like growth factor-2, insulin, Bcl-2, and Bcl-X<sub>L</sub>.

20        19. A therapeutic graft for implantation in mammalian myocardial tissue or scar tissue in a heart, said graft comprising biodegradable or non-biodegradable scaffolding supporting cells, wherein said cells comprise a combination of:

25              adult cardiomyocytes and endothelial cells;  
                  pediatric cardiomyocytes and endothelial cells; or  
                  myoblasts and endothelial cells.

20        20. The graft of claim 19, wherein said scaffolding comprises Dacron or polyglycolic acid polymers with or without polylactic acid polymers.

-75-

21. The graft of claim 19, wherein said graft further includes an implantable pacemaker.

5        22. The graft of claim 19, wherein said cells are transfected to deliver recombinant molecules to said myocardial tissue or scar tissue.

23. The graft of claim 22, further comprising growth factors.

10      24. The graft of claim 23, wherein said growth factors are chosen from the group consisting of: insulin-like growth factors I and II; transforming growth factor - $\beta$ 1; platelet-derived growth factor -B; basic fibroblast growth factor; and, vascular endothelial growth factor.

15      25. The graft of claim 19, wherein said cells are suspended on a biodegradable mesh.

26. A therapeutic graft for use in scar tissue in a mammalian heart, said graft comprising transplanted cells, wherein said cells comprise:

adult cardiomyocytes;

20      adult fibroblasts;

fetal fibroblasts;

smooth muscle cells;

endothelial cells; or

skeletal myoblasts.

25

27. A therapeutic graft for use in myocardial tissue in a mammalian heart, said graft comprising transplanted cells, wherein said transplanted cells comprise:

-76-

adult fibroblasts;  
fetal fibroblasts;  
smooth muscle cells; or  
endothelial cells.

5

28. A method of forming a stable myocardial graft in a mammal, said method comprising transplanting cells into myocardial tissue in the heart of said mammal, wherein said cells comprise:

adult fibroblasts;  
fetal fibroblasts;  
smooth muscle cells; or  
endothelial cells.

10

29. A method of treating defective, damaged or scarified heart tissue, said method comprising transplanting, into said tissue, a graft of cells comprising:

15

adult cardiomyocytes;  
adult fibroblasts;  
fetal fibroblasts;  
smooth muscle cells;  
endothelial cells; or  
20 skeletal myoblasts.

25

30. The method of claim 29, wherein, prior to transplantation, at least one of said cells is genetically engineered to express a recombinant protein.

31. The method of claim 30, wherein said recombinant protein stimulates growth, survival, or angiogenesis in said tissue.

-77-

32. The method of claim 31, wherein said recombinant protein is selected from the group including: fibroblast growth factor, vascular endothelial growth factor, platelet-derived growth factor- $\beta$ , transforming growth factor- $\beta$ , insulin-like growth factor-1, insulin-like growth factor-2, insulin, Bcl-2, and Bcl-X<sub>L</sub>.

1/16




Fig. 1




Fig. 2

SUBSTITUTE SHEET (RULE 26)

2/16




Fig. 3




Fig. 4

SUBSTITUTE SHEET (RULE 26)

3/16

## Experimental Design:





Fig. 5A

## Experimental Design:



All rats were sacrificed  
for histological and  
Langendorff studies

Fig. 5B

4/16




Fig. 6A




Fig. 6B

SUBSTITUTE SHEET (RULE 26)

5/16




Fig. 6C




Fig. 6D

6/16




Fig. 7A




Fig. 7B

7/16



Fig. 7C




Fig. 7D

8/16




Fig. 8

9/16




Fig. 9A




Fig. 9B

10/16




Fig. 9C




Fig. 9D

11/16




Fig. 10

12/16




Fig. 11

13/16




Fig. 12

14/16





Fig. 13



SUBSTITUTE SHEET (RULE 26)




Fig. 15




Fig. 16

SUBSTITUTE SHEET (RULE 26)

**INTERNATIONAL SEARCH REPORT**

International application No. PCT/US99/13850
---

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :C12N 15/00; A01N 63/00; A01N 43/04  
US CL : 435/320.1; 424/93.1; 514/44

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/320.1; 424/93.1; 514/44; 435/357, 360, 363, 366, 374, 375

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,602,301A (Field et al) 11 February 1997, col. 1, lines 40-67 and col. 2, lines 1-35.	1-12
Y	US 5,543,318 (Smith et al) 06 August 1996, col. 2, lines 1-32.	1-23
Y	US 5,733,727A (Field et al) 31 March 1998, col. 1, lines 41-67 and col. 2, lines 1-35.	1-13

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

10 SEPTEMBER 1999

Date of mailing of the international search report

07 OCT 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Faxsimile No. (703) 305-3230

Authorized officer

Jon Shuman

Telephone No. (703) 308-0196

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/US99/13850

**B. FIELDS SEARCHED**

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, DIALOG, NTIS, CA, MEDLINE, BIOSIS, BIOSCI, BIOTECH  
search terms: fetal cardiomyocyte, heart, myocardium, transplant, inject, gene therapy,  
transplant, graft, reconstructive surgery, cardiothoracic, growth factor

THIS PAGE BLANK (USPTO)